WorldWideScience

Sample records for medimmune llc influenza

  1. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.

    Science.gov (United States)

    2003-01-01

    MedImmune Vaccines (formerly Aviron) has developed a cold-adapted live influenza virus vaccine [FluMist] that can be administered by nasal spray. FluMist is the first live virus influenza vaccine and also the first nasally administered vaccine to be marketed in the US. The vaccine will be formulated to contain live attenuated (att) influenza virus reassortants of the strains recommended by the US Public Health Service for each 'flu season. The vaccine is termed cold-adapted (ca) because the virus has been adapted to replicate efficiently at 25 degrees C in the nasal passages, which are below normal body temperature. The strains used in the seasonal vaccine will also be made temperature sensitive (ts) so that their replication is restricted at 37 degrees C (Type B strains) and 39 degrees C (Type A strains). The combined effect of the antigenic properties and the att, ca and ts phenotypes of the influenza strains contained in the vaccine enables the viruses to replicate in the nasopharynx to produce protective immunity. The original formulation of FluMist requires freezer storage throughout distribution. Because many international markets do not have distribution channels well suited to the sale of frozen vaccines, Wyeth and MedImmune are collaborating to develop a second generation, refrigerator-stable, liquid trivalent cold-adapted influenza vaccine (CAIV-T), which is in phase III trials. Initially, the frozen formulation will only be available in the US. For the 2003-2004 season, FluMist will contain A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) (A/Moscow/10/99-like) and B/Hong Kong/330/2001. Aviron was acquired by MedImmune on 15 January 2002. Aviron is now a wholly-owned subsidiary of MedImmune and is called MedImmune Vaccines. Aviron acquired FluMist in March 1995 through a Co-operative Research and Development Agreement (CRADA) with the US NIAID, and a licensing agreement with the University of Michigan, Ann Arbor, USA. In June 2000, the CRADA was

  2. Influenza

    Directory of Open Access Journals (Sweden)

    Forleo-Neto Eduardo

    2003-01-01

    Full Text Available A influenza (gripe é doença infecciosa aguda de origem viral que acomete o trato respiratório e a cada inverno atinge mais de 100 milhões de pessoas na Europa, Japão e Estados Unidos, causando anualmente a morte de cerca de 20 a 40 mil pessoas somente neste último país. O agente etiológico é o Myxovirus influenzae, ou vírus da gripe. Este subdivide-se nos tipos A, B e C, sendo que apenas os do tipo A e B apresentam relevância clínica em humanos. O vírus influenza apresenta altas taxas de mutação, o que resulta freqüentemente na inserção de novas variantes virais na comunidade, para as quais a população não apresenta imunidade. São poucas as opções disponíveis para o controle da influenza. Dentre essas, a vacinação constitui a forma mais eficaz para o controle da doença e de suas complicações. Em função das mutações que ocorrem naturalmente no vírus influenza, recomenda-se que a vacinação seja realizada anualmente. No Brasil, segundo dados obtidos pelo Projeto VigiGripe - ligado à Universidade Federal de São Paulo -, verifica-se que a influenza apresenta pico de atividade entre os meses de maio e setembro. Assim, a época mais indicada para a vacinação corresponde aos meses de março e abril. Para o tratamento específico da influenza estão disponíveis quatro medicamentos antivirais: os fármacos clássicos amantadina e rimantidina e os antivirais de segunda geração oseltamivir e zanamivir. Os últimos, acrescentam alternativas para o tratamento da influenza e ampliam as opções disponíveis para o seu controle.

  3. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells.

    Science.gov (United States)

    Hussain, Althaf I; Cordeiro, Melissa; Sevilla, Elizabeth; Liu, Jonathan

    2010-05-14

    Currently MedImmune manufactures cold-adapted (ca) live, attenuated influenza vaccine (LAIV) from specific-pathogen free (SPF) chicken eggs. Difficulties in production scale-up and potential exposure of chicken flocks to avian influenza viruses especially in the event of a pandemic influenza outbreak have prompted evaluation and development of alternative non-egg based influenza vaccine manufacturing technologies. As part of MedImmune's effort to develop the live attenuated influenza vaccine (LAIV) using cell culture production technologies we have investigated the use of high yielding, cloned MDCK cells as a substrate for vaccine production by assessing host range and virus replication of influenza virus produced from both SPF egg and MDCK cell production technologies. In addition to cloned MDCK cells the indicator cell lines used to evaluate the impact of producing LAIV in cells on host range and replication included two human cell lines: human lung carcinoma (A549) cells and human muco-epidermoid bronchiolar carcinoma (NCI H292) cells. The influenza viruses used to infect the indicators cell lines represented both the egg and cell culture manufacturing processes and included virus strains that composed the 2006-2007 influenza seasonal trivalent vaccine (A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2) and B/Malaysia/2506/04). Results from this study demonstrate remarkable similarity between influenza viruses representing the current commercial egg produced and developmental MDCK cell produced vaccine production platforms. MedImmune's high yielding cloned MDCK cells used for the cell culture based vaccine production were highly permissive to both egg and cell produced ca attenuated influenza viruses. Both the A549 and NCI H292 cells regardless of production system were less permissive to influenza A and B viruses than the MDCK cells. Irrespective of the indicator cell line used the replication properties were similar between egg and the cell produced

  4. 77 FR 29633 - Alta Wind VII, LLC, Alta Wind IX, LLC, Alta Wind X, LLC, Alta Wind XI, LLC, Alta Wind XII, LLC...

    Science.gov (United States)

    2012-05-18

    ..., Alta Wind XIV, LLC, Alta Wind XV, LLC, Alta Windpower Development, LLC, TGP Development Company, LLC... XIII, LLC, Alta Wind XIV, LLC, Alta Wind XV, LLC, Alta Windpower Development, LLC, and TGP Development...

  5. 78 FR 29364 - Exelon Corporation, Exelon Wind 1, LLC, Exelon Wind 2, LLC, Exelon Wind 3, LLC, Exelon Wind 4...

    Science.gov (United States)

    2013-05-20

    ...-005, QF07-257-004] Exelon Corporation, Exelon Wind 1, LLC, Exelon Wind 2, LLC, Exelon Wind 3, LLC, Exelon Wind 4, LLC, Exelon Wind 5, LLC, Exelon Wind 6, LLC, Exelon Wind 7, LLC, Exelon Wind 8, LLC, Exelon Wind 9, LLC, Exelon Wind 10, LLC, Exelon Wind 11, LLC, High Plains Wind Power, LLC v. Xcel Energy...

  6. 75 FR 23263 - Alta Wind I, LLC; Alta Wind II, LLC; Alta Wind III, LLC; Alta Wind IV, LLC; Alta Wind V, LLC...

    Science.gov (United States)

    2010-05-03

    ...; Alta Wind VII, LLC; Alta Wind VIII, LLC; Alta Windpower Development, LLC; TGP Development Company, LLC... Development, LLC, and TGP Development Company, LLC (Petitioners) filed jointly a petition for declaratory...

  7. 77 FR 61597 - Avalon Wind, LLC; Avalon Wind 2, LLC; Catalina Solar, LLC; Catalina Solar 2, LLC; Pacific Wind...

    Science.gov (United States)

    2012-10-10

    ... Energy Regulatory Commission Avalon Wind, LLC; Avalon Wind 2, LLC; Catalina Solar, LLC; Catalina Solar 2, LLC; Pacific Wind Lessee, LLC; Pacific Wind 2, LLC; Valentine Solar, LLC; EDF Renewable Development, Inc.; Notice of Petition for Declaratory Order Take notice that on September 27, 2012, Avalon Wind...

  8. 78 FR 32385 - Exelon Generation Company, LLC; CER Generation II, LLC; Constellation Mystic Power, LLC...

    Science.gov (United States)

    2013-05-30

    ... Generation Company, LLC; CER Generation II, LLC; Constellation Mystic Power, LLC; Constellation NewEnergy, Inc.; Constellation Power Source Generation, Inc.; Criterion Power Partners, LLC; Notice of Petition...) Rules of Practice and Procedure, 18 CFR 385.207, Exelon Generation Company, LLC, CER Generation II, LLC...

  9. Influenza vaccination

    DEFF Research Database (Denmark)

    Østerhus, Sven Frederick

    2015-01-01

    The Cochrane Library was systematically searched for meta-analyses regarding influenza vaccination of various populations, both healthy and sick. An effect in reducing the number of cases of influenza, influenza-like illness or complications to influenza was found in some studies, but, generally......, the quality of the studies was low, and several studies lacked hard clinical endpoints. Data on adverse effects were scarce. More randomised controlled trials investigating the effects of influenza vaccination are warranted....

  10. 75 FR 55315 - Seminole Energy Services, LLC; Seminole Gas Company, LLC; Seminole High Plains, LLC; Lakeshore...

    Science.gov (United States)

    2010-09-10

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Seminole Energy Services, LLC; Seminole Gas Company, LLC; Seminole High Plains, LLC; Lakeshore Energy Services, LLC; Vanguard Energy Services, LLC Notice of Amended Designation...

  11. 77 FR 40608 - Notice of Petition for Enforcement and Declaratory Order; Exelon Wind 1, LLC; Exelon Wind 2, LLC...

    Science.gov (United States)

    2012-07-10

    ... Energy Regulatory Commission Notice of Petition for Enforcement and Declaratory Order; Exelon Wind 1, LLC; Exelon Wind 2, LLC; Exelon Wind 3, LLC; Exelon Wind 4, LLC; Exelon Wind 5, LLC; Exelon Wind 6, LLC; Exelon Wind 7, LLC; Exelon Wind 8, LLC; Exelon Wind 9, LLC; Exelon Wind 10, LLC; Exelon Wind 11, LLC...

  12. 77 FR 14010 - Rocky Ridge Wind Project, LLC, Blackwell Wind, LLC, CPV Cimarron Renewable Energy Company, LLC...

    Science.gov (United States)

    2012-03-08

    ..., LLC, Blackwell Wind, LLC, CPV Cimarron Renewable Energy Company, LLC, Minco Wind Interconnection Services, LLC, Shiloh III Lessee, LLC, California Ridge Wind Energy LLC, Perrin Ranch Wind, LLC, Erie Wind... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket Nos. EG12-16-000, EG12-17-000...

  13. 75 FR 45623 - Morris Energy Group, LLC v.PSEG Energy Resources & Trade LLC; PSEG Fossil LLC; and PSEG Power LLC...

    Science.gov (United States)

    2010-08-03

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. EL10-79-000] Morris Energy Group, LLC v.PSEG Energy Resources & Trade LLC; PSEG Fossil LLC; and PSEG Power LLC; Notice of Complaint...) filed a complaint against PSEG Energy Resources & Trade, LLC, PSEG Fossil LLC and PSEG Power LLC (PSEG...

  14. Meningitis - H. influenzae

    Science.gov (United States)

    H. influenzae meningitis; H. flu meningitis; Haemophilus influenzae type b meningitis ... H. influenzae meningitis is caused by Haemophilus influenzae type b bacteria. This illness is not the same as the flu ( influenza ), ...

  15. 77 FR 48138 - Topaz Solar Farms LLC; High Plains Ranch II, LLC; Bethel Wind Energy LLC; Rippey Wind Energy LLC...

    Science.gov (United States)

    2012-08-13

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket Nos. EG12-63-000; EG12-64-000; EG12-65-000; EG12-66-000; EG12- 67-000; EG12-68-000; EG12-69-000] Topaz Solar Farms LLC; High Plains Ranch II, LLC; Bethel Wind Energy LLC; Rippey Wind Energy LLC; Pacific Wind, LLC; Colorado Highlands...

  16. 77 FR 70423 - Black Bear Hydro Partners, LLC and Black Bear Development Holdings, LLC and Black Bear SO, LLC...

    Science.gov (United States)

    2012-11-26

    ... Bear Hydro Partners, LLC and Black Bear Development Holdings, LLC and Black Bear SO, LLC; Notice of..., 2012, Black Bear Hydro Partners, LLC, sole licensee (transferor) and Black Bear Development Holdings, LLC and Black Bear SO, LLC (transferees) filed an application for the partial the transfer of licenses...

  17. 77 FR 42714 - Eagle Creek Hydropower, LLC, Eagle Creek Land Resources, LLC, Eagle Creek Water Resources, LLC...

    Science.gov (United States)

    2012-07-20

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 9690-109] Eagle Creek Hydropower, LLC, Eagle Creek Land Resources, LLC, Eagle Creek Water Resources, LLC; Notice of Application...: Eagle Creek Hydropower, LLC; Eagle Creek Land Resources, LLC; and Eagle Creek Water Resources, LLC. e...

  18. 75 FR 47301 - Cedro Hill Wind LLC; Butler Ridge Wind Energy Center, LLC; High Majestic Wind Energy Center, LLC...

    Science.gov (United States)

    2010-08-05

    ...; Butler Ridge Wind Energy Center, LLC; High Majestic Wind Energy Center, LLC; Wessington Wind Energy Center, LLC; Juniper Canyon Wind Power LLC; Loraine Windpark Project, LLC; White Oak Energy LLC; Meadow... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. EG10-25-000; EG10-26-000...

  19. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.

    Science.gov (United States)

    Grohskopf, Lisa A; Sokolow, Leslie Z; Broder, Karen R; Walter, Emmanuel B; Bresee, Joseph S; Fry, Alicia M; Jernigan, Daniel B

    2017-08-25

    , Connecticut); and expansion of the age indication for FluLaval Quadrivalent (IIV4; ID Biomedical Corporation of Quebec, Quebec City, Quebec, Canada), previously licensed for ≥3 years, to ≥6 months.• Pregnant women may receive any licensed, recommended, age-appropriate influenza vaccine.• Afluria (IIV3; Seqirus, Parkville, Victoria, Australia) may be used for persons aged ≥5 years, consistent with Food and Drug Administration-approved labeling.• FluMist Quadrivalent (LAIV4; MedImmune, Gaithersburg, Maryland) should not be used during the 2017-18 season due to concerns about its effectiveness against influenza A(H1N1)pdm09 viruses in the United States during the 2013-14 and 2015-16 influenza seasons.This report focuses on the recommendations for use of vaccines for the prevention and control of influenza during the 2017-18 season in the United States. A Background Document containing further information and a summary of these recommendations are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to licensed influenza vaccines used within Food and Drug Administration-licensed indications, including those licensed after the publication date of this report. Updates and other information are available at CDC's influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check CDC's influenza website periodically for additional information.

  20. Rock Equity Holdings, LLC

    Science.gov (United States)

    The EPA is providing notice of an Administrative Penalty Assessment in the form of an Expedited Storm Water Settlement Agreement against Rock Equity Holdings, LLC, for alleged violations at The Cove at Kettlestone/98th Street Reconstruction located at 3015

  1. 75 FR 1052 - Terra-Gen Dixie Valley, LLC; TGP Dixie Development Company, LLC; New York Canyon, LLC; Notice of...

    Science.gov (United States)

    2010-01-08

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. EL10-29-000] Terra-Gen Dixie Valley, LLC; TGP Dixie Development Company, LLC; New York Canyon, LLC; Notice of Filing December 30, 2009. Take notice that on December 24, 2009, Terra-Gen Dixie Valley, LLC, TGP Dixie Development Company, LLC...

  2. Influenza (Flu)

    Science.gov (United States)

    ... develop influenza. Weakened immune system. Cancer treatments, anti-rejection drugs, corticosteroids and HIV/AIDS can weaken your ... for Disease Control and Prevention recommends annual flu vaccination for everyone over the age of 6 months. ...

  3. Knight Capital Americas LLC

    DEFF Research Database (Denmark)

    Austin, Robert D.; Meister, Darren

    2015-01-01

    It took 19 years to build Knight Capital Americas LLC into the largest market maker on the New York Stock Exchange, but on August 1, 2012, it took only 45 minutes for the firm to be wiped out by an information technology (IT) problem: a change in the company's software caused it to lose more than...

  4. Avian Influenza.

    Science.gov (United States)

    Zeitlin, Gary Adam; Maslow, Melanie Jane

    2005-05-01

    The current epidemic of H5N1 highly pathogenic avian influenza in Southeast Asia raises serious concerns that genetic reassortment will result in the next influenza pandemic. There have been 164 confirmed cases of human infection with avian influenza since 1996. In 2004, there were 45 cases of human H5N1 in Vietnam and Thailand, with a mortality rate more than 70%. In addition to the potential public health hazard, the current zoonotic epidemic has caused severe economic losses. Efforts must be concentrated on early detection of bird outbreaks with aggressive culling, quarantining, and disinfection. To prepare for and prevent an increase in human cases, it is essential to improve detection methods and stockpile effective antivirals. Novel therapeutic modalities, including short-interfering RNAs and new vaccine strategies that use plasmid-based genetic systems, offer promise should a pandemic occur.

  5. 76 FR 36914 - Astoria Generating Company, L.P., NRG Power Marketing LLC, Arthur Kill Power LLC, Astoria Gas...

    Science.gov (United States)

    2011-06-23

    ... Generating Company, L.P., NRG Power Marketing LLC, Arthur Kill Power LLC, Astoria Gas Turbine Power LLC... Power Marketing LLC, Arthur Kill Power LLC, Astoria Gas Turbine Power LLC, Dunkirk Power LLC, Huntley... when a document is added to a subscribed docket(s). For assistance with any FERC Online service, please...

  6. Avian influenza

    DEFF Research Database (Denmark)

    EFSA Panel on Animal Health and Welfare; More, Simon; Bicout, Dominique

    2017-01-01

    Previous introductions of highly pathogenic avian influenza virus (HPAIV) to the EU were most likely via migratory wild birds. A mathematical model has been developed which indicated that virus amplification and spread may take place when wild bird populations of sufficient size within EU become...... infected. Low pathogenic avian influenza virus (LPAIV) may reach similar maximum prevalence levels in wild bird populations to HPAIV but the risk of LPAIV infection of a poultry holding was estimated to be lower than that of HPAIV. Only few non-wild bird pathways were identified having a non...

  7. 78 FR 9907 - TGP Development Company, LLC; TGP Flying Cloud Holdings, LLC; WEC TX Company, LLC v. Arizona...

    Science.gov (United States)

    2013-02-12

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. EL13-45-000] TGP Development Company, LLC; TGP Flying Cloud Holdings, LLC; WEC TX Company, LLC v. Arizona Public Service Company... section 206 of the Federal Power Act, 16 U.S.C. 824(e) (2006), TGP Development Company, LLC, TGP Flying...

  8. 75 FR 59705 - SourceGas Distribution LLC; Bay Gas Storage, LLC; Enterprise Texas Pipeline LLC; Dow Intrastate...

    Science.gov (United States)

    2010-09-28

    ...; Docket No. PR10-110-000; Docket No. PR10-112-000; Docket No. PR10- 113-000 (Not Consolidated) SourceGas Distribution LLC; Bay Gas Storage, LLC; Enterprise Texas Pipeline LLC; Dow Intrastate Gas Company; ONEOK Field Services Company, L.L.C.; Corning Natural Gas Corporation; Notice of Baseline Filings September 21, 2010...

  9. Avian Influenza (Bird Flu)

    Science.gov (United States)

    ... in People Spread of Bird Flu Viruses Between Animals and People Examples of Human Infections with Avian Influenza A ... Subtypes Transmission of Avian Influenza A Viruses Between Animals and People Related Links Research Glossary of Influenza (Flu) Terms ...

  10. 75 FR 76453 - Top of the World Wind Energy, LLC; Kit Carson Windpower, LLC; Chestnut Flats Wind, LLC; Minco...

    Science.gov (United States)

    2010-12-08

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket Nos. EG10-65-000; EG10-66-000; EG10-67-000; EG10-68-000; EG10- 69-000; EG10-70-000; EG10-71-000] Top of the World Wind Energy, LLC; Kit Carson Windpower, LLC; Chestnut Flats Wind, LLC; Minco Wind, LLC; Arizona Solar One LLC; Criterion...

  11. 75 FR 1049 - Wausau Paper Printing & Writing, LLC,

    Science.gov (United States)

    2010-01-08

    ...] Wausau Paper Printing & Writing, LLC, Wausau Paper Mills, LLC; Notice of Application for Transfer of... Paper Printing & Writing, LLC (transferor) and Wausau Paper Mills, LLC (transferee) filed an application...

  12. Avian influenza

    Directory of Open Access Journals (Sweden)

    Tjandra Y. Aditama

    2006-06-01

    Full Text Available Avian influenza, or “bird flu”, is a contagious disease of animals which crossed the species barrier to infect humans and gave a quite impact on public health in the world since 2004, especially due to the threat of pandemic situation. Until 1st March 2006, laboratory-confirmed human cases have been reported in seven countries: Cambodia, Indonesia, Thailand, Viet Nam, China, Iraq and Turkey with a total of 174 cases and 94 dead (54.02%. Indonesia has 27 cases, 20 were dead (74.07%. AI cases in Indonesia are more in male (62.5% and all have a symptom of fever. An influenza pandemic is a rare but recurrent event. An influenza pandemic happens when a new subtype emerges that has not previously circulated in humans. For this reason, avian H5N1 is a strain with pandemic potential, since it might ultimately adapt into a strain that is contagious among humans. Impact of the pandemic could include high rates of illness and worker absenteeism are expected, and these will contribute to social and economic disruption. Historically, the number of deaths during a pandemic has varied greatly. Death rates are largely determined by four factors: the number of people who become infected, the virulence of the virus, the underlying characteristics and vulnerability of affected populations, and the effectiveness of preventive measures. Accurate predictions of mortality cannot be made before the pandemic virus emerges and begins to spread. (Med J Indones 2006; 15:125-8Keywords: Avian Influenza, Pandemic

  13. ADULT INFLUENZA VACCINATION GUIDELINE

    African Journals Online (AJOL)

    immunisation, and successful influenza vaccines are available each year for the predominant serotypes of the virus. 2. THE VIRUS2.6-9. The influenza viruses are enveloped viruses with a segmented. RNA genome. There are three types, influenza A, B and C based on antigenic differences. Both influenza A and B viruses.

  14. 76 FR 34692 - Astoria Generating Company, L.P., NRG Power Marketing LLC, Arthur Kill Power LLC, Astoria Gas...

    Science.gov (United States)

    2011-06-14

    ... Generating Company, L.P., NRG Power Marketing LLC, Arthur Kill Power LLC, Astoria Gas Turbine Power LLC... Generating Company, L.P., NRG Power Marketing LLC, Arthur Kill Power LLC, Astoria Gas Turbine Power LLC... notification when a document is added to a subscribed docket(s). For assistance with any FERC Online service...

  15. 78 FR 21151 - Boise White Paper, LLC, A Subsidiary of Boise Paper Holdings, LLC, Including On-Site Leased...

    Science.gov (United States)

    2013-04-09

    ... Paper, LLC, A Subsidiary of Boise Paper Holdings, LLC, Including On-Site Leased Workers From Guardsmark.... Helens, OR; Boise White Paper, LLC, A Subsidiary of Boise Paper Holdings, LLC, Vancouver, WA; Amended... workers and former workers of Boise White Paper, LLC, a subsidiary of Boise Paper Holdings, LLC, St...

  16. 75 FR 70076 - Tennessee Southern Railroad Company, Patriot Rail, LLC, Patriot Rail Holdings LLC, and Patriot...

    Science.gov (United States)

    2010-11-16

    ... Control Exemption--Columbia & Cowlitz Railway, LLC, DeQueen and Eastern Railroad, LLC, Golden Triangle...), DeQueen and Eastern Railroad, LLC (DQE), Golden Triangle Railroad, LLC (GTRA), Mississippi & Skuna Valley..., and spur tracks, in Howard and Sevier Counties, Ark.; Docket No. FD 35428, Golden Triangle Railroad...

  17. 75 FR 77862 - FFP Missouri 16, LLC, Solia 9 Hydroelectric, LLC; Notice of Competing Preliminary Permit...

    Science.gov (United States)

    2010-12-14

    ... Missouri 16, LLC, Solia 9 Hydroelectric, LLC; Notice of Competing Preliminary Permit Applications Accepted.... On August 6, 2010, FFP Missouri 16, LLC (FFP) and Solia 9 Hydroelectric, LLC filed preliminary permit...-2822. Solia 9 Hydroelectric's proposed Lock and Dam 15 Hydropower Project (Project No. 13827-000) would...

  18. 77 FR 14011 - Rainbow Ranch Wind, LLC, Rainbow West Wind, LLC; Notice of Petition for Enforcement

    Science.gov (United States)

    2012-03-08

    ... Energy Regulatory Commission Rainbow Ranch Wind, LLC, Rainbow West Wind, LLC; Notice of Petition for... Policies Act of 1978 (PURPA), 16 USA 8242-3(h), Rainbow Ranch Wind, LLC (Rainbow Ranch) and Rainbow West Wind, LLC (Rainbow West) (collectively, Petitioners) filed a petition requesting the Federal Energy...

  19. PDG Construction, LLC Information Sheet

    Science.gov (United States)

    PDG Construction, LLC d/b/a Princeton Design Guild (the Company) is located in Bell Meade, New Jersey. The settlement involves renovation activities conducted at property constructed prior to 1978, located in Hopewell, New Jersey.

  20. Influenza (Flu) Viruses

    Science.gov (United States)

    ... and antigenic shift. Transmission of Influenza Viruses from Animals to People Influenza A viruses also are found in many different animals, including ducks, chickens, pigs, whales, horses and seals. ...

  1. Haemophilus Influenzae Type b

    Science.gov (United States)

    ... Text Size Email Print Share Haemophilus Influenzae type b Page Content Article Body If you’re like ... may have been unfamiliar with Haemophilus influenzae type b (Hib) infections until your pediatrician recommended a vaccine ...

  2. Avian Influenza in Birds

    Science.gov (United States)

    ... However, some ducks can be infected without any signs of illness. Top of Page Avian Influenza in Wild Birds Avian influenza A viruses have ... hours. Some ducks can be infected without any signs of illness. Avian influenza outbreaks are of concern in domesticated birds for ...

  3. 77 FR 60981 - TGP Granada, LLC and Roosevelt Wind Ranch, LLC v. Public Service Company of New Mexico, Tortoise...

    Science.gov (United States)

    2012-10-05

    ...; EL12-43-000, EL12-43-001 TGP Granada, LLC and Roosevelt Wind Ranch, LLC v. Public Service Company of New Mexico, Tortoise Capital Resources Corp.; TGP Granada, LLC and Roosevelt Wind Ranch, LLC; Notice... over capacity on the Eastern Interconnection Project. \\1\\ TGP Granada, LLC v. Pub. Serv. Co. of New...

  4. 76 FR 36910 - Astoria Generating Company, L.P., NRG Power Marketing LLC, Arthur Kill Power LLC, Astoria Gas...

    Science.gov (United States)

    2011-06-23

    ... Generating Company, L.P., NRG Power Marketing LLC, Arthur Kill Power LLC, Astoria Gas Turbine Power LLC... Generating Company, L.P., NRG Power Marketing LLC, Arthur Kill Power LLC, Astoria Gas Turbine Power [[Page... subscribed docket(s). For assistance with any FERC Online service, please e-mail [email protected

  5. 78 FR 34092 - Lock+ Hydro Friends Fund XXX, LLC; FFP Project 121, LLC; Notice of Competing Preliminary Permit...

    Science.gov (United States)

    2013-06-06

    .... 14504-000] Lock+ Hydro Friends Fund XXX, LLC; FFP Project 121, LLC; Notice of Competing Preliminary... Applications Lock+ Hydro Friends Fund XXX, LLC and FFP Project 121, LLC filed preliminary permit applications... regular business day. See id. at 385.2001(a)(2). Lock+ Hydro Friends Fund XXX, LLC's application is for a...

  6. 75 FR 5780 - Green Borders Geothermal, LLC, Complainant, v. Terra-Gen Dixie Valley, LLC, Respondent; Notice of...

    Science.gov (United States)

    2010-02-04

    ... Energy Regulatory Commission Green Borders Geothermal, LLC, Complainant, v. Terra-Gen Dixie Valley, LLC... Geothermal, LLC (Green Borders) filed a formal complaint against Terra-Gen Dixie Valley, LLC (f/k/a Caithness Dixie Valley, LLC) (Terra-Gen) pursuant to section 206 of the Federal Power Act, and 18 CFR 385.206...

  7. Clinical Validation of a Point-of-Care Multiplexed In Vitro Immunoassay Using Monoclonal Antibodies (the MSD Influenza Test) in Four Hospitals in Vietnam

    NARCIS (Netherlands)

    van Doorn, H. Rogier; Kinh, Nguyen Van; Tuan, Ha Manh; Tuan, Tran Anh; Minh, Ngo Ngoc Quang; Bryant, Juliet E.; Hang, Vu thi Ty; Uyen, Le thi Tham; Thinh, Le Quoc; Anh, Tran thi Ngoc; Lan, Nguyen Phu Huong; Trung, Nguyen Vu; Taylor, Walter; Merson, Laura; Wertheim, Heiman F. L.; Farrar, Jeremy; Wolbers, Marcel; Chau, Nguyen Van Vinh; de Jong, Menno D.

    2012-01-01

    Point-of-care (POC) diagnostic tests for influenza can considerably shorten the time to clinical decision making. An investigational POC test based on a multiplexed immunoassay was developed by Meso Scale Diagnostics, LLC (MSD), with the objective to make a more sensitive rapid test that can also

  8. Flublok Seasonal Influenza (Flu) Vaccination

    Science.gov (United States)

    ... Vaccine Safety and Pregnant Women Febrile Seizures Following Vaccination Flu Vaccine and People with Egg Allergies Guillain- ... Flu Vaccines Quadrivalent Influenza Vaccine Intradermal Influenza (Flu) Vaccination Fluzone High-Dose Seasonal Influenza Vaccine Cell-Based ...

  9. Carrington Real Estate Services, LLC and Carrington Mortgage Services, LLC Information Sheet

    Science.gov (United States)

    Carrington Real Estate Services, LLC and Carrington Mortgage Services, LLC (the Company) is located in Anaheim, California. The settlement involves the sale of properties constructed prior to 1978, located in Bakersfield and Ridgecrest, California.

  10. 75 FR 81264 - Critical Path Transmission, LLC; Clear Power, LLC; v. California Independent System Operator, Inc...

    Science.gov (United States)

    2010-12-27

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. EL11-11-000] Critical Path Transmission, LLC; Clear Power, LLC; v. California Independent System Operator, Inc.; Notice of Complaint... and 306 of the Federal Power Act, 16 U.S.C. 824e and 825e (2006), Critical Path Transmission, LLC and...

  11. 76 FR 56428 - Southern Cross Transmission LLC; Pattern Power Marketing LLC; Notice of Filing

    Science.gov (United States)

    2011-09-13

    ... Transmission LLC; Pattern Power Marketing LLC; Notice of Filing Take notice that on September 6, 2011, pursuant... Marketing LLC (PPM) jointly filed an application requesting that the Commission direct (1) the City of... with any FERC Online service, please e-mail [email protected] , or call (866) 208-3676 (toll...

  12. 77 FR 12835 - American Land Company, LLC, Burnshire Hydroelectric, LLC; Notice of Transfer of Exemption

    Science.gov (United States)

    2012-03-02

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 3287-006] American Land Company, LLC, Burnshire Hydroelectric, LLC; Notice of Transfer of Exemption 1. By letter filed February 14... Hydroelectric, LLC. The project is located on the North Fork, Shenandoah River in Shenandoah County, Virginia...

  13. Swine Influenza/Variant Influenza Viruses

    Science.gov (United States)

    ... Humans Key Facts about Human Infections with Variant Viruses Interim Guidance for Clinicians on Human Infections Background, Risk Assessment & Reporting Reported Infections with Variant Influenza Viruses in the United States since 2005 Past Outbreaks ...

  14. Tom Ford Construction, LLC Information Sheet

    Science.gov (United States)

    Tom Ford Construction, LLC (the Company) is located in Brentwood, Tennessee. The settlement involves renovation activities conducted at a property constructed prior to 1978, located in Nashville, Tennessee.

  15. Influenza: prevention, prophylaxis and treatment

    African Journals Online (AJOL)

    Influenza A tends to cause moderate to severe illness in all age groups, and can infect humans and animals, including birds. Influenza B causes milder disease only in humans, primarily in children. Influenza C has rarely been reported to affect humans. The problem with the influenza virus is that it undergoes antigenic.

  16. Avian influenza virus

    Science.gov (United States)

    Avian influenza virus (AIV) is type A influenza that is adapted to avian host species. Although the virus can be isolated from numerous avian species, the natural host reservoir species are dabbling ducks, shorebirds and gulls. Domestic poultry species (poultry being defined as birds that are rais...

  17. Seasonal Influenza: An Overview

    Science.gov (United States)

    Li, Christina; Freedman, Marian

    2009-01-01

    Seasonal influenza is a major cause of morbidity and mortality in the United States. It also has major social and economic consequences in the form of high rates of absenteeism from school and work as well as significant treatment and hospitalization costs. In fact, annual influenza epidemics and the resulting deaths and lost days of productivity…

  18. Towards universal influenza vaccines?

    NARCIS (Netherlands)

    A.D.M.E. Osterhaus (Albert); R.A.M. Fouchier (Ron); G.F. Rimmelzwaan (Guus)

    2011-01-01

    textabstractVaccination is the most cost-effective way to reduce the considerable disease burden of seasonal influenza. Although seasonal influenza vaccines are effective, their performance in the elderly and immunocompromised individuals would benefit from improvement. Major problems related to the

  19. Combination Chemotherapy for Influenza

    Directory of Open Access Journals (Sweden)

    Robert G. Webster

    2010-07-01

    Full Text Available The emergence of pandemic H1N1 influenza viruses in April 2009 and the continuous evolution of highly pathogenic H5N1 influenza viruses underscore the urgency of novel approaches to chemotherapy for human influenza infection. Anti-influenza drugs are currently limited to the neuraminidase inhibitors (oseltamivir and zanamivir and to M2 ion channel blockers (amantadine and rimantadine, although resistance to the latter class develops rapidly. Potential targets for the development of new anti-influenza agents include the viral polymerase (and endonuclease, the hemagglutinin, and the non-structural protein NS1. The limitations of monotherapy and the emergence of drug-resistant variants make combination chemotherapy the logical therapeutic option. Here we review the experimental data on combination chemotherapy with currently available agents and the development of new agents and therapy targets.

  20. 78 FR 24803 - Hilco SP Rail, LLC-Acquisition and Operation Exemption-RG Steel Railroad Holding, LLC

    Science.gov (United States)

    2013-04-26

    ... DEPARTMENT OF TRANSPORTATION Surface Transportation Board [Docket No. FD 35734] Hilco SP Rail, LLC--Acquisition and Operation Exemption--RG Steel Railroad Holding, LLC Hilco SP Rail, LLC (Hilco), a noncarrier... Holding, LLC, and operate as a common carrier over an approximately 12-mile line of railroad in Sparrows...

  1. 77 FR 63873 - Heartland Bakery Company, LLC, a Subsidiary of Maplehurst Bakeries, LLC, Including On-Site Leased...

    Science.gov (United States)

    2012-10-17

    ... Employment and Training Administration Heartland Bakery Company, LLC, a Subsidiary of Maplehurst Bakeries... workers of Heartland Bakery Company, LLC, a subsidiary of Maplehurst Bakeries, LLC, including on-site... were employed on-site at the Du Quoin, Illinois location of Heartland Bakery Company, LLC. The...

  2. 77 FR 12280 - FFP Missouri 17, LLC BOST2 Hydroelectric, LLC; Notice Announcing Filing Priority for Preliminary...

    Science.gov (United States)

    2012-02-29

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project Nos. 13824-000, 13826-000] FFP Missouri 17, LLC BOST2 Hydroelectric, LLC; Notice Announcing Filing Priority for Preliminary Permit... Hydroelectric, LLC, Project No. 13826-000. 2. FFP Missouri 17, LLC, Project No. 13824-000. Dated: February 22...

  3. 76 FR 15971 - Liberty Gas Storage, LLC and LA Storage, LLC; Notice of Joint Application for Abandonment and...

    Science.gov (United States)

    2011-03-22

    ... Federal Energy Regulatory Commission Liberty Gas Storage, LLC and LA Storage, LLC; Notice of Joint..., 2011, Liberty Gas Storage, LLC (Liberty) and LA Storage, LLC (LA Storage) filed with the Federal Energy... Commission pursuant to section 7(b) of the NGA for Liberty to abandon by transfer certain facilities to LA...

  4. 77 FR 36041 - Nevada 5, Inc. and Oakland Transportation Holdings LLC-Control Exemption-GTR Leasing LLC and US...

    Science.gov (United States)

    2012-06-15

    ... DEPARTMENT OF TRANSPORTATION Surface Transportation Board [Docket No. FD 35635] Nevada 5, Inc. and Oakland Transportation Holdings LLC--Control Exemption--GTR Leasing LLC and US Rail Holdings LLC \\1\\ \\1... carrier, through Oakland's acquisition of GTR Leasing LLC (GTR), the parent company of Rail Holdings.\\2...

  5. 76 FR 13272 - Columbia & Cowlitz Railway, LLC-Corporate Family Transaction Exemption-Patriot Woods Railroad, LLC

    Science.gov (United States)

    2011-03-10

    ... Surface Transportation Board Columbia & Cowlitz Railway, LLC--Corporate Family Transaction Exemption--Patriot Woods Railroad, LLC Columbia & Cowlitz Railway, LLC (CLC) and Patriot Woods Railroad, LLC (Woods... corporate family. CLC seeks to lease and operate all of Woods' lines of railroad consisting of approximately...

  6. 75 FR 49527 - Caps Visual Communications, LLC; Black Dot Group; Formerly Known as Caps Group Acquisition, LLC...

    Science.gov (United States)

    2010-08-13

    ... Employment and Training Administration Caps Visual Communications, LLC; Black Dot Group; Formerly Known as... Adjustment Assistance on June 24, 2010, applicable to workers of Caps Visual Communications, LLC, Black Dot..., Caps Visual Communications, LLC, Black Dot Group, formerly known as Caps Group Acquisition, LLC...

  7. 77 FR 65874 - Kinder Morgan Pony Express Pipeline LLC, Hiland Crude, LLC; Notice of Petition For Declaratory Order

    Science.gov (United States)

    2012-10-31

    ... Pony Express Pipeline LLC, Hiland Crude, LLC; Notice of Petition For Declaratory Order Take notice that..., 18 CFR 385.207(a)(2)(2012), Kinder Morgan Pony Express Pipeline LLC and Hiland Crude, LLC, filed a... terms, as described in filing. Any person desiring to intervene or protest in any of the above...

  8. 76 FR 78641 - Cedar Creek Wind Energy, LLC, Milford Wind Corridor Phase I, LLC; Notice of Filing

    Science.gov (United States)

    2011-12-19

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. RC11-1-002; Docket No. RC11-2-002] Cedar Creek Wind Energy, LLC, Milford Wind Corridor Phase I, LLC; Notice of Filing Take...) June 16, 2011 Order.\\1\\ \\1\\ Cedar Creek Wind Energy, LLC and Milford Wind Corridor Phase I, LLC, 135...

  9. 77 FR 70478 - RG Steel Wheeling, LLC, Wheeling Office, A Division Of RG Steel, LLC, Including On-Site Leased...

    Science.gov (United States)

    2012-11-26

    ... Unlimited and Green Energy Initiatives LLC, Including Workers Whose Wages Were Reported Through Severstal..., Wheeling Office, a division of RG Steel, LLC, including on-site leased workers from Pro Unlimited and Green Energy Initiatives, LLC, Wheeling, West Virginia (TA-W-81,880) and Mountain State Carbon, LLC, including...

  10. 76 FR 36532 - Iberdrola Renewables, Inc., PacifiCorp, NextEra Energy Resources, LLC, Invenergy Wind North...

    Science.gov (United States)

    2011-06-22

    ..., Invenergy Wind North America LLC, Horizon Wind Energy LLC v. Bonneville Power Administration; Notice of... Resources, LLC, Invenergy Wind North America LLC, and Horizon Wind Energy LLC (Complainants) filed a formal...

  11. 76 FR 61689 - Sutton Hydroelectric Company, LLC

    Science.gov (United States)

    2011-10-05

    ... Hydroelectric Company, LLC Notice of Site Visit On February 6, 2008, Sutton Hydroelectric Company, LLC (Sutton Hydroelectric) filed a notice of intent and a preliminary application document to license its proposed Sutton Hydroelectric Project No. 12693. The project would be located at the U.S. Army Corps of Engineers' (Corps...

  12. Pandemic influenza: certain uncertainties.

    Science.gov (United States)

    Morens, David M; Taubenberger, Jeffery K

    2011-09-01

    For at least five centuries, major epidemics and pandemics of influenza have occurred unexpectedly and at irregular intervals. Despite the modern notion that pandemic influenza is a distinct phenomenon obeying such constant (if incompletely understood) rules such as dramatic genetic change, cyclicity, "wave" patterning, virus replacement, and predictable epidemic behavior, much evidence suggests the opposite. Although there is much that we know about pandemic influenza, there appears to be much more that we do not know. Pandemics arise as a result of various genetic mechanisms, have no predictable patterns of mortality among different age groups, and vary greatly in how and when they arise and recur. Some are followed by new pandemics, whereas others fade gradually or abruptly into long-term endemicity. Human influenza pandemics have been caused by viruses that evolved singly or in co-circulation with other pandemic virus descendants and often have involved significant transmission between, or establishment of, viral reservoirs within other animal hosts. In recent decades, pandemic influenza has continued to produce numerous unanticipated events that expose fundamental gaps in scientific knowledge. Influenza pandemics appear to be not a single phenomenon but a heterogeneous collection of viral evolutionary events whose similarities are overshadowed by important differences, the determinants of which remain poorly understood. These uncertainties make it difficult to predict influenza pandemics and, therefore, to adequately plan to prevent them. Published 2011. This article is a US Government work and is in the public domain in the USA.

  13. Pandemic influenza: certain uncertainties

    Science.gov (United States)

    Morens, David M.; Taubenberger, Jeffery K.

    2011-01-01

    SUMMARY For at least five centuries, major epidemics and pandemics of influenza have occurred unexpectedly and at irregular intervals. Despite the modern notion that pandemic influenza is a distinct phenomenon obeying such constant (if incompletely understood) rules such as dramatic genetic change, cyclicity, “wave” patterning, virus replacement, and predictable epidemic behavior, much evidence suggests the opposite. Although there is much that we know about pandemic influenza, there appears to be much more that we do not know. Pandemics arise as a result of various genetic mechanisms, have no predictable patterns of mortality among different age groups, and vary greatly in how and when they arise and recur. Some are followed by new pandemics, whereas others fade gradually or abruptly into long-term endemicity. Human influenza pandemics have been caused by viruses that evolved singly or in co-circulation with other pandemic virus descendants and often have involved significant transmission between, or establishment of, viral reservoirs within other animal hosts. In recent decades, pandemic influenza has continued to produce numerous unanticipated events that expose fundamental gaps in scientific knowledge. Influenza pandemics appear to be not a single phenomenon but a heterogeneous collection of viral evolutionary events whose similarities are overshadowed by important differences, the determinants of which remain poorly understood. These uncertainties make it difficult to predict influenza pandemics and, therefore, to adequately plan to prevent them. PMID:21706672

  14. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden

    OpenAIRE

    Tisa, V.; Barberis, I.; Faccio, V.; Paganino, C.; Trucchi, C.; Martini, M.; Ansaldi, F.

    2016-01-01

    Summary Influenza illness is caused by influenza A and influenza B strains. Although influenza A viruses are perceived to carry greater risk because they account for the majority of influenza cases in most seasons and have been responsible for influenza pandemics, influenza B viruses also impose a substantial public health burden, particularly among children and at-risk subjects. Furthermore, since the 2001-2002 influenza season, both influenza B lineages, B/Victoria-like viruses and B/Yamaga...

  15. Vaccination against seasonal influenza

    CERN Multimedia

    DG Unit

    2009-01-01

    As every year, the Medical Service is taking part in the campaign to promote vaccination against seasonal influenza. Vaccination against seasonal influenza is especially recommended for people suffering from chronic lung, cardio-vascular or kidney conditions or diabetes, for those recovering from a serious illness or surgical operation and for everyone over the age of 65. The influenza virus is transmitted by air and contact with contaminated surfaces, hence the importance of washing hands regularly with soap and / or disinfection using a hydro-alcoholic solution. From the onset of symptoms (fever> 38°, chills, cough, muscle aches and / or joint pain, fatigue) you are strongly recommended to stay at home to avoid spreading the virus. In the present context of the influenza A (H1N1) pandemic, it is important to dissociate these two illnesses and emphasise that the two viruses and the vaccines used to combat them are quite different and that protection against one will not pr...

  16. Seasonal Influenza Questions & Answers

    Science.gov (United States)

    ... in Long-Term Care Facilities Guidance: Use of Mask to Control Influenza Transmission Guidance: Prevention & Control in ... overall health impact (e.g., infections, hospitalizations, and deaths) of a flu season varies from season to ...

  17. Vírus influenza

    Directory of Open Access Journals (Sweden)

    Fernanda de-Paris

    2013-06-01

    Full Text Available Um dos registros mais antigos da gripe descrita como doença é de autoria de Hipócrates, em meados do ano 412 a.C. Desta forma, seu agente etiológico, o vírus influenza, tem circulação entre a população humana há muito tempo.  Entretanto, o primeiro isolamento do vírus influenza humano ocorreu somente em 1933, realizado por Smith, Andrewes e Laidlaw, pesquisadores do “National Institute for Medical Research” – Londres. Este vírus isolado foi considerado o primeiro vírus influenza humano e denominado de “influenza A”.

  18. Underutilization of Influenza Vaccine

    Directory of Open Access Journals (Sweden)

    Marshall K. Cheney

    2013-04-01

    Full Text Available Yearly influenza vaccination continues to be underutilized by those who would most benefit from it. The Health Belief Model was used to explain differences in beliefs about influenza vaccination among at-risk individuals resistant to influenza vaccination. Survey data were collected from 74 members of at-risk groups who were not vaccinated for influenza during the previous flu season. Accepting individuals were more likely to perceive flu as a threat to health and perceive access barriers, and cues to action were the most important influence on whether they plan to get vaccinated. In comparison, resistant individuals did not feel threatened by the flu, access barriers were not a problem, and they did not respond favorably to cues to action. Perceived threat, perceived access barriers, and cues to action were significantly associated with plans to be vaccinated for influenza in the next flu season. Participants who saw influenza as a threat to their health had 5.4 times the odds of planning to be vaccinated than those who did not. Participants reporting barriers to accessing influenza vaccination had 7.5 times the odds of reporting plans to be vaccinated. Those responding positively to cues to action had 12.2 times the odds of planning to be vaccinated in the next flu season than those who did not. Accepting and resistant individuals have significant differences in their beliefs, which require different intervention strategies to increase vaccination rates. These findings provide important information to researchers and practitioners working to increase influenza vaccination rates.

  19. Animal and human influenzas.

    Science.gov (United States)

    Peiris, M; Yen, H-L

    2014-08-01

    Influenza type A viruses affect humans and other animals and cause significant morbidity, mortality and economic impact. Influenza A viruses are well adapted to cross species barriers and evade host immunity. Viruses that cause no clinical signs in wild aquatic birds may adapt in domestic poultry to become highly pathogenic avian influenza viruses which decimate poultry flocks. Viruses that cause asymptomatic infection in poultry (e.g. the recently emerged A/H7N9 virus) may cause severe zoonotic disease and pose a major pandemic threat. Pandemic influenza arises at unpredictable intervals from animal viruses and, in its global spread, outpaces current technologies for making vaccines against such novel viruses. Confronting the threat of influenza in humans and other animals is an excellent example of a task that requires a One Health approach. Changes in travel, trade in livestock and pets, changes in animal husbandry practices, wet markets and complex marketing chains all contribute to an increased risk of the emergence of novel influenza viruses with the ability to cross species barriers, leading to epizootics or pandemics. Coordinated surveillance at the animal- human interface for pandemic preparedness, risk assessment, risk reduction and prevention at source requires coordinated action among practitioners in human and animal health and the environmental sciences. Implementation of One Health in the field can be challenging because of divergent short-term objectives. Successful implementation requires effort, mutual trust, respect and understanding to ensure that long-term goals are achieved without adverse impacts on agricultural production and food security.

  20. Avian And Other Zoonotic Influenza

    Science.gov (United States)

    ... outbreaks in poultry have seriously impacted livelihoods, the economy and international trade in affected countries. Other avian influenza A( ... outbreaks in poultry have seriously impacted livelihoods, the economy and international trade in affected countries. Other avian influenza A( ...

  1. Types of Haemophilus influenzae Infections

    Science.gov (United States)

    ... Links Global Hib Vaccination Hib Vaccination Meningitis Pneumonia Sepsis Types of Haemophilus influenzae Infections Recommend on Facebook Tweet Share Compartir H. influenzae most often cause pneumonia, but can also cause severe illnesses like ...

  2. MC Contracting, Paint, & Roofing, LLC Information Sheet

    Science.gov (United States)

    MC Contracting, Paint, & Roofing, LLC, d/b/a M.C. Painting & Contractor and M.C. Painting Group (the Company) is located in Philadelphia, Pennsylvania. The settlement involves renovation activities conducted at property constructed prior to 1978.

  3. Pike International, LLC et al. Information Sheet

    Science.gov (United States)

    Pike International LLC, et al. (the Company) is located in New Haven, Connecticut. The Complaint involves the lease of, and renovation activities conducted at, property constructed prior to 1978, located in New Haven, Connecticut.

  4. RA Construction KC, LLC Information Sheet

    Science.gov (United States)

    RA Construction KC, LLC (the Company) is located in Gladstone, Missouri. The settlement involves renovation activities conducted at a property constructed prior to 1978, located in Kansas City, Missouri.

  5. Improving pandemic influenza risk assessment

    Science.gov (United States)

    Assessing the pandemic risk posed by specific non-human influenza A viruses remains a complex challenge. As influenza virus genome sequencing becomes cheaper, faster and more readily available, the ability to predict pandemic potential from sequence data could transform pandemic influenza risk asses...

  6. Influenza pandemic planning in Europe.

    NARCIS (Netherlands)

    Paget, J.; Aguilera, J.F.

    2001-01-01

    The World Health Organization strongly recommends that all countries prepare in advance multidisciplinary pandemic plans to prevent and control the next influenza pandemic. We carried out a survey of influenza surveillance methods among members of the European Influenza Surveillance Schemes, EISS,

  7. Influenza pandemic planning.

    Science.gov (United States)

    Cox, Nancy J; Tamblyn, Susan E; Tam, Theresa

    2003-05-01

    Periodically, novel influenza viruses emerge and spread rapidly through susceptible populations, resulting in worldwide epidemics or pandemics. Three pandemics occurred in the 20th century. The first and most devastating of these, the "Spanish Flu" (A/H1N1) pandemic of 1918-1919, is estimated to have resulted in 20-50 million or more deaths worldwide, with unusually high mortality among young adults [C.W. Potter, Chronicle of influenza pandemics, in: K.G. Nicholson, R.G. Webster, A.J. Hay (Eds.), Textbook of Influenza, Blackwell Science, Oxford, 1998, p. 3]. Mortality associated with the 1957 "Asian Flu" (A/H2N2) and the 1968 "Hong Kong Flu" (A/H3N2) pandemics was less severe, with the highest excess mortality in the elderly and persons with chronic diseases [J. Infect. Dis. 178 (1998) 53]. However, considerable morbidity, social disruption and economic loss occurred during both of these pandemics [J. Infect. Dis. 176 (Suppl. 1) (1997) S4]. It is reasonable to assume that future influenza pandemics will occur, given historical evidence and current understanding of the biology, ecology, and epidemiology of influenza. Influenza viruses are impossible to eradicate, as there is a large reservoir of all subtypes of influenza A viruses in wild aquatic birds. In agricultural-based communities with high human population density such as are found in China, conditions exist for the emergence and spread of pandemic viruses. It is also impossible to predict when the next pandemic will occur. Moreover, the severity of illness is also unpredictable, so contingency plans must be put in place now during the inter-pandemic period. These plans must be flexible enough to respond to different levels of disease.

  8. 77 FR 9231 - FFP Missouri 17, LLC; BOST2 Hydroelectric, LLC; Notice Announcing Preliminary Permit Drawing

    Science.gov (United States)

    2012-02-16

    .... 13826-000] FFP Missouri 17, LLC; BOST2 Hydroelectric, LLC; Notice Announcing Preliminary Permit Drawing... of the Commission, or her designee, will conduct a random drawing to determine the filing priority of... applications as provided in section 4.37 of its regulations.\\2\\ The priority established by this drawing will...

  9. 76 FR 4893 - FFP Missouri 13, LLC, Grays Hydro, LLC; Notice Announcing Preliminary Permit Drawing

    Science.gov (United States)

    2011-01-27

    .... 13772-000] FFP Missouri 13, LLC, Grays Hydro, LLC; Notice Announcing Preliminary Permit Drawing January... Commission, or her designee, will, by random drawing, determine the filing priority for the two applicants identified in this notice. The drawing is open to the public and will be held in room 2C, the Commission...

  10. 75 FR 34170 - Plastic Omnium Automotive Exteriors, LLC, Anderson, SC; Plastic Omnium Automotive Exteriors, LLC...

    Science.gov (United States)

    2010-06-16

    ... Employment and Training Administration Plastic Omnium Automotive Exteriors, LLC, Anderson, SC; Plastic Omnium... Assistance on March 18, 2010, applicable to workers of Plastic Omnium Automotive Exteriors, LLC, Anderson... have occurred involving workers in support of the Anderson, South Carolina location of Plastic Omnium...

  11. 75 FR 45108 - Enterprise Alabama Intrastate, LLC Yankee Gas Services Company Kinder Morgan Tejas Pipeline LLC...

    Science.gov (United States)

    2010-08-02

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. PR10-63-000; Docket No. PR10-64-000; Docket No. PR10-66- 000] Enterprise Alabama Intrastate, LLC Yankee Gas Services Company Kinder Morgan Tejas Pipeline LLC (Not Consolidated); Notice of Baseline Filings July 26, 2010. Take...

  12. 75 FR 76726 - Transmission Technology Solutions, LLC; Western Grid Development, LLC (Complainants) v...

    Science.gov (United States)

    2010-12-09

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Transmission Technology Solutions, LLC; Western Grid Development, LLC... Procedure, 18 CFR 385.206 and section 206 of the Federal Power Act (FPA), Transmission Technology Solutions...

  13. 78 FR 77618 - Airworthiness Directives; M7 Aerospace LLC Airplanes

    Science.gov (United States)

    2013-12-24

    ... Federal Aviation Administration 14 CFR Part 39 RIN 2120-AA64 Airworthiness Directives; M7 Aerospace LLC...). SUMMARY: We propose to adopt a new airworthiness directive (AD) for all M7 Aerospace LLC Models SA226-AT... bulkhead. This proposed AD also requires reporting certain inspection results to M7 Aerospace LLC. We are...

  14. Equine influenza in Brazil

    Directory of Open Access Journals (Sweden)

    Patricia Filippsen Favaro

    2016-06-01

    Full Text Available Equine influenza virus (EIV (H3N8 and H7N7 is the causative agent of equine influenza, or equine flu. The H7N7 subtype has been considered to be extinct worldwide since 1980. Affected animals have respiratory symptoms that can be worsened by secondary bacterial respiratory infection, thereby leading to great economic losses in the horse-breeding industry. In Brazil, equine influenza outbreaks were first reported in 1963 and studies on hemagglutination antibodies against viral subtypes in Brazilian horses have been conducted since then. The objective of the present review was to present the history of the emergence of EIV around the world and in Brazil and the studies that have thus far been developed on EIV in Brazilian equines.

  15. 77 FR 39695 - HollyFrontier Refining and Marketing LLC v. Osage Pipe Line Company, LLC; Notice of Complaint

    Science.gov (United States)

    2012-07-05

    ... Refining and Marketing LLC v. Osage Pipe Line Company, LLC; Notice of Complaint Take notice that on June 25...; 18 CFR 343.1(a) and 343.2(c), HollyFrontier Refining and Marketing LLC (Complainant) filed a formal... assistance with any FERC Online service, please email [email protected] , or call (866) 208-3676...

  16. 78 FR 5798 - Grouse Creek Wind Park, LLC, Grouse Creek Wind Park II, LLC; Notice of Petition for Enforcement

    Science.gov (United States)

    2013-01-28

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Grouse Creek Wind Park, LLC, Grouse Creek Wind Park II, LLC; Notice of... Utility Regulatory Policies Act of 1978 (PURPA), Grouse Creek Wind Park, LLC and Grouse Creek Wind Park II...

  17. 78 FR 49509 - Lock+ Hydro Friends Fund XXX, LLC; FFP Project 121, LLC; Notice Announcing Preliminary Permit...

    Science.gov (United States)

    2013-08-14

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [ Project No. 13625-003; Project No. 14504-000] Lock+ Hydro Friends Fund XXX, LLC; FFP Project 121, LLC; Notice Announcing Preliminary Permit... and Jefferson County, Ohio. The applications were filed by Lock+ Hydro Friends Fund XXX, LLC for...

  18. 75 FR 11916 - Chrysler Group LLC, Formerly Known as Chrysler LLC, Conner Avenue Assembly Plant, Including On...

    Science.gov (United States)

    2010-03-12

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF LABOR Employment and Training Administration Chrysler Group LLC, Formerly Known as Chrysler LLC, Conner Avenue Assembly Plant, Including On-Site Leased Workers From Aerotek, CDI, Syncreon and Caravan Knight Facilities Management LLC; Detriot, MI; Amended...

  19. 75 FR 11916 - Chrysler Transportation LLC, a Subsidiary of Chrysler LLC, Including On-Site Leased Workers from...

    Science.gov (United States)

    2010-03-12

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF LABOR Employment and Training Administration Chrysler Transportation LLC, a Subsidiary of Chrysler LLC, Including On-Site Leased Workers from Caravan Knight Facilities Management LLC; Detroit, MI: Amended Certification Regarding Eligibility To Apply for Worker...

  20. 75 FR 40818 - Green Energy Express LLC; 21st Century Transmission Holdings, LLC; Notice of Petition for...

    Science.gov (United States)

    2010-07-14

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Green Energy Express LLC; 21st Century Transmission Holdings, LLC; Notice of Petition for Declaratory Order July 8, 2010. Take notice that on July 2, 2010, Green Energy Express LLC and...

  1. Influenza Vaccines: Unmet Needs and Recent Developments

    Science.gov (United States)

    Noh, Ji Yun

    2013-01-01

    Influenza is a worldwide public health concern. Since the introduction of trivalent influenza vaccine in 1978, vaccination has been the primary means of prevention and control of influenza. Current influenza vaccines have moderate efficacy, good safety, and acceptable tolerability; however, they have unsatisfactory efficacy in older adults, are dependent on egg supply for production, and are time-consuming to manufacture. This review outlines the unmet medical needs of current influenza vaccines. Recent developments in influenza vaccines are also described. PMID:24475351

  2. Hablemos de la Influenza

    Centers for Disease Control (CDC) Podcasts

    2010-12-08

    En la charla, un médico responde a las preguntas frecuentes sobre la vacuna contra la influenza (gripe).  Created: 12/8/2010 by Centro Nacional para la Inmunización y Enfermedades Respiratorias (NCIRD).   Date Released: 12/8/2010.

  3. Vaccination against seasonal influenza

    CERN Multimedia

    SC Unit

    2009-01-01

    As every year, the Medical Service is taking part in the campaign to promote vaccination against seasonal influenza. Vaccination against seasonal influenza is especially recommended for people suffering from chronic lung, cardio-vascular or kidney conditions or diabetes, for those recovering from a serious illness or surgical operation and for everyone over the age of 65. The influenza virus is transmitted by air and contact with contaminated surfaces, hence the importance of washing hands regularly with soap and / or disinfection using a hydro-alcoholic solution. From the onset of symptoms (fever> 38°, chills, cough, muscle aches and / or joint pain, fatigue) you are strongly recommended to stay at home to avoid spreading the virus. In the present context of the influenza A (H1N1) pandemic, it is important to dissociate these two illnesses and emphasise that the two viruses and the vaccines used to combat them are quite different and that protection against one will not provide protection against the...

  4. Equine influenza: An overview

    Directory of Open Access Journals (Sweden)

    S. P. Waghmare

    2010-08-01

    Full Text Available Equine influenza virus is a leading cause of respiratory disease in the horses. The disease is the OIE listed disease of equines, ponies, mules and donkeys and spreads very fast. The sporadic outbreaks of the disease have occurred all over the country. Many cases have been reported in Delhi, Meerut, Saharanpur, Jaipur, Hisar, Calcutta, Ahmedabad. Nearly all the horses at Matheran (Hill station were infected with influenza. The disease has spread like wildfire at the stables of Royal Western India Turf Club (RWITC at Pune and suspended the Mumbai racing season for prolonged period of time resulting in marked economic losses. After affecting racing in Mumbai, Calcutta and New Delhi, the dreaded equine influenza has spread to Karnataka and Mysore. An outbreak of disease has marred the racing season across the country. The disease was first detected in Jammu & Kashmir before entering the central region Horses at the army polo clubs and Delhi equestrian center were also affected. As per the recent survey conducted by the army across India, it has been found that 5400 horses are infected so far, especially thoroughbred most severely. Nearly, 95 % of horses on a major farm in India are suspected of suffering from equine influenza. The government also banned inter-state movement of horses for three months to contain the disease. [Vet World 2010; 3(4.000: 194-197

  5. Haemophilus influenzae Disease (Including Hib) Symptoms

    Science.gov (United States)

    ... Links Global Hib Vaccination Hib Vaccination Meningitis Pneumonia Sepsis ... Haemophilus influenzae , including H. influenzae type b or Hib, can cause many different kinds of infections . Symptoms depend on ...

  6. 78 FR 69910 - Joint Industry Plan; BATS Exchange, Inc., BATS-Y Exchange, Inc., BOX Options Exchange LLC, C2...

    Science.gov (United States)

    2013-11-21

    ... International Securities Exchange LLC, NASDAQ OMX BX, Inc., NASDAQ OMX PHLX LLC, The NASDAQ Stock Market LLC... Exchange, Inc., Financial Industry Regulatory Authority, Inc., International Securities Exchange, LLC, Miami International Securities Exchange LLC, NASDAQ OMX BX, Inc., NASDAQ OMX PHLX LLC, The NASDAQ Stock...

  7. Novel vaccines against influenza viruses

    OpenAIRE

    Kang, Sang-Moo; Song, Jae-Min; Compans, Richard W.

    2011-01-01

    Killed and live attenuated influenza virus vaccines are effective in preventing and curbing the spread of influenza epidemics when the strains present in the vaccines are closely matched with the predicted epidemic strains. These vaccines are primarily targeted to induce immunity to the variable major target antigen, hemagglutinin (HA) of influenza virus. However, current vaccines are not effective in preventing the emergence of new pandemic or highly virulent viruses. New approaches are bein...

  8. 78 FR 9687 - Prineville Energy Storage, LLC; Notice of Preliminary Permit Application Accepted for Filing and...

    Science.gov (United States)

    2013-02-11

    ... Energy Regulatory Commission Prineville Energy Storage, LLC; Notice of Preliminary Permit Application..., 2012, Prineville Energy Storage, LLC, filed an application for a preliminary permit, pursuant to...-hours. Applicant Contact: Mr. Matthew Shapiro, Chief Executive Officer, Prineville Energy Storage, LLC...

  9. [Neurological complication of influenza infections].

    Science.gov (United States)

    Brydak, Lidia B

    2002-01-01

    The aim of this study was to present neurological complications of influenza infections. Infections caused by influenza viruses can be very serious and may lead even to death resulted from the post-infectious complications. The most often occurring complications are pneumonia, bronchitis, bronchiolitis, myocarditis and otitis media. The other group is neurological post-influenza complications, including dementia, epileptic disorders, cerebrovascular disease, febrile convulsions, toxic encephalopathy, encephalitis, meningitis, subarachnoid hemorrhages, lethargic encephalitis, psychosis or increase in the number of cases of Parkinson's disease. The first way of prevention of influenza is vaccination that results in healthy, social and economic benefits.

  10. 75 FR 61463 - The Narragansett Electric Company; Arcadia Gas Storage, LLC; Salt Plains Storage, LLC; Jefferson...

    Science.gov (United States)

    2010-10-05

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. PR10-114-000; Docket No. PR10-117-000; Docket No. PR10-118- 000; Docket No. PR10-119-000; Docket No. PR10-120-000; Docket No. PR10- 121-000; Docket No. PR10-122-000 (Not Consolidated)] The Narragansett Electric Company; Arcadia Gas Storage, LLC; Salt Plains Storage, LLC;...

  11. 78 FR 58533 - FirstEnergy Generation, LLC, Allegheny Energy Supply Company, LLC, and Green Valley Hydro, LLC...

    Science.gov (United States)

    2013-09-24

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project Nos. 2280-017, 2343-084, 2459-245, 2516-057, 2517-036, 3494- 091, 3671-086, 2391-046, 2425-052, and 2509-046] FirstEnergy Generation, LLC, Allegheny Energy Supply...

  12. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study

    NARCIS (Netherlands)

    Caini, S.; Huang, Q.S.; Ciblak, M.A.; Kusznierz, G.; Owen, R.; Wangchuk, S.; Henriques, C.M.P.; Njouom, R.; Fasce, R.A.; Yu, H.J.; Feng, L.Z.; Zambon, M.; Clara, A.W.; Kosasih, H.; Puzelli, S.; Kadjo, H.A.; Emukule, G.; Heraud, J.M.; Ang, L.W.; Venter, M.; Mironenko, A.; Brammer, L.; Mai, L.T.Q.; Schellevis, F.G.; Plotkin, S.; Paget, J.

    2015-01-01

    Introduction: Literature on influenza focuses on influenza A, despite influenza B having a large public health impact. The Global Influenza B Study aims to collect information on global epidemiology and burden of disease of influenza B since 2000. Methods: Twenty-six countries in the Southern (n=5)

  13. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study

    NARCIS (Netherlands)

    Caini, S.; Huang, Q.S.; Ciblak, M.A.; Kusznierz, G.; Owen, R.; Wangchuk, S.; Henriques, C.M.; Njouom, R.; Fasce, R.A.; Yu, H.; Feng, L.; Zambon, M.; Clara, A.W.; Kosasih, H.; Puzelli, S.; Kadjo, H.A.; Emukule, G.; Heraud, J.M.; Ang, L.W.; Venter, M.; Mironenko, A.; Brammer, L.; Mai, T.Q. le; Schellevis, F.; Plotkin, S.; Paget, J.

    2015-01-01

    INTRODUCTION: Literature on influenza focuses on influenza A, despite influenza B having a large public health impact. The Global Influenza B Study aims to collect information on global epidemiology and burden of disease of influenza B since 2000. METHODS: Twenty-six countries in the Southern (n =

  14. Epidemiological and virological characteristics of influenza B: results of the global influenza B study.

    NARCIS (Netherlands)

    Caini, S.; Sue Huang, Q.; Ciblak, M.A.; Kusznierz, G.; Owen, R.; Wangchuk, S.; Henriques, C.M.P.; Njouom, R.; Fasce, R.A.; Yu, H.; Feng, L.; Zambon, M.; Clara, A.W.; Kosasih, H.; Puzelli, S.; Kasjo, H.A.; Emukule, G.; Hereaud, J.M.; Ang, L.W.; Venter, M.; Mironenko, A.; Brammer, L.; Mai, L.T.Q.; Schellevis, F.; Plotkin, S.; Paget, J.

    2015-01-01

    Introduction: Literature on influenza focuses on influenza A, despite influenza B having a large public health impact. The Global Influenza B Study aims to collect information on global epidemiology and burden of disease of influenza B since 2000. Methods Twenty-six countries in the Southern (n = 5)

  15. Anti-pandemic influenza A(H1N1) virus potential of catechin and gallic acid.

    Science.gov (United States)

    You, Huey-Ling; Huang, Chao-Chun; Chen, Chung-Jen; Chang, Cheng-Chin; Liao, Pei-Lin; Huang, Sheng-Teng

    2017-12-26

    The pandemic influenza A (H1N1) virus has spread worldwide and infected a large proportion of the human population. Discovery of new and effective drugs for the treatment of influenza is a crucial issue for the global medical community. According to our previous study, TSL-1, a fraction of the aqueous extract from the tender leaf of Toonasinensis, has demonstrated antiviral activities against pandemic influenza A (H1N1) through the down-regulation of adhesion molecules and chemokine to prevent viral attachment. The aim of the present study was to identify the active compounds in TSL-1 which exert anti-influenza A (H1N1) virus effects. XTT assay was used to detect the cell viability. Meanwhile, the inhibitory effect on the pandemic influenza A (H1N1) virus was analyzed by observing plaque formation, qRT-PCR, neuraminidase activity, and immunofluorescence staining of influenza A-specific glycoprotein. Both catechin and gallic acid were found to be potent inhibitors in terms of influenza virus mRNA replication and MDCK plaque formation. Additionally, both compounds inhibited neuraminidase activities and viral glycoprotein. The 50% effective inhibition concentration (EC 50 ) of catechin and gallic acid for the influenza A (H1N1) virus were 18.4 μg/mL and 2.6 μg/mL, respectively; whereas the 50% cytotoxic concentrations (CC 50 ) of catechin and gallic acid were >100 μg/mL and 22.1 μg/mL, respectively. Thus, the selectivity indexes (SI) of catechin and gallic acid were >5.6 and 22.1, respectively. The present study demonstrates that catechin might be a safe reagent for long-term use to prevent influenza A (H1N1) virus infection; whereas gallic acid might be a sensitive reagent to inhibit influenza virus infection. We conclude that these two phyto-chemicals in TSL-1 are responsible for exerting anti-pandemic influenza A (H1N1) virus effects. Copyright © 2017. Published by Elsevier Taiwan LLC.

  16. [Influenza vaccine and adjuvant].

    Science.gov (United States)

    Nakayama, Tetsuo

    2011-01-01

    Adjuvant is originated from the Latin word "adjuvare" which means "help" in English to enhance the immunological responses when given together with antigens. The beginning of adjuvant was mineral oil which enhanced the immune response when it was given with inactivated Salmonella typhimurium. Aluminium salt was used to precipitate diphtheria toxoid and increased level of antibody response was demonstrated when administered with alum-precipitated antigens. Since 1930, aluminium salt has been used as DTaP (diphtheria-tetanus-acellular pertussis vaccine) adjuvant. Many candidates were tested for adjuvant activity but only aluminum salt is allowed to use for human vaccines. New adjuvant MF59, oil-in-water emulsion type, was developed for influenza vaccine for elderly (Fluad) and series of AS adjuvant are used for hepatitis B, pandemic flue, and human papiloma virus vaccines. Oil-adjuvanted influenza pandemic vaccines induced higher antibody response than alum-adjuvanted vaccine with higher incidence of adverse events, especially for local reactions. Alum-adjuvanted whole virion inactivated H5N1 vaccine was developed in Japan, and it induced relatively well immune responses in adults. When it applied for children, febrile reaction was noted in approximately 60% of the subjects, with higher antibodies. Recent investigation on innate immunity demonstrates that adjuvant activity is initiated from the stimulation on innate immunity and/or inflammasome, resulting in cytokine induction and antigen uptake by monocytes and macrophages. The probable reason for high incidence of febrile reaction should be investigated to develop a safe and effective influenza vaccine.

  17. Influenza vaccinations : who needs them and when?

    NARCIS (Netherlands)

    Hak, Eelko; Hoes, Arno W; Verheij, Theo J M

    2002-01-01

    Influenza vaccination programmes should aim at reducing the burden from influenza among those who need it most. The primary aim of this literature review is to identify who should receive priority in influenza vaccination programmes. Risk factors for severe post-influenza complications include

  18. Rekonvalescens og sygemelding efter influenza

    DEFF Research Database (Denmark)

    Pedersen, Court

    2009-01-01

    Seasonal influenza has a significant impact on individuals and society alike. In otherwise healthy adults, a typical case of seasonal influenza is associated with six to eight days of clinical symptoms, and about four to five days of sick leave. Transmission mainly takes place during the initial...

  19. Avian influenza surveillance and diagnosis

    Science.gov (United States)

    Rapid detection and accurate identification of low (LPAI) and high pathogenicity avian influenza (HPAI) is critical to controlling infections and disease in poultry. Test selection and algorithms for the detection and diagnosis of avian influenza virus (AIV) in poultry may vary somewhat among differ...

  20. Influenza SIRS with Minimal Pneumonitis.

    Science.gov (United States)

    Erramilli, Shruti; Mannam, Praveen; Manthous, Constantine A

    2016-01-01

    Although systemic inflammatory response syndrome (SIRS) is a known complication of severe influenza pneumonia, it has been reported very rarely in patients with minimal parenchymal lung disease. We here report a case of severe SIRS, anasarca, and marked vascular phenomena with minimal or no pneumonitis. This case highlights that viruses, including influenza, may cause vascular dysregulation causing SIRS, even without substantial visceral organ involvement.

  1. Influenza SIRS with Minimal Pneumonitis

    OpenAIRE

    Erramilli, Shruti; Mannam, Praveen; Manthous, Constantine A.

    2016-01-01

    Although systemic inflammatory response syndrome (SIRS) is a known complication of severe influenza pneumonia, it has been reported very rarely in patients with minimal parenchymal lung disease. We here report a case of severe SIRS, anasarca, and marked vascular phenomena with minimal or no pneumonitis. This case highlights that viruses, including influenza, may cause vascular dysregulation causing SIRS, even without substantial visceral organ involvement.

  2. Influenza as a human disease

    Indian Academy of Sciences (India)

    First page Back Continue Last page Graphics. Influenza as a human disease. Commonly perceived as a mild disease, affects every one, sometimes a couple of times in a year. Globally, seasonal influenza epidemics result in about three to five million yearly cases of severe illness and about 250,000 to 500,000 yearly ...

  3. Novel vaccines against influenza viruses.

    Science.gov (United States)

    Kang, S M; Song, J M; Compans, R W

    2011-12-01

    Killed and live attenuated influenza virus vaccines are effective in preventing and curbing the spread of influenza epidemics when the strains present in the vaccines are closely matched with the predicted epidemic strains. These vaccines are primarily targeted to induce immunity to the variable major target antigen, hemagglutinin (HA) of influenza virus. However, current vaccines are not effective in preventing the emergence of new pandemic or highly virulent viruses. New approaches are being investigated to develop universal influenza virus vaccines as well as to apply more effective vaccine delivery methods. Conserved vaccine targets including the influenza M2 ion channel protein and HA stalk domains are being developed using recombinant technologies to improve the level of cross protection. In addition, recent studies provide evidence that vaccine supplements can provide avenues to further improve current vaccies. Copyright © 2011 Elsevier B.V. All rights reserved.

  4. A multioutput LLC-type parallel resonant converter

    Science.gov (United States)

    Liu, Rui; Lee, C. Q.; Upadhyay, Anand K.

    1992-07-01

    When an LLC-type parallel resonant converter (LLC-PRC) operates above resonant frequency, the switching transistors can be turned off at zero voltage. Further study reveals that the LLC-PRC possesses the advantage of lower converter voltage gain as compared with the conventional PRC. Based on analytic results, a complete set of design curves is obtained, from which a systematic design procedure is developed. Experimental results from a 150 W 150 kHz multioutput LLC-type PRC power supply are presented.

  5. Now and future influenza vaccines.

    Science.gov (United States)

    Ruben, F L

    1990-03-01

    Influenza is a modern day plague. In the young, the clinical picture is classical, but in the elderly, the disease may go unsuspected until complications such as pneumonia develop. Influenza A and B viruses are responsible, and these viruses mutate with great regularity. Antibodies to the HA and NA surface antigens of influenza viruses, both naturally and vaccine induced, are protective. The earliest influenza vaccines were crude, toxic, and ineffective. With modern purification techniques, the egg-grown viruses have been turned into safe, immunogenic, and effective killed-virus vaccines--whole virus and split virus. Surveillance permits the correct virus strains to be incorporated into each new vaccine. Those who have been experiencing the worst effects of influenza have been identified. These individuals need to be immunized each year. In the future, live influenza virus vaccines may offer the benefits of ease of administration and longer-lasting protection. Synthetic peptides, genetically engineered antigens, and even nonantigen (anti-idiotype) vaccines are possible, but such vaccines will require adjuvant enhancement. For the present, greater efforts must be made to use existing influenza vaccines.

  6. Animal influenza epidemiology.

    OpenAIRE

    Ducatez, Mariette; Webster, R G; Webby, R J

    2008-01-01

    Influenza A viruses exist within their natural host, aquatic birds, in a number of antigenic subtypes. Only a few of these subtypes have successfully crossed into other avian and mammalian hosts. This brief review will focus on just three examples of viruses that have successfully passed between species; avian H5NI1 and H9N2 viruses and H3N2 viruses which have transmitted from aquatic birds to humans and then to swine. Although there are a number of other subtypes that have also transmitted s...

  7. Psychological determinants of influenza vaccination.

    Science.gov (United States)

    Bock, Jens-Oliver; Hajek, André; König, Hans-Helmut

    2017-08-29

    Previous studies investigated the determinants of individuals' decision to vaccinate against influenza primarily focusing on social as well as certain proximal determinants, for example, behavioral beliefs. Thus, so far, the analysis of psychological factors as determinants of influenza vaccination was mainly limited to beliefs, attitudes or perceptions that were directly related to influenza vaccination and its perceived impact. However, considering general psychological factors, like general self-efficacy, optimism or subjective well-being, might further enhance the understanding of why certain people vaccinate while others do not. The aim was to investigate the relationship between various general psychological factors and older people's decision to vaccinate against seasonal flu. The data of individuals aged 60 or older (n = 5037; in 2014) were used from the Germany Ageing Survey. The data were collected in face-to-face interviews and in self-administered questionnaires. They include questions on the use of influenza vaccination and the psychological factors of optimism, self-efficacy, self-esteem, perceived stress, self-regulation, life satisfaction, and negative affect as well as positive affect. The psychological determinants of regular influenza vaccination were investigated using multiple logistic regressions. 53.2% of all participants were regular users of influenza vaccination. There were significant bivariate correlations of all cited psychological factor with influenza vaccination except for life satisfaction and negative affect. After controlling for numerous potential socio-demographic, morbidity- and lifestyle-related confounders, regular influenza vaccination was still positively associated with lower levels of self-esteem and a higher level of perceived stress. There are significant associations of general individual psychological constructs with the decision to vaccinate against influenza. Future research might determine the impact of

  8. 75 FR 68396 - Mississippi & Skuna Valley Railroad, LLC-Acquisition and Operation Exemption-Mississippi & Skuna...

    Science.gov (United States)

    2010-11-05

    ... Railway, LLC, Dequeen and Eastern Railroad, LLC, Golden Triangle Railroad, LLC, Mississippi & Skuna Valley... and Operation Exemption--DeQueen and Eastern Railroad Company; (3) Docket No. FD 35428, Golden Triangle Railroad, LLC--Acquisition and Operation Exemption--Golden Triangle Railroad Company; (4) Docket...

  9. 75 FR 68400 - Columbia & Cowlitz Railway, LLC-Acquisition and Operation Exemption-Columbia & Cowlitz Railway...

    Science.gov (United States)

    2010-11-05

    ... Eastern Railroad, LLC, Golden Triangle Railroad, LLC, Mississippi & Skuna Valley Railroad, LLC, Patriot... Railroad Company; (2) Docket No. FD 35428, Golden Triangle Railroad, LLC--Acquisition and Operation Exemption--Golden Triangle Railroad Company; (3) Docket No. FD 35429, Mississippi & Skuna Valley Railroad...

  10. Influenza em animais heterotérmicos Influenza in heterothermics

    Directory of Open Access Journals (Sweden)

    Dalva Assunção Portari Mancini

    2004-06-01

    Full Text Available O objetivo foi pesquisar Ortomyxovirus em animais heterotérmicos. Coletou-se sangue de serpentes dos gêneros Bothrops e Crotalus e de sapo e rãs dos gêneros Bufo e Rana, para a detecção dos receptores de hemácias e anticorpos específicos, ao vírus influenza, pelos testes de hemaglutinação e inibição da hemaglutinação, respectivamente. Pelo teste de hemaglutinação, verificou-se que serpentes e sapos em cativeiro apresentaram receptores em suas hemácias para o vírus influenza, humano e eqüino do tipo A e tipo B. O mesmo ocorreu com serpentes recém chegadas. Quanto ao teste de inibição da hemaglutinação dos soros dos répteis observou-se títulos protetores de anticorpos aos vírus influenza tipo A (origens humana e eqüina e tipo B. Com soro de sapo não se observou reação de inibição da hemaglutinação porém, 83,3% das rãs obtiveram médias de 40UIH para algumas cepas. Conclui-se que animais heterotérmicos podem oferecer condições de hospedeiros aos vírus influenza, assim como susceptibilidade à infecção.The objective was to study Orthomyxovirus in heterothermic animals. Blood samples from snakes (genus Bothrops and Crotalus and from toads and frogs (genus Bufo and Rana were collected to evaluate the red cell receptors and antibodies specific to influenza virus by the hemagglutination and hemagglutination inhibition tests, respectively. Both snakes and toads kept in captivity presented receptors in their red cells and antibodies specific to either influenza virus type A (human and equine origin or influenza type B. The same was observed with recently captured snakes. Concerning the influenza hemagglutination inhibition antibodies protective levels were observed in the reptiles' serum, against influenza type A and type B. Unlike the toads, 83.3% of the frogs presented mean levels of Ab 40HIU for some influenza strains. It was concluded that heterothermic animals could offer host conditions to the influenza

  11. [Neurological outcome associated with influenza viral infection].

    Science.gov (United States)

    Kamimura, N; Matsuzaka, T; Tsuji, Y

    1997-04-01

    Several neurological complications associated with Influenza virus infection are known as a febrile convulsion, polyneuritis, meningitis, encephalomyelitis and encephalopathy. Influenza encephalopathy is the most severe complication associated with Influenza. It may be classified into several subtypes according to the clinical symptoms and laboratory data. In this review, Reye's syndrome, acute necrotizing encephalopathy and hemorrhagic shock and encephalopathy syndrome (HSE) are described in detail. The 1995 influenza pandemia in Nagasaki prefecture was markedly neurovirulent and lethal. Twelve cases developed influenza encephalopathy, and the mortality rate between them was 50%. Almost all of them had never be inoculated of influenza vaccine before.

  12. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines

    Science.gov (United States)

    Sridhar, Saranya; Brokstad, Karl A.; Cox, Rebecca J.

    2015-01-01

    Influenza is a major respiratory pathogen causing annual outbreaks and occasional pandemics. Influenza vaccination is the major method of prophylaxis. Currently annual influenza vaccination is recommended for groups at high risk of complications from influenza infection such as pregnant women, young children, people with underlying disease and the elderly, along with occupational groups such a healthcare workers and farm workers. There are two main types of vaccines available: the parenteral inactivated influenza vaccine and the intranasal live attenuated influenza vaccine. The inactivated vaccines are licensed from 6 months of age and have been used for more than 50 years with a good safety profile. Inactivated vaccines are standardized according to the presence of the viral major surface glycoprotein hemagglutinin and protection is mediated by the induction of vaccine strain specific antibody responses. In contrast, the live attenuated vaccines are licensed in Europe for children from 2–17 years of age and provide a multifaceted immune response with local and systemic antibody and T cell responses but with no clear correlate of protection. Here we discuss the immunological immune responses elicited by the two vaccines and discuss future work to better define correlates of protection. PMID:26343192

  13. 76 FR 4103 - ETC Tiger Pipeline, LLC; Notice of Filing

    Science.gov (United States)

    2011-01-24

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. AC11-25-000] ETC Tiger Pipeline, LLC; Notice of Filing January 13, 2011. Take notice that on December 30, 2010, ETC Tiger Pipeline, LLC submitted a request for a waiver of the reporting requirement to file the FERC Form 2 for 2010...

  14. 75 FR 38799 - ETC Tiger Pipeline, LLC; Notice of Application

    Science.gov (United States)

    2010-07-06

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. CP10-459-000] ETC Tiger Pipeline, LLC; Notice of Application June 25, 2010. Take notice that on June 15, 2010, ETC Tiger Pipeline, LLC (ETC Tiger), 711 Louisiana Street, Suite 900, Houston, Texas 77002, filed an application in Docket...

  15. 77 FR 20442 - Sunwest Rollover Member LLC; Notice of Application

    Science.gov (United States)

    2012-04-04

    ... or, for lawyers, a certificate of service. Hearing requests should state the nature of the writer's... (``TIC Investors'') and limited liability company interests (``LLC Investors'') in properties owned by... of Title 11 of the United States Code. \\4\\ The TIC Investors and the LLC Investors are referred to...

  16. 77 FR 56837 - Enterprise Intrastate LLC; Notice of Filing

    Science.gov (United States)

    2012-09-14

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. PR12-34-000] Enterprise Intrastate LLC; Notice of Filing Take notice that on September 6, 2012, Enterprise Intrastate LLC (Enterprise.... Enterprise Intrastate is revising its SOC to replace all references to ``Enterprise Intrastate L.P.'' with...

  17. 76 FR 42704 - Sky River LLC; Notice of Filing

    Science.gov (United States)

    2011-07-19

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket Nos. ER11-3277-000; ER11-3277-001] Sky River LLC; Notice of Filing Take notice that, on July 8, 2011, Sky River LLC filed to amend its Open Access Transmission Tariff (OATT) filing, submitted on April 1, 2011 and amended on April 7...

  18. 76 FR 48841 - Liberty Gas Storage, LLC; Notice of Filing

    Science.gov (United States)

    2011-08-09

    ... Energy Regulatory Commission Liberty Gas Storage, LLC; Notice of Filing Take notice that on July 25, 2011, Liberty Gas Storage, LLC (Liberty) submitted a request for confirmation that it is not required to file... Liberty exceed 200,000 Dth for three consecutive calendar years. Liberty argues that given the low levels...

  19. 75 FR 45610 - Liberty Gas Storage LLC; Notice of Amendment

    Science.gov (United States)

    2010-08-03

    ... Energy Regulatory Commission Liberty Gas Storage LLC; Notice of Amendment Take notice that on July 26, Liberty Gas Storage LLC (``Liberty''), 101 Ash Street, San Diego, CA 92101, filed in the above referenced... directed to William Rapp, Liberty Gas Storage, 101 Ash Street, San Diego, CA 92101, phone (619) 699-5050...

  20. 75 FR 67352 - Liberty Natural Gas, LLC; Notice of Application

    Science.gov (United States)

    2010-11-02

    ... Energy Regulatory Commission Liberty Natural Gas, LLC; Notice of Application October 26, 2010. On October 14, 2010, Liberty Natural Gas, LLC (Liberty) filed with the Federal Energy Regulatory Commission... Onshore Pipeline is a part of the Liberty Natural Gas Project, which will include a deepwater port (Port...

  1. 75 FR 74703 - Leader One Energy, LLC; Notice of Application

    Science.gov (United States)

    2010-12-01

    ... FEDERAL ENERGY REGULATORY COMMISSION [Docket Nos. CP11-33-000; PF10-15-000] Leader One Energy, LLC; Notice of Application November 23, 2010 Take notice that on November 15, 2010, Leader One Energy, LLC (Leader One), 4643 South Ulster Street, Suite 1100, Denver, Colorado 80237, filed in Docket No. CP11-33...

  2. 78 FR 938 - Burton Creek Hydro Inc., Sollos Energy, LLC'

    Science.gov (United States)

    2013-01-07

    ... Licensing of a Small Hydroelectric Project of 5 Megawatts or Less. 2. Sollos Energy, LLC, Mr. Samuel Perry... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 7577-012] Burton Creek Hydro Inc., Sollos Energy, LLC' Notice of Transfer of Exemption 1. By letter filed December 19, 2012...

  3. 77 FR 54787 - Airworthiness Directives; M7 Aerospace LLC Airplanes

    Science.gov (United States)

    2012-09-06

    ...-17177; AD 2012-18-01] RIN 2120-AA64 Airworthiness Directives; M7 Aerospace LLC Airplanes AGENCY: Federal... new airworthiness directive (AD) for all M7 Aerospace LLC Models SA226-AT, SA226-T, SA226-T(B), SA226... information identified in this AD, contact M7 Aerospace LP, 10823 NE Entrance Road, San Antonio, Texas 78216...

  4. 76 FR 46786 - Millennium Pipeline Company, LLC; Notice of Application

    Science.gov (United States)

    2011-08-03

    ... Energy Regulatory Commission Millennium Pipeline Company, LLC; Notice of Application Take notice that on July 14, 2011, Millennium Pipeline Company, LLC (Millennium), One Blue Hill Plaza, Seventh Floor, P.O.... These facilities will enable Millennium to increase firm deliveries to its interconnection with...

  5. Avian And Other Zoonotic Influenza

    Science.gov (United States)

    ... consultations Fact sheets Fact files Questions & answers Features Multimedia Contacts Influenza (Avian and other zoonotic) Fact sheet ... respiratory tract infection (fever and cough), early sputum production and rapid progression to severe pneumonia, sepsis with ...

  6. Influenza SIRS with minimal pneumonitis

    Directory of Open Access Journals (Sweden)

    Shruti Erramilli

    2016-08-01

    Full Text Available While systemic inflammatory response syndrome (SIRS, is a known complication of severe influenza pneumonia, it has been reported very rarely in patients with minimal parenchymal lung disease. We here report a case of severe SIRS, anasarca and marked vascular phenomena with minimal or no pneumonitis. This case highlights that viruses, including influenza, may cause vascular dysregulation causing SIRS, even without substantial visceral organ involvement.

  7. Stockpiling Ventilators for Influenza Pandemics

    OpenAIRE

    Huang, Hsin-Chan; Araz, Ozgur M.; Morton, David P.; Johnson, Gregory P.; Damien, Paul; Clements, Bruce; Meyers, Lauren Ancel

    2017-01-01

    In preparing for influenza pandemics, public health agencies stockpile critical medical resources. Determining appropriate quantities and locations for such resources can be challenging, given the considerable uncertainty in the timing and severity of future pandemics. We introduce a method for optimizing stockpiles of mechanical ventilators, which are critical for treating hospitalized influenza patients in respiratory failure. As a case study, we consider the US state of Texas during mild, ...

  8. Characteristics of seasonal influenza A and B in Latin America: influenza surveillance data from ten countries.

    NARCIS (Netherlands)

    Caini, S.; Alonso, W.J.; Balmaseda, A.; Bruno, A.; Busto, P.; Castillo, L.; Lozano, C. de; Mora, D. de; Fasce, R. A.; Ferreira de Almeida, W.A.; Kusznierz, G.F.; Lara, J.; Matute, M.L.; Moreno, B.; Pessanha Henriques, C.M.; Rudi, J.M.; El-Guerche Séblain, C.; Schellevis, F.; Paget, J.

    2017-01-01

    Introduction: The increased availability of influenza surveillance data in recent years justifies an actual and more complete overview of influenza epidemiology in Latin America. We compared the influenza surveillance systems and assessed the epidemiology of influenza A and B, including the

  9. Characteristics of seasonal influenza A and B in Latin America: Influenza surveillance data from ten countries

    NARCIS (Netherlands)

    Caini, S.; Alonso, W.J.; Balmaseda, A.; Bruno, A.; Bustos, P.; Castillo, L.; Lozano, C.; Mora, D. De; Fasce, R.A.; Ferreira de Almeida, W.A.; Kusznierz, G.F.; Lara, J.; Matute, M.L.; Moreno, B.; Henriques, C.M.; Rudi, J.M.; El-Guerche Seblain, C.; Schellevis, F.; Paget, J.

    2017-01-01

    INTRODUCTION: The increased availability of influenza surveillance data in recent years justifies an actual and more complete overview of influenza epidemiology in Latin America. We compared the influenza surveillance systems and assessed the epidemiology of influenza A and B, including the

  10. Reverse Genetics of Influenza B Viruses.

    Science.gov (United States)

    Nogales, Aitor; Perez, Daniel R; Santos, Jefferson; Finch, Courtney; Martínez-Sobrido, Luis

    2017-01-01

    Annual influenza epidemics are caused not only by influenza A viruses but also by influenza B viruses. Initially established for the generation of recombinant influenza A viruses, plasmid-based reverse genetics techniques have allowed researchers the generation of wild type and mutant viruses from full-length cDNA copies of the influenza viral genome. These reverse genetics approaches have allowed researchers to answer important questions on the biology of influenza viruses by genetically engineering infectious recombinant viruses. This has resulted in a better understanding of the molecular biology of influenza viruses, including both viral and host factors required for genome replication and transcription. With the ability to generate recombinant viruses containing specific mutations in the viral genome, these reverse genetics tools have also allowed the identification of viral and host factors involved in influenza pathogenesis, transmissibility, host-range interactions and restrictions, and virulence. Likewise, reverse genetics techniques have been used for the implementation of inactivated or live-attenuated influenza vaccines and the identification of anti-influenza drugs and their mechanism of antiviral activity. In 2002, these reverse genetics approaches allowed also the recovery of recombinant influenza B viruses entirely from plasmid DNA. In this chapter we describe the cloning of influenza B/Brisbane/60/2008 viral RNAs into the ambisense pDP-2002 plasmid and the experimental procedures for the successful generation of recombinant influenza B viruses.

  11. 75 FR 24747 - SCI, LLC/Zener-Rectifier Operations Division A Wholly Owned Subsidiary of SCI, LLC/ON...

    Science.gov (United States)

    2010-05-05

    ... Operations Division A Wholly Owned Subsidiary of SCI, LLC/ON Semiconductor Including On-Site Leased Workers... Division, a wholly owned subsidiary of SCI, LLC/ON Semiconductor, Phoenix, Arizona. The notice was... in the production of semiconductor devices. The company reports that workers leased from Superior...

  12. 78 FR 46661 - Self-Regulatory Organizations; New York Stock Exchange LLC; NYSE MKT LLC; Order Instituting...

    Science.gov (United States)

    2013-08-01

    ...-2013-25] Self-Regulatory Organizations; New York Stock Exchange LLC; NYSE MKT LLC; Order Instituting... coordinator for the securities in which the specialist is registered by exercising leadership and managing... securities in which the specialist is registered by exercising leadership and managing trading crowd activity...

  13. 77 FR 10740 - Riverbank Hydro No. 22, LLC; FFP Project 93, LLC; Notice Announcing Preliminary Permit Drawing

    Science.gov (United States)

    2012-02-23

    ...] Riverbank Hydro No. 22, LLC; FFP Project 93, LLC; Notice Announcing Preliminary Permit Drawing The..., will conduct a random drawing to determine the filing priority of the applicants identified in this... regulations.\\2\\ The priority established by this drawing will be used to determine which applicant, among...

  14. 78 FR 4842 - Linden VFT, LLC v. Brookfield Energy Marketing, LP, Cargill Power Markets, LLC; Notice of Complaint

    Science.gov (United States)

    2013-01-23

    ... v. Brookfield Energy Marketing, LP, Cargill Power Markets, LLC; Notice of Complaint Take notice that... Brookfield Energy Marketing, LP and Cargill Power Markets, LLC (Respondents) alleging that, Respondents... subscribed docket(s). For assistance with any FERC Online service, please email [email protected

  15. 76 FR 40945 - Entergy Nuclear Indian Point 2, LLC, Entergy Nuclear Indian Point 3, LLC, Entergy Nuclear...

    Science.gov (United States)

    2011-07-12

    ... From the Federal Register Online via the Government Publishing Office NUCLEAR REGULATORY...] Entergy Nuclear Indian Point 2, LLC, Entergy Nuclear Indian Point 3, LLC, Entergy Nuclear Operations, Inc.... Schneiderman, Attorney General for the State of New York, the petitioner, has asked the U.S. Nuclear Regulatory...

  16. 75 FR 16091 - Glen Falls Hydro, LLC; Essex Energy Partners, LLC; Notice of Application for Transfer of License...

    Science.gov (United States)

    2010-03-31

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Glen Falls Hydro, LLC; Essex Energy Partners, LLC; Notice of Application for Transfer of License, and Soliciting Comments and Motions To Intervene March 24, 2010. On March 8, 2010...

  17. 78 FR 8588 - Rg Steel Sparrows Point LLC, Formerly Known as Severstal Sparrows Point LLC, a Subsidiary of RG...

    Science.gov (United States)

    2013-02-06

    ... Consulting, Crown Security, Eastern Automation, EDS(HP), Teksystems, URS Corporation, and B More Industrial... from B More Industrial Services LLC were employed on-site at the Sparrows Point, Maryland location of RG Steel Sparrows Point LLC. The Department has determined that these workers from B More Industrial...

  18. 75 FR 20591 - AES Sparrows Point LNG, LLC and Mid-Atlantic Express, LLC; Notice of Final General Conformity...

    Science.gov (United States)

    2010-04-20

    ...] AES Sparrows Point LNG, LLC and Mid-Atlantic Express, LLC; Notice of Final General Conformity... revised draft Final General Conformity Determination (GCD) for Pennsylvania to assess the potential air... the above-referenced dockets. In accordance with the General Conformity Regulations under the Code of...

  19. 75 FR 36380 - Green County Operating Services, LLC; El Cajon Energy, LLC; Notice of Effectiveness of Exempt...

    Science.gov (United States)

    2010-06-25

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Green County Operating Services, LLC; El Cajon Energy, LLC; Notice of Effectiveness of Exempt Wholesale Generator Status June 18, 2010. Take notice that during the month of April/May...

  20. Avian influenza : a review article

    Directory of Open Access Journals (Sweden)

    A. Yalda

    2006-07-01

    Full Text Available The purpose of this paper is to provides general information about avian influenza (bird flu and specific information about one type of bird flu, called avian influenza A (H5N1, that has caused infections in birds in Asia and Europe and in human in Asia. The main materials in this report are based on the World Health Organization (WHO , world organization for animal health (OIE , food and agriculture organization of the united nations (FAO information and recommendations and review of the published literature about avian influenza. Since December 2003, highly pathogenic H5N1 avian influenza viruses have swept through poultry populations across Asia and parts of Europe. The outbreaks are historically unprecedented in scale and geographical spread. Their economic impact on the agricultural sector of the affected countries has been large. Human cases, with an overall fatality rate around 50%, have also been reported and almost all human infections can be linked to contact with infected poultry. Influenza viruses are genetically unstable and their behaviour cannot be predicted so the risk of further human cases persists. The human health implications have now gained importance, both for illness and fatalities that have occurred following natural infection with avian viruses, and for the potential of generating a re-assortant virus that could give rise to the next human influenza pandemic.

  1. Targeting influenza virosomes to ovarian carcinoma cells

    NARCIS (Netherlands)

    Mastrobattista, E; Schoen, P; Wilschut, J; Crommelin, DJA; Storm, G

    2001-01-01

    Reconstituted influenza virus envelopes (virosomes) containing the viral hemagglutinin (HA) have attracted attention as delivery vesicles for cytosolic drug delivery as they possess membrane fusion activity. Here, we show that influenza virosomes can be targeted towards ovarian carcinoma cells

  2. Influenza vaccination for children with asthma

    OpenAIRE

    Friedman, Bat-Chen; Goldman, Ran D.

    2010-01-01

    QUESTION Parents of children with asthma are encouraged by many health organizations to vaccinate their children against seasonal influenza viruses. Is the influenza vaccine efficient in preventing asthma exacerbation? Are current vaccinations safe to administer to children with asthma?

  3. Crosstalk between animal and human influenza viruses

    Science.gov (United States)

    Ozawa, Makoto; Kawaoka, Yoshihiro

    2017-01-01

    Although outbreaks of highly pathogenic avian influenza in wild and domestic birds have been posing the threat of a new influenza pandemic for the last decade, the first pandemic of the 21st century came from swine viruses. This fact emphasizes the complexity of influenza viral ecology and the difficulty of predicting influenza viral dynamics. Complete control of influenza viruses seems impossible. However, we must minimize the impact of animal and human influenza outbreaks by learning lessons from past experiences and recognizing the current status. Here, we review the most recent influenza virology data in the veterinary field, including aspects of zoonotic agents and recent studies that assessed the pandemic potential of H5N1 highly pathogenic avian influenza viruses. PMID:25387011

  4. Variant (Swine Origin) Influenza Viruses in Humans

    Science.gov (United States)

    ... Types Seasonal Avian Swine Variant Other Variant Influenza Viruses: Background and CDC Risk Assessment and Reporting Language: ... Background CDC Assessment Reporting Background On Variant Influenza Viruses Swine flu viruses do not normally infect humans. ...

  5. 75 FR 60138 - Chrysler Financial Services Americas, LLC, a Subsidiary of Finco Intermediate Holding Co., LLC...

    Science.gov (United States)

    2010-09-29

    ... Employment and Training Administration Chrysler Financial Services Americas, LLC, a Subsidiary of Finco... directly competitive with the financial services supplied by the subject firm, and there has not been a... request for reconsideration states that ``the workers at Chrysler Financial Services, Troy, Michigan were...

  6. Characterization of influenza vaccine immunogenicity using influenza antigen microarrays.

    Directory of Open Access Journals (Sweden)

    Jordan V Price

    Full Text Available Existing methods to measure influenza vaccine immunogenicity prohibit detailed analysis of epitope determinants recognized by immunoglobulins. The development of highly multiplex proteomics platforms capable of capturing a high level of antibody binding information will enable researchers and clinicians to generate rapid and meaningful readouts of influenza-specific antibody reactivity.We developed influenza hemagglutinin (HA whole-protein and peptide microarrays and validated that the arrays allow detection of specific antibody reactivity across a broad dynamic range using commercially available antibodies targeted to linear and conformational HA epitopes. We derived serum from blood draws taken from 76 young and elderly subjects immediately before and 28±7 days post-vaccination with the 2008/2009 trivalent influenza vaccine and determined the antibody reactivity of these sera to influenza array antigens.Using linear regression and correcting for multiple hypothesis testing by the Benjamini and Hochberg method of permutations over 1000 resamplings, we identified antibody reactivity to influenza whole-protein and peptide array features that correlated significantly with age, H1N1, and B-strain post-vaccine titer as assessed through a standard microneutralization assay (p<0.05, q <0.2. Notably, we identified several peptide epitopes that were inversely correlated with regard to age and seasonal H1N1 and B-strain neutralization titer (p<0.05, q <0.2, implicating reactivity to these epitopes in age-related defects in response to H1N1 influenza. We also employed multivariate linear regression with cross-validation to build models based on age and pre-vaccine peptide reactivity that predicted vaccine-induced neutralization of seasonal H1N1 and H3N2 influenza strains with a high level of accuracy (84.7% and 74.0%, respectively.Our methods provide powerful tools for rapid and accurate measurement of broad antibody-based immune responses to influenza

  7. Influenza B viruses : not to be discounted

    NARCIS (Netherlands)

    van de Sandt, Carolien E; Bodewes, Rogier; Rimmelzwaan, Guus F; de Vries, Rory D

    2015-01-01

    In contrast to influenza A viruses, which have been investigated extensively, influenza B viruses have attracted relatively little attention. However, influenza B viruses are an important cause of morbidity and mortality in the human population and full understanding of their biological and

  8. Influenza and risk of later celiac disease

    DEFF Research Database (Denmark)

    Kårhus, Line Lund; Gunnes, Nina; Størdal, Ketil

    2018-01-01

    OBJECTIVES: Influenza has been linked to autoimmune conditions, but its relationship to subsequent celiac disease (CD) is unknown. Our primary aim was to determine the risk of CD after influenza. A secondary analysis examined the risk of CD following pandemic influenza vaccination. METHODS...

  9. Anti-influenza M2e antibody

    Energy Technology Data Exchange (ETDEWEB)

    Bradbury, Andrew M.

    2013-04-16

    Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.

  10. Anti-influenza M2e antibody

    Energy Technology Data Exchange (ETDEWEB)

    Bradbury, Andrew M [Santa Fe, NM

    2011-12-20

    Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.

  11. Influenza: prevention, prophylaxis and treatment | Jones | South ...

    African Journals Online (AJOL)

    Influenza spreads rapidly to affect 515% of the global population on an annual basis. It is estimated that influenza causes between three and five million cases of severe illness and between a quarter and half a million deaths every year. In South Africa during the period from 1997 to 2001, influenza and pneumonia ...

  12. 77 FR 34783 - Highly Pathogenic Avian Influenza

    Science.gov (United States)

    2012-06-12

    ... Avian Influenza AGENCY: Animal and Plant Health Inspection Service, USDA. ACTION: Interim rule... importation of bird and poultry products from regions where any subtype of highly pathogenic avian influenza... avian influenza (HPAI). On January 24, 2011, we published in the Federal Register (76 FR 4046-4056...

  13. 76 FR 24793 - Highly Pathogenic Avian Influenza

    Science.gov (United States)

    2011-05-03

    ... Inspection Service 9 CFR Parts 93, 94, and 95 RIN 0579-AC36 Highly Pathogenic Avian Influenza AGENCY: Animal... products from regions where any subtype of highly pathogenic avian influenza is considered to exist. The... vaccinated for certain types of avian influenza, or that have moved through regions where any subtype of...

  14. European surveillance network for influenza in pigs

    NARCIS (Netherlands)

    Simon, Gaëlle; Larsen, Lars E.; Dürrwald, Ralf; Foni, Emanuela; Harder, Timm; Reeth, Van Kristien; Markowska-Daniel, Iwona; Reid, Scott M.; Dan, Adam; Maldonado, Jaime; Huovilainen, Anita; Billinis, Charalambos; Davidson, Irit; Agüero, Montserrat; Vila, Thaïs; Hervé, Séverine; Breum, Solvej Østergaard; Chiapponi, Chiara; Urbaniak, Kinga; Kyriakis, Constantinos S.; Brown, Ian H.; Loeffen, Willie; Meulen, Van der Karen; Schlegel, Michael; Bublot, Michel; Kellam, Paul; Watson, Simon; Lewis, Nicola S.; Pybus, Oliver G.; Webby, Richard; Chen, Hualan; Vincent, Amy L.

    2014-01-01

    Swine influenza causes concern for global veterinary and public health officials. In continuing two previous networks that initiated the surveillance of swine influenza viruses (SIVs) circulating in European pigs between 2001 and 2008, a third European Surveillance Network for Influenza in Pigs

  15. Swine Influenza (Swine Flu) in Pigs

    Science.gov (United States)

    ... Avian Swine Variant Pandemic Other Key Facts about Swine Influenza (Swine Flu) in Pigs Language: English (US) Español Recommend on Facebook Tweet ... visit the CDC seasonal flu website . What is Swine Influenza? Swine Influenza (swine flu) is a respiratory ...

  16. Influenza Vaccination in Community Dwelling Elderly Persons

    NARCIS (Netherlands)

    A.C.G. Voordouw (Bettie)

    2005-01-01

    textabstractAn influenza epidemic was first described in 1173, although there are reports of influenza as early as 412 BC. Recurrent epidemics and incidental pandemics caused by influenza virus are documented since the last 400 years. These were based upon clinical observation and epidemiology.

  17. Pandemic swine influenza virus: Preparedness planning | Ojogba ...

    African Journals Online (AJOL)

    The novel H1N1 influenza virus that emerged in humans in Mexico in early 2009 and transmitted efficiently in the human population with global spread was declared a pandemic strain. The introduction of different avian and human influenza virus genes into swine influenza viruses often result in viruses of increased fitness ...

  18. Effective influenza vaccines for children

    Science.gov (United States)

    Banzhoff, Angelika; Stoddard, Jeffrey J.

    2012-01-01

    Seasonal influenza causes clinical illness and hospitalization in all age groups; however, conventional inactivated vaccines have only limited efficacy in young children. MF59®, an oil-in-water emulsion adjuvant, has been used since the 1990s to enhance the immunogenicity of influenza vaccines in the elderly, a population with waning immune function due to immunosenescence.   Clinical trials now provide information to support a favorable immunogenicity and safety profile of MF59-adjuvanted influenza vaccine in young children. Published data indicate that Fluad®, a trivalent seasonal influenza vaccine with MF59, was immunogenic and well tolerated in young children, with a benefit/risk ratio that supports routine clinical use. A recent clinical trial also shows that Fluad provides high efficacy against PCR-confirmed influenza. Based on the results of clinical studies in children, the use of MF59-adjuvanted vaccine offers the potential to enhance efficacy and make vaccination a viable prevention and control strategy in this population. PMID:22327501

  19. Traditional and New Influenza Vaccines

    Science.gov (United States)

    Wong, Sook-San

    2013-01-01

    SUMMARY The challenges in successful vaccination against influenza using conventional approaches lie in their variable efficacy in different age populations, the antigenic variability of the circulating virus, and the production and manufacturing limitations to ensure safe, timely, and adequate supply of vaccine. The conventional influenza vaccine platform is based on stimulating immunity against the major neutralizing antibody target, hemagglutinin (HA), by virus attenuation or inactivation. Improvements to this conventional system have focused primarily on improving production and immunogenicity. Cell culture, reverse genetics, and baculovirus expression technology allow for safe and scalable production, while adjuvants, dose variation, and alternate routes of delivery aim to improve vaccine immunogenicity. Fundamentally different approaches that are currently under development hope to signal new generations of influenza vaccines. Such approaches target nonvariable regions of antigenic proteins, with the idea of stimulating cross-protective antibodies and thus creating a “universal” influenza vaccine. While such approaches have obvious benefits, there are many hurdles yet to clear. Here, we discuss the process and challenges of the current influenza vaccine platform as well as new approaches that are being investigated based on the same antigenic target and newer technologies based on different antigenic targets. PMID:23824369

  20. Universal influenza vaccines, science fiction or soon reality?

    Science.gov (United States)

    de Vries, Rory D; Altenburg, Arwen F; Rimmelzwaan, Guus F

    2015-01-01

    Currently used influenza vaccines are only effective when the vaccine strains match the epidemic strains antigenically. To this end, seasonal influenza vaccines must be updated almost annually. Furthermore, seasonal influenza vaccines fail to afford protection against antigenically distinct pandemic influenza viruses. Because of an ever-present threat of the next influenza pandemic and the continuous emergence of drift variants of seasonal influenza A viruses, there is a need for an universal influenza vaccine that induces protective immunity against all influenza A viruses. Here, we summarize some of the efforts that are ongoing to develop universal influenza vaccines.

  1. Influenza Pandemic Infrastructure Response in Thailand

    Centers for Disease Control (CDC) Podcasts

    2009-03-05

    Influenza viruses change antigenic properties, or drift, every year and they create seasonal outbreaks. Occasionally, influenza viruses change in a major way, called a “shift." If an influenza virus shifts, the entire human population is susceptible to the new influenza virus, creating the potential for a pandemic. On this podcast, CDC's Dr. Scott Dowell discusses responding to an influenza pandemic.  Created: 3/5/2009 by Emerging Infectious Diseases.   Date Released: 3/5/2009.

  2. The human side of influenza

    Science.gov (United States)

    Oshansky, Christine M.; Thomas, Paul G.

    2012-01-01

    A clear understanding of immunity in individuals infected with influenza virus is critical for the design of effective vaccination and treatment strategies. Whereas myriad studies have teased apart innate and adaptive immune responses to influenza infection in murine models, much less is known about human immunity as a result of the ethical and technical constraints of human research. Still, these murine studies have provided important insights into the critical correlates of protection and pathogenicity in human infection and helped direct the human studies that have been conducted. Here, we examine and review the current literature on immunity in humans infected with influenza virus, noting evidence offered by select murine studies and suggesting directions in which future research is most warranted. PMID:22362872

  3. On the epidemiology of influenza

    Directory of Open Access Journals (Sweden)

    Scragg Robert

    2008-02-01

    Full Text Available Abstract The epidemiology of influenza swarms with incongruities, incongruities exhaustively detailed by the late British epidemiologist, Edgar Hope-Simpson. He was the first to propose a parsimonious theory explaining why influenza is, as Gregg said, "seemingly unmindful of traditional infectious disease behavioral patterns." Recent discoveries indicate vitamin D upregulates the endogenous antibiotics of innate immunity and suggest that the incongruities explored by Hope-Simpson may be secondary to the epidemiology of vitamin D deficiency. We identify – and attempt to explain – nine influenza conundrums: (1 Why is influenza both seasonal and ubiquitous and where is the virus between epidemics? (2 Why are the epidemics so explosive? (3 Why do they end so abruptly? (4 What explains the frequent coincidental timing of epidemics in countries of similar latitude? (5 Why is the serial interval obscure? (6 Why is the secondary attack rate so low? (7 Why did epidemics in previous ages spread so rapidly, despite the lack of modern transport? (8 Why does experimental inoculation of seronegative humans fail to cause illness in all the volunteers? (9 Why has influenza mortality of the aged not declined as their vaccination rates increased? We review recent discoveries about vitamin D's effects on innate immunity, human studies attempting sick-to-well transmission, naturalistic reports of human transmission, studies of serial interval, secondary attack rates, and relevant animal studies. We hypothesize that two factors explain the nine conundrums: vitamin D's seasonal and population effects on innate immunity, and the presence of a subpopulation of "good infectors." If true, our revision of Edgar Hope-Simpson's theory has profound implications for the prevention of influenza.

  4. Influenza infection and Kawasaki disease

    Directory of Open Access Journals (Sweden)

    Xijing Huang

    2015-06-01

    Full Text Available INTRODUCTION: The objective of this study was to investigate the possible link between influenza (Flu infection and Kawasaki disease (KD. METHODS: We examined the medical records of 1,053 KD cases and 4,669 influenza infection cases hospitalized at our institute from January 1, 2011 to December 31, 2013. Cases of KD with concomitant influenza infection formed the KD + Flu group. Each KD + Flu case was matched with 2 KD cases and 2 influenza infection cases, and these cases were assigned to the KD group and Flu group, respectively. The differences in the principal clinical manifestations, course of disease, incomplete KD rate, intravenous immunoglobulin (IVIG resistance rate, and echocardiographic detection results between the KD + Flu group and KD group were compared. The fever durations and laboratory test results of these three groups were compared. RESULTS: 1 The seasonal variations of the KD + Flu group, KD group and Flu group were similar. 2 The morbidity rate of incomplete KD was higher in the KD + Flu group compared with the KD group. 3 Patients in the KD + Flu group exhibited a longer time to KD diagnosis compared with patients in the KD group. 4 The KD + Flu group exhibited the longest fever duration among the three groups. 5 The CRP and ESR values in the KD + Flu group were higher those in the Flu or KD groups. CONCLUSIONS: Concomitant influenza infection affects the clinical manifestations of KD and can impact the laboratory test results and the diagnosis and treatment of the disease. However, it remains unclear whether influenza contributes to KD etiology.

  5. Vaccination against seasonal influenza

    CERN Document Server

    GS Department

    2010-01-01

    This year, as usual, the Medical Service is helping to promote vaccination against seasonal influenza. Vaccination against seasonal flu is especially recommended for anyone who suffers from chronic pulmonary, cardio-vascular or kidney disease or diabetes, is recovering from a serious illness or major surgery, or is over 65 years of age. The flu virus is transmitted through the air and through contact with contaminated surfaces, so frequent hand-washing with soap and/or an antiseptic hand wash is of great importance. As soon as the first symptoms appear (fever above 38°, shivering, coughing, muscle and/or joint pains, generalised weakness), you are strongly recommended to stay at home to avoid spreading the virus. Anyone working on the CERN site who wishes to be vaccinated against seasonal flu should go to the Infirmary (Building 57, ground floor), with their dose of vaccine. The Medical Service will issue a prescription on the day of the vaccination for the purposes of reimbursement through UNIQA...

  6. DNA repair in Haemophilus influenzae

    International Nuclear Information System (INIS)

    Bagci, H.

    1979-01-01

    A mutant (hex - ) of Haemophilus influenzae which does not discriminate between low efficiency (LE) and high efficiency (HE) markers has been isolated. The mutant is like wild type in its sensitivity to ultraviolet (UV) radiation, methyl methane sulfonate (MMS), mitomycin C (MC) and nitrous acid (NA). As compared to the wild type, the mutant shows much higher spontaneous as well as bromouracil (BrU)-induced mutation frequencies. Biological inactivation of transforming DNA that had been UV-irradiated or treated with MMS has been studied on the widely used wild type Haemophilus influenzae Rd and several repair deficient mutant strains

  7. Seasonal Inactivated Influenza Virus Vaccines

    OpenAIRE

    Couch, Robert B.

    2008-01-01

    Inactivated influenza virus vaccines are the primary modality used for prevention of influenza. A system of annual identification of new strains causing illnesses, selections for vaccines, chick embryo growth, inactivation, processing, packaging, distribution and usage has been in place for decades. Current vaccines contain 15 µg of the HA of an A/H1N1, A/H3N2 and B strain and are given parenterally to induce serum anti-HA antibody for prevention of subsequent infection and illness from natur...

  8. Rock Equity Holdings, LLC - Clean Water Act Public Notice

    Science.gov (United States)

    The EPA is providing notice of an Administrative Penalty Assessment in the form of an Expedited Storm Water Settlement Agreement against Rock Equity Holdings, LLC, for alleged violations at The Cove at Kettlestone/98th Street Reconstruction located at 3015

  9. CITGO Petroleum Corporation and PDV Midwest Refining, LLC Settlement

    Science.gov (United States)

    CITGO Petroleum Corporation and PDV Midwest Refining, LLC (collectively, CITGO) have agreed to pay a $1,955,000 civil penalty, perform environmental projects totaling more than $2 million, and spend an estimated $42 million in injunctive relief to resolve.

  10. Influenza virus infection among pediatric patients reporting diarrhea and influenza-like illness

    Directory of Open Access Journals (Sweden)

    Uyeki Timothy M

    2010-01-01

    Full Text Available Abstract Background Influenza is a major cause of morbidity and hospitalization among children. While less often reported in adults, gastrointestinal symptoms have been associated with influenza in children, including abdominal pain, nausea, vomiting, and diarrhea. Methods From September 2005 and April 2008, pediatric patients in Indonesia presenting with concurrent diarrhea and influenza-like illness were enrolled in a study to determine the frequency of influenza virus infection in young patients presenting with symptoms less commonly associated with an upper respiratory tract infection (URTI. Stool specimens and upper respiratory swabs were assayed for the presence of influenza virus. Results Seasonal influenza A or influenza B viral RNA was detected in 85 (11.6% upper respiratory specimens and 21 (2.9% of stool specimens. Viable influenza B virus was isolated from the stool specimen of one case. During the time of this study, human infections with highly pathogenic avian influenza A (H5N1 virus were common in the survey area. However, among 733 enrolled subjects, none had evidence of H5N1 virus infection. Conclusions The detection of influenza viral RNA and viable influenza virus from stool suggests that influenza virus may be localized in the gastrointestinal tract of children, may be associated with pediatric diarrhea and may serve as a potential mode of transmission during seasonal and epidemic influenza outbreaks.

  11. Detection of influenza C virus but not influenza D virus in Scottish respiratory samples

    Science.gov (United States)

    Smith, Donald B.; Gaunt, Eleanor R.; Digard, Paul; Templeton, Kate; Simmonds, Peter

    2016-01-01

    Background A newly proposed genus of influenza virus (influenza D) is associated with respiratory disease in pigs and cattle. The novel virus is most closely related to human influenza C virus and can infect ferrets but infection has not been reported in humans. Objectives To ascertain if influenza D virus can be detected retrospectively in patient respiratory samples. Study design 3300 human respiratory samples from Edinburgh, Scotland, covering the period 2006–2008, were screened in pools of 10 by RT-PCR using primers capable of detecting both influenza C and D viruses. Results Influenza D was not detected in any sample. Influenza C was present in 6 samples (0.2%), compared with frequencies of 3.3% and 0.9% for influenza A and B viruses from RT-PCR testing of respiratory samples over the same period. Influenza C virus was detected in samples from individuals 45 years old, with cases occurring throughout the year. Phylogenetic analysis of nearly complete sequences of all seven segments revealed the presence of multiple, reassortant lineages. Conclusion We were unable to detect viruses related to influenza D virus in human respiratory samples. Influenza C virus was less prevalent than influenza A and B viruses, was associated with mild disease in the young (45 years) and comprised multiple, reassortant lineages. Inclusion of influenza C virus as part of a diagnostic testing panel for respiratory infections would be of limited additional value. PMID:26655269

  12. Haemophilus influenzae Disease (Including Hib) Diagnosis and Treatment

    Science.gov (United States)

    ... Search Form Controls Cancel Submit Search The CDC Haemophilus influenzae Disease (Including Hib) Note: Javascript is disabled or ... Page Diagnosis Treatment Complications Diagnosis Doctors usually diagnose Haemophilus influenzae , including H. influenzae type b or Hib, infection ...

  13. Universal influenza vaccines, science fiction or soon reality?

    NARCIS (Netherlands)

    R.D. de Vries (Rory); A.F. Altenburg (Arwen); G.F. Rimmelzwaan (Guus)

    2015-01-01

    textabstractCurrently used influenza vaccines are only effective when the vaccine strains match the epidemic strains antigenically. To this end, seasonal influenza vaccines must be updated almost annually. Furthermore, seasonal influenza vaccines fail to afford protection against antigenically

  14. 76 FR 2713 - Croscill Acquisition, LLC, Currently Known as Croscill Home, LLC, Plant No. 8, Oxford, NC...

    Science.gov (United States)

    2011-01-14

    ..., LLC had their wages reported under a separate unemployment insurance (UI) tax account under the name... distribution services from China, Turkey and India. The amended notice applicable to TA-W-70,044 is hereby...

  15. 78 FR 19530 - RG Steel Sparrows Point LLC, Formerly Known as Severstal Sparrows Point LLC, a Subsidiary of RG...

    Science.gov (United States)

    2013-04-01

    ... Consulting, Crown Security, Eastern Automation, EDS (HP), TekSystems, URS Corporation, B More Industrial... Automation, EDS (HP), TekSystems, URS Corporation, B More Industrial Services LLC, and Recycling & Treatment...

  16. 77 FR 38884 - Professional Transportation, Inc.-Asset Acquisition-CUSA ES, LLC and CUSA CSS, LLC

    Science.gov (United States)

    2012-06-29

    ... CSS, LLC AGENCY: Surface Transportation Board. ACTION: Notice of Finance Application. SUMMARY... quality of the human environment or the conservation of energy resources. It is ordered: 1. Comments must...

  17. 78 FR 25130 - Self-Regulatory Organizations; BOX Options Exchange LLC; Notice of Filing and Immediate...

    Science.gov (United States)

    2013-04-29

    ... Error rules of the NASDAQ Stock Market LLC (``NOM''), NASDAQ OMX PHLX LLC (``PHLX''), Chicago Board... transaction was the result of an ``obvious error'' pursuant to objective standards. When a market marker...

  18. 77 FR 52373 - Self-Regulatory Organizations; NASDAQ Stock Market, LLC; Notice of Filing and Immediate...

    Science.gov (United States)

    2012-08-29

    ...-Regulatory Organizations; NASDAQ Stock Market, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to Membership in The NASDAQ Stock Market LLC August 23, 2012. Pursuant to Section... is hereby given that on August [[Page 52374

  19. 75 FR 53688 - Constellation Mystic Power, LLC; Supplemental Notice That Initial Market-Based Rate Filing...

    Science.gov (United States)

    2010-09-01

    ...-000] Constellation Mystic Power, LLC; Supplemental Notice That Initial Market-Based Rate Filing... the above-referenced proceeding of Constellation Mystic Power, LLC's application for market-based rate...

  20. 75 FR 32977 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2010-06-10

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed... Permit Opening Transactions by Market Makers To Accommodate Closing Transactions of Other Market... International Securities Exchange, LLC (``Exchange'' or ``ISE'') filed with the Securities and Exchange...

  1. 77 FR 48148 - Energy Alternatives Wholesale, LLC; Supplemental Notice That Initial Market-Based Rate Filing...

    Science.gov (United States)

    2012-08-13

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Energy Alternatives Wholesale, LLC; Supplemental Notice That Initial Market... in the above-referenced proceeding, of Energy Alternatives Wholesale, LLC's application for market...

  2. 75 FR 38802 - DCP Raptor Pipeline, LLC; Notice of Baseline Filing

    Science.gov (United States)

    2010-07-06

    ...] DCP Raptor Pipeline, LLC; Notice of Baseline Filing June 28, 2010. Take notice that on June 22, 2010, DCP Raptor Pipeline, LLC submitted a baseline filing of its Statement of Operating Conditions for...

  3. 75 FR 18828 - Wisconsin Electric Power Company, Wisconsin Gas LLC, Wisconsin Public Service Corporation...

    Science.gov (United States)

    2010-04-13

    ... Energy Regulatory Commission Wisconsin Electric Power Company, Wisconsin Gas LLC, Wisconsin Public Service Corporation: Complainants; ANR Pipeline Company: Respondent; Notice of Complaint April 6, 2010....206 (2009), Wisconsin Electric Power Company, Wisconsin Gas LLC, and Wisconsin Public Service...

  4. 75 FR 38809 - Southern Turner Cimarron I, LLC; Notice of Filing

    Science.gov (United States)

    2010-07-06

    ...] Southern Turner Cimarron I, LLC; Notice of Filing June 25, 2010. Take notice that on June 24, 2010, Southern Turner Cimarron I, LLC filed a supplement confirming passive ownership structure for informational...

  5. [Effectiveness of influenza vaccination in healthy adults--a fourfold decrease in influenza morbidity during one influenza season].

    Science.gov (United States)

    Chlíbek, R; Beran, J; Splino, M

    2002-04-01

    Despite the existence and availability of effective and safe influenza vaccines, influenza still remains an important cause of morbidity and mortality worldwide, incl. all economic consequences and the increased number of days of work incapacity. Vaccination against influenza is an effective method of prevention of the disease and its complications. Nevertheless many people still do not trust the effectiveness of anti-influenza vaccination, incl. many physicians, nurses and other health professionals. The objective of the present study is to evaluate the effectiveness of vaccination against influenza in healthy adults aged 18-60 years, vaccinated with one of the five commonly available vaccines. The evaluation is based on notifications of influenza and influenza--like diseases. The trial comprised 375 subjects vaccinated against influenza during a given season, as a control group served 340 non-vaccinated subjects. Both groups of volunteers were investigated for six months. During this period the incidence of influenza or influenza--like diseases was recorded, the presence of local and general influenza symptoms, the number of days of work incapacity and the number of visits to the doctor. These data were obtained by the postal correspondence method. In the group of 375 vaccinated subjects 17 (4.5%) became ill. In the group of non-vaccinated subjects 65 (19.1%) became ill. The difference in the incidence of influenza was statistically significant. In subjects vaccinated against influenza a 73-76% effectiveness of vaccination was achieved. Subjects in the non-vaccinated group reported more than a fourfold incidence of influenza as compared with vaccinated subjects. The symptoms of the disease did not differ significantly in the two groups. The most frequent symptom of the disease which was recorded in both groups was fever higher than 38 degrees C, pain in the joints, myalgia and finally cough. More than two thirds of the sick volunteers visited their doctor while

  6. Virus-Vectored Influenza Virus Vaccines

    Science.gov (United States)

    Tripp, Ralph A.; Tompkins, S. Mark

    2014-01-01

    Despite the availability of an inactivated vaccine that has been licensed for >50 years, the influenza virus continues to cause morbidity and mortality worldwide. Constant evolution of circulating influenza virus strains and the emergence of new strains diminishes the effectiveness of annual vaccines that rely on a match with circulating influenza strains. Thus, there is a continued need for new, efficacious vaccines conferring cross-clade protection to avoid the need for biannual reformulation of seasonal influenza vaccines. Recombinant virus-vectored vaccines are an appealing alternative to classical inactivated vaccines because virus vectors enable native expression of influenza antigens, even from virulent influenza viruses, while expressed in the context of the vector that can improve immunogenicity. In addition, a vectored vaccine often enables delivery of the vaccine to sites of inductive immunity such as the respiratory tract enabling protection from influenza virus infection. Moreover, the ability to readily manipulate virus vectors to produce novel influenza vaccines may provide the quickest path toward a universal vaccine protecting against all influenza viruses. This review will discuss experimental virus-vectored vaccines for use in humans, comparing them to licensed vaccines and the hurdles faced for licensure of these next-generation influenza virus vaccines. PMID:25105278

  7. Universal influenza virus vaccines and therapeutic antibodies.

    Science.gov (United States)

    Nachbagauer, R; Krammer, F

    2017-04-01

    Current influenza virus vaccines are effective when well matched to the circulating strains. Unfortunately, antigenic drift and the high diversity of potential emerging zoonotic and pandemic viruses make it difficult to select the right strains for vaccine production. This problem causes vaccine mismatches, which lead to sharp drops in vaccine effectiveness and long response times to manufacture matched vaccines in case of novel pandemic viruses. To provide an overview of universal influenza virus vaccines and therapeutic antibodies in preclinical and clinical development. PubMed and clinicaltrials.gov were used as sources for this review. Universal influenza virus vaccines that target conserved regions of the influenza virus including the haemagglutinin stalk domain, the ectodomain of the M2 ion channel or the internal matrix and nucleoproteins are in late preclinical and clinical development. These vaccines could confer broad protection against all influenza A and B viruses including drift variants and thereby abolish the need for annual re-formulation and re-administration of influenza virus vaccines. In addition, these novel vaccines would enhance preparedness against emerging influenza virus pandemics. Finally, novel therapeutic antibodies against the same conserved targets are in clinical development and could become valuable tools in the fight against influenza virus infection. Both universal influenza virus vaccines and therapeutic antibodies are potential future options for the control of human influenza infections. Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

  8. Formulation of influenza T cell peptides : in search of a universal influenza vaccine

    NARCIS (Netherlands)

    Soema, Peter Christiaan

    2015-01-01

    Current seasonal influenza vaccines rely on the induction of antibodies to neutralize the virus. However, influenza viruses frequently undergo genetic mutations due to antigenic drift and shift, altering the surface proteins hemagglutinin and neuraminidase to which antibodies usually bind. This

  9. Influenza vaccines for avian species

    Science.gov (United States)

    Beginning in Southeast Asia, in 2003, a multi-national epizootic outbreak of H5N1 highly pathogenic avian influenza (HPAI) was identified in commercial poultry and wild bird species. This lineage, originally identified in Southern China in 1996 and then Hong Kong in 1997, caused severe morbidity an...

  10. New vaccines against influenza virus

    Science.gov (United States)

    Lee, Young-Tae; Kim, Ki-Hye; Ko, Eun-Ju; Lee, Yu-Na; Kim, Min-Chul; Kwon, Young-Man; Tang, Yinghua; Cho, Min-Kyoung; Lee, Youn-Jeong

    2014-01-01

    Vaccination is one of the most effective and cost-benefit interventions that prevent the mortality and reduce morbidity from infectious pathogens. However, the licensed influenza vaccine induces strain-specific immunity and must be updated annually based on predicted strains that will circulate in the upcoming season. Influenza virus still causes significant health problems worldwide due to the low vaccine efficacy from unexpected outbreaks of next epidemic strains or the emergence of pandemic viruses. Current influenza vaccines are based on immunity to the hemagglutinin antigen that is highly variable among different influenza viruses circulating in humans and animals. Several scientific advances have been endeavored to develop universal vaccines that will induce broad protection. Universal vaccines have been focused on regions of viral proteins that are highly conserved across different virus subtypes. The strategies of universal vaccines include the matrix 2 protein, the hemagglutinin HA2 stalk domain, and T cell-based multivalent antigens. Supplemented and/or adjuvanted vaccination in combination with universal target antigenic vaccines would have much promise. This review summarizes encouraging scientific advances in the field with a focus on novel vaccine designs. PMID:24427759

  11. Dynamic modeling for pandemic influenza

    NARCIS (Netherlands)

    Postma, M.J.

    It is now widely agreed upon that most infectious diseases require a dynamic approach to validly analyze infectious disease control. Given the size of the spread and the potential impact, pandemic influenza certainly presents an area where dynamic modeling is much needed. In this article, a dynamic

  12. Influenza: prevention, prophylaxis and treatment

    African Journals Online (AJOL)

    Influenza illness causes substantial morbidity and mortality, with healthcare costs and lost productivity due to absenteeism resulting in both direct and indirect costs and, ultimately, a formidable economic burden.2. This article has been peer reviewed. Full text available at www.safpj.co.za. SA Fam Pract 2008;50(2):38-41.

  13. Control strategies against avian influenza

    Science.gov (United States)

    Since 1959, 40 epizootics of high pathogenicity avian influenza (HPAI) have occurred (Figure 1). Thirty-five of these epizootic HPAI viruses were geographically-limited (mostly to single countries), involved farm-to-farm spread and were eradicated from poultry by stamping-out programs; i.e. the HPAI...

  14. Efficacy of Influenza Vaccination and Tamiflu? Treatment ? Comparative Studies with Eurasian Swine Influenza Viruses in Pigs

    OpenAIRE

    Duerrwald, Ralf; Schlegel, Michael; Bauer, Katja; Vissiennon, Th?ophile; Wutzler, Peter; Schmidtke, Michaela

    2013-01-01

    Recent epidemiological developments demonstrated that gene segments of swine influenza A viruses can account for antigenic changes as well as reduced drug susceptibility of pandemic influenza A viruses. This raises questions about the efficacy of preventive measures against swine influenza A viruses. Here, the protective effect of vaccination was compared with that of prophylactic Tamiflu® treatment against two Eurasian swine influenza A viruses. 11-week-old pigs were infected by aerosol nebu...

  15. Mid-Season Influenza Vaccine Effectiveness Estimates for the 2013-2014 Influenza Season

    Science.gov (United States)

    2014-05-21

    Naval Health Research Center Mid-Season Influenza Vaccine Effectiveness Estimates for the 2013–2014 Influenza Season Angelia A. Cost...2000–2013 P A G E 1 5 Brief report: mid-season influenza vaccine effectiveness estimates for the 2013–2014 influenza season Angelia A. Cost, PhD...hospitals near the U.S.– Mexico border from 25 November 2013 through 16 January 2014. Infl uenza cases were individ- uals who had positive laboratory

  16. Avian influenza in shorebirds: experimental infection of ruddy turnstones (Arenaria interpres) with avian influenza virus

    OpenAIRE

    Hall, Jeffrey S.; Krauss, Scott; Franson, J. Christian; TeSlaa, Joshua L.; Nashold, Sean W.; Stallknecht, David E.; Webby, Richard J.; Webster, Robert G.

    2012-01-01

    Please cite this paper as: Hall et al. (2012) Avian influenza in shorebirds: experimental infection of ruddy turnstones (Arenaria interpres) with avian influenza virus. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2012.00358.x. Background  Low pathogenic avian influenza viruses (LPAIV) have been reported in shorebirds, especially at Delaware Bay, USA, during spring migration. However, data on patterns of virus excretion, minimal infectious doses, and clinical outcome are l...

  17. Formulation of influenza T cell peptides: in search of a universal influenza vaccine

    OpenAIRE

    Soema, Peter Christiaan

    2015-01-01

    Current seasonal influenza vaccines rely on the induction of antibodies to neutralize the virus. However, influenza viruses frequently undergo genetic mutations due to antigenic drift and shift, altering the surface proteins hemagglutinin and neuraminidase to which antibodies usually bind. This could render vaccine-induced antibody responses ineffective, resulting in an ineffective influenza vaccine. Influenza vaccines based on the induction of T cell responses might be cross-reactive, since ...

  18. 76 FR 78325 - Self-Regulatory Organizations; NASDAQ Stock Market LLC; Notice of Filing and Immediate...

    Science.gov (United States)

    2011-12-16

    ...-Regulatory Organizations; NASDAQ Stock Market LLC; Notice of Filing and Immediate Effectiveness of a Proposed... November 30, 2011. The NASDAQ Stock Market LLC (``NASDAQ'' or ``Exchange'') filed with the Securities and... Change The NASDAQ Stock Market LLC proposes to amend Rule 7056 entitled ``NASDAQ Options Fee Disputes...

  19. 76 FR 28226 - Ndahendekire Barbara v. African Shipping; Njoroge Muhia; Alco Logistics, Llc; Brenda Alexander...

    Science.gov (United States)

    2011-05-16

    ... Muhia; Alco Logistics, Llc; Brenda Alexander; and AIR 7 Seas Transportlogistics, Inc.; Notice of Filing...; Njoroge Muhia, ALCO Logistics, LLC; Brenda Alexander; and Air 7 Seas Transport Logistics, Inc...; Respondent ALCO Logistics, LLC, is a freight forwarding and logistics company; Respondent Brenda Alexander is...

  20. 77 FR 76013 - Sempra LNG Marketing, LLC; Application for Blanket Authorization To Export Previously Imported...

    Science.gov (United States)

    2012-12-26

    ... Cameron LNG Terminal (Cameron Terminal) owned by Sempra LNG Marketing's affiliate Cameron LNG, LLC, in... DEPARTMENT OF ENERGY [FE Docket No. 12-155-LNG] Sempra LNG Marketing, LLC; Application for Blanket..., by Sempra LNG Marketing, LLC (Sempra LNG Marketing), requesting blanket authorization to export...

  1. 78 FR 47433 - GENCAP Strategies LLC, et al.; Notice of Application

    Science.gov (United States)

    2013-08-05

    ... Strategies LLC, et al.; Notice of Application July 30, 2013. AGENCY: Securities and Exchange Commission (the...)(A) and (B) of the Act. Applicants: GENCAP Strategies LLC (formerly, Active Relief, LLC) (the...) secondary market transactions in Shares to occur at negotiated market prices; (c) certain series to pay...

  2. 76 FR 78620 - Notice of Intent To Grant an Exclusive License; Voltage Networking, LLC; Correction

    Science.gov (United States)

    2011-12-19

    ...; Voltage Networking, LLC; Correction AGENCY: National Security Agency, Department of Defense (DoD). ACTION... Notice of Intent to Grant an Exclusive License; Voltage Networking, LLC. In the SUMMARY section, in the... Networking, LLC. Subsequent to the publication of that notice, DoD discovered that the word ``non-assignable...

  3. 75 FR 6378 - Covanta Pylmouth Renewable Energy Limited Partnership Covanta Energy Marketing LLC Covanta Power...

    Science.gov (United States)

    2010-02-09

    ..., ER10-410-000] Covanta Pylmouth Renewable Energy Limited Partnership Covanta Energy Marketing LLC... Pylmouth Renewable Energy Limited Partnership, Covanta Energy Marketing LLC, and Covanta Power, LLC filed... assistance with any FERC Online service, please e-mail [email protected] , or call (866) 208-3676...

  4. 76 FR 19069 - Application to Export Electric Energy; Cargill Power Markets, LLC

    Science.gov (United States)

    2011-04-06

    ... Application to Export Electric Energy; Cargill Power Markets, LLC AGENCY: Office of Electricity Delivery and Energy Reliability, DOE. ACTION: Notice of application. SUMMARY: Cargill Power Markets, LLC (CPM) has... directly with Eugene J. Becker, Vice President, Cargill Power Markets, LLC, 9350 Excelsior Blvd., MS 150...

  5. 76 FR 4724 - Catawba Sox, LLC Formerly Known as Catawba Sox, Inc. Including Workers Whose Unemployment...

    Science.gov (United States)

    2011-01-26

    ... Whose Unemployment Insurance UI) Wages Are Paid Through Ellis Hosiery Mill, LLC, Newton, NC; Amended... unemployment insurance (UI) tax account under the name Ellis Hosiery Mill, LLC, formerly known as Catawba Sox... workers whose unemployment insurance (UI) wages are paid through Ellis Hosiery Mill, LLC, Newton, North...

  6. 77 FR 25210 - Advisors Series Trust and Orinda Asset Management, LLC; Notice of Application

    Science.gov (United States)

    2012-04-27

    ... Series Trust and Orinda Asset Management, LLC; Notice of Application April 23, 2012. AGENCY: Securities.... APPLICANTS: Advisors Series Trust (the ``Trust'') and Orinda Asset Management, LLC (the ``Advisor''). FILING... Street, Milwaukee, WI 53202 and Orinda Asset Management, LLC, 4 Orinda Way, Suite 100B, Orinda, CA 94563...

  7. 77 FR 64422 - Approval and Promulgation of Air Quality Implementation Plans; Illinois; Greif Packaging, LLC...

    Science.gov (United States)

    2012-10-22

    ... Promulgation of Air Quality Implementation Plans; Illinois; Greif Packaging, LLC Adjusted Standard AGENCY... State Implementation Plan (SIP) an adjusted standard for the Greif Packaging, LLC facility located at 5... submitted an Adjusted Standard for the Greif Packaging, LLC facility located at 5 S 220 Frontenac Road in...

  8. 75 FR 70689 - Kaiser Aluminum Fabricated Products, LLC; Kaiser Aluminum-Greenwood Forge Division; Currently...

    Science.gov (United States)

    2010-11-18

    ... DEPARTMENT OF LABOR Employment and Training Administration [TA-W-70,376] Kaiser Aluminum Fabricated Products, LLC; Kaiser Aluminum- Greenwood Forge Division; Currently Known As Contech Forgings, LLC..., applicable to workers of Kaiser Aluminum Fabricated Products, LLC, Kaiser Aluminum-Greenwood Forge Division...

  9. 77 FR 73651 - Cascade Energy Storage, LLC; Notice of Preliminary Permit Application Accepted for Filing and...

    Science.gov (United States)

    2012-12-11

    ... No. 14464-000] Cascade Energy Storage, LLC; Notice of Preliminary Permit Application Accepted for..., Cascade Energy Storage, LLC, filed an application for a preliminary permit, pursuant to section 4(f) of... Executive Officer, Cascade Energy Storage, LLC, 1210 W. Franklin Street, Ste. 2, Boise, Idaho 83702; phone...

  10. 77 FR 38622 - Whitewater Green Energy, LLC; Notice of Preliminary Permit Application Accepted for Filing and...

    Science.gov (United States)

    2012-06-28

    ... Energy Regulatory Commission Whitewater Green Energy, LLC; Notice of Preliminary Permit Application..., 2012, Whitewater Green Energy, LLC, filed an application for a preliminary permit, pursuant to section... gigawatt-hours. Applicant Contact: Mr. David Harmon, Whitewater Green Energy, LLC, 601 7th Avenue, P.O. Box...

  11. 76 FR 7832 - Evans Solutions, LLC; Notice of Declaration of Intention and Soliciting Comments, Protests, and...

    Science.gov (United States)

    2011-02-11

    ... Energy Regulatory Commission Evans Solutions, LLC; Notice of Declaration of Intention and Soliciting... Intention. b. Docket No: DI10-20-000. c. Date Filed: September 21, 2010. d. Applicant: Evans Solutions, LLC...). h. Applicant Contact: Reginald Evans, Evans Solutions, LLC, P.O. Box 1303, Sumter, SC 29150...

  12. 77 FR 13593 - AMENICO Green Solutions, LLC; Notice of Preliminary Permit Application Accepted for Filing and...

    Science.gov (United States)

    2012-03-07

    ... Federal Energy Regulatory Commission AMENICO Green Solutions, LLC; Notice of Preliminary Permit... Green Solutions, LLC filed an application for a preliminary permit, pursuant to section 4(f) of the..., Manager, AMENICO Green Solutions, LLC, 5 Main Street, Pittsfield, NH 03263; phone: (603) 228- 3611. FERC...

  13. 75 FR 4759 - Polychlorinated Biphenyls: Manufacturing (Import) Exemption for Veolia ES Technical Solutions, LLC

    Science.gov (United States)

    2010-01-29

    ... Veolia ES Technical Solutions, LLC AGENCY: Environmental Protection Agency (EPA). ACTION: Withdrawal of proposed rule. SUMMARY: On November 14, 2006, Veolia ES Technical Solutions, LLC, (Veolia) submitted a... Veolia ES Technical Solutions, LLC. ] Since that time, Veolia submitted a request to withdraw its...

  14. 75 FR 26794 - Alticor, Inc., Including Access Business Group International LLC and Amway Corporation, Buena...

    Science.gov (United States)

    2010-05-12

    ..., Inc., Including Access Business Group International LLC and Amway Corporation, Buena Park, CA; Alticor, Inc., Including Access Business Group International LLC, and Amway Corporation, Ada, MI; Amended... of Alticor, Inc., including Access Business Group International LLC and Amway Corporation, Buena Park...

  15. 75 FR 32221 - Alticor, Inc., Including Access Business Group International, LLC, and Amway Corporation...

    Science.gov (United States)

    2010-06-07

    ... Access Business Group International, LLC, and Amway Corporation, Including On-Site Leased Workers from... Business Group International, LLC and Amway Corporation. The notice was published in the Federal Register... issued as follows: All workers of Alticor, Inc., including Access Business Group International, LLC and...

  16. 76 FR 45878 - Alticor, Inc., Including Access Business Group International LLC and Amway Corporation, Buena...

    Science.gov (United States)

    2011-08-01

    ...,420B] Alticor, Inc., Including Access Business Group International LLC and Amway Corporation, Buena Park, CA; Alticor, Inc., Including Access Business Group International LLC and Amway Corporation...., Including Access Business Group International LLC and Amway Corporation, Including On-Site Leased Workers...

  17. 78 FR 30295 - Constellation Energy Commoditiesgroup, Inc., ENI USA Gas Marketing LLC, Sequent Energy Canada...

    Science.gov (United States)

    2013-05-22

    ... Marketing & authority to import/export Trading USA, natural gas from/to Canada/ Inc. Mexico and to import....) Inc. Nextera Energy Power Marketing, LLC, Trunkline LNG Export, LLC, Gasfin Development USA LLC, Louis... Granting Authority To Import and Export Natural Gas, To Import Liquefied Natural Gas, To Export Liquefied...

  18. 78 FR 2392 - Startrans IO, LLC; Notice of Initiation of Proceeding and Refund Effective Date

    Science.gov (United States)

    2013-01-11

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. EL13-26-000] Startrans IO, LLC; Notice of Initiation of Proceeding and Refund Effective Date On December 31, 2012, the Commission... proposed transmission revenue requirement rates by Startrans IO, LLC. Startrans IO, LLC, 141 FERC ] 61,271...

  19. 78 FR 32464 - Amantea Nonwovens, LLC, Including On-Site Leased Workers From Express Employment Professionals...

    Science.gov (United States)

    2013-05-30

    ... DEPARTMENT OF LABOR Employment and Training Administration [TA-W-82,471] Amantea Nonwovens, LLC..., 2013, applicable to workers of Amantea Nonwovens, L.L.C. including on-site leased workers from Express... Staffmark were employed on-site at the Cincinnati, Ohio location of Amantea Nonwovens, L.L.C. The Department...

  20. Effect of influenza vaccination on the prognosis of hospitalized influenza patients.

    Science.gov (United States)

    Casado, Itziar; Domínguez, Angela; Toledo, Diana; Chamorro, Judith; Force, Lluis; Soldevila, Núria; Astray, Jenaro; Egurrola, Mikel; Godoy, Pere; Mayoral, José M; Tamames, Sonia; Sanz, Francisco; Castilla, Jesús

    2016-01-01

    This study aimed to assess whether influenza vaccination reduces the risk of severe and fatal outcomes in influenza inpatients aged ≥65 years. During the 2013-2014 influenza season persons aged ≥65 years hospitalized with laboratory-confirmed influenza were selected in 19 Spanish hospitals. A severe influenza case was defined as admission to the intensive care unit, death in hospital or within 30 days after admission. Logistic regression was used to compare the influenza vaccination status between severe and non-severe influenza inpatients. Of 433 influenza confirmed patients, 81 (19%) were severe cases. Vaccination reduced the risk of severe illness (odds ratio: 0.57; 95%CI: 0.33-0.98). The cumulative number of influenza vaccine doses received since the 2010-2011 season was associated with a lower risk of severe influenza (odds ratio: 0.78; 95% CI 0.66-0.91). Adherence to seasonal influenza vaccination in the elderly may reduce the risk of severe influenza outcomes.

  1. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza.

    NARCIS (Netherlands)

    Rondy, Marc; Launay, Odile; Castilla, Jesus; Costanzo, Simona; Puig-Barberà, Joan; Gefenaite, Giedre; Larrauri, Amparo; Rizzo, Caterina; Pitigoi, Daniela; Syrjänen, Ritva K; Machado, Ausenda; Kurečić Filipović, Sanja; Krisztina Horváth, Judit; Paradowska-Stankiewicz, Iwona; Marbus, Sierk; Moren, Alain

    2017-01-01

    In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015-16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza

  2. Molecular detection and typing of influenza viruses. Are we ready for an influenza pandemic?

    NARCIS (Netherlands)

    MacKay, W.G.; Loon, A.M. van; Niedrig, M.; Meijer, A.; Lina, B.; Niesters, H.G.M.

    2008-01-01

    BACKGROUND: We cannot predict when an influenza pandemic will occur or which variant of the virus will cause it. Little information is currently available on the ability of laboratories to detect and subtype influenza viruses including the avian influenza viruses. OBJECTIVES: To assess the ability

  3. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis

    NARCIS (Netherlands)

    De Keyser, J; Zwanikken, C

    1998-01-01

    Despite reports that influenza vaccination appears to be safe in multiple sclerosis there is uncertainty which patients may benefit from it. By using a questionnaire we compared the effects of influenza illness (1995-1996 season) and influenza vaccination (autumn of 1996) on neurologic symptoms in

  4. Influenza B viruses: not to be discounted.

    Science.gov (United States)

    van de Sandt, Carolien E; Bodewes, Rogier; Rimmelzwaan, Guus F; de Vries, Rory D

    2015-01-01

    In contrast to influenza A viruses, which have been investigated extensively, influenza B viruses have attracted relatively little attention. However, influenza B viruses are an important cause of morbidity and mortality in the human population and full understanding of their biological and epidemiological properties is imperative to better control this important pathogen. However, some of its characteristics are still elusive and warrant investigation. Here, we review evolution, epidemiology, pathogenesis and immunity and identify gaps in our knowledge of influenza B viruses. The divergence of two antigenically distinct influenza B viruses is highlighted. The co-circulation of viruses of these two lineages necessitated the development of quadrivalent influenza vaccines, which is discussed in addition to possibilities to develop universal vaccination strategies.

  5. Updates on Influenza Vaccination in Children.

    Science.gov (United States)

    Campbell, Angela J P; Grohskopf, Lisa A

    2018-03-01

    Influenza vaccination is recommended for all children 6 months of age and older who do not have contraindications. This article provides an overview of information concerning burden of influenza among children in the United States; US-licensed influenza vaccines; vaccine immunogenicity, effectiveness, and safety; and recent updates relevant to use of these vaccines in pediatric populations. Influenza antiviral medications are discussed. Details concerning vaccine-related topics may be found in the current US Centers for Disease Control and Prevention/Advisory Committee on Immunization Practices recommendations for use of influenza vaccines (https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html). Additional information on influenza antivirals is located at https://www.cdc.gov/flu/professionals/antivirals/index.htm. Published by Elsevier Inc.

  6. 75 FR 68397 - DeQueen and Eastern Railroad, LLC-Acquisition and Operation Exemption-DeQueen and Eastern...

    Science.gov (United States)

    2010-11-05

    ..., DeQueen and Eastern Railroad, LLC, Golden Triangle Railroad, LLC, Mississippi & Skuna Valley Railroad, LLC... & Cowlitz Railway Company; (2) Docket No. FD 35428, Golden Triangle Railroad, LLC--Acquisition and Operation Exemption--Golden Triangle Railroad Company; (3) Docket No. FD 35429, Mississippi & Skuna Valley Railroad...

  7. 76 FR 24069 - Self-Regulatory Organizations; NASDAQ OMX PHLX LLC; Order Approving Proposed Rule Change, as...

    Science.gov (United States)

    2011-04-29

    ... No. 1, Relating to Amendments to NASDAQ OMX PHLX LLC's Limited Liability Company Agreement, By-Laws... Limited Liability Company Agreement (``LLC Agreement'') and By-Laws to substantially conform them to The NASDAQ Stock Market LLC's (``NASDAQ'') Second Amended Limited Liability Company Agreement (``NASDAQ LLC...

  8. Influenza and bacterial pneumonia - constant companions

    OpenAIRE

    Wunderink, Richard G

    2010-01-01

    Sequential or concomitant influenza and bacterial pneumonia are two common syndromes seen in community-acquired pneumonia. Inadequacies of diagnostic testing make separating simple pneumonia with either bacteria or influenza from concomitant or sequential influenza with both microorganisms difficult, although the novel 2009 H1N1 epidemic may improve the availability of molecular testing for viruses. Given the frequency of viral pneumonia and diagnostic limitations, empirical antivirals may be...

  9. Optimization of Influenza Antiviral Response in Texas

    Science.gov (United States)

    2015-03-01

    originated 38 from Texas- Mexico border counties, TAVRS would average the 150 treatable curves that apply to that influenza scenario to be used in... INFLUENZA ANTIVIRAL RESPONSE IN TEXAS by Travis L. Chambers March 2015 Advisor: Nedialko B. Dimitrov Co-Advisor: Michael Atkinson Second...DATES COVERED March 2015 Master ’s Thesis 4. TITLE AND SUBTITLE OPTIMIZATION OF INFLUENZA ANTIVIRAL RESPONSE IN TEXAS 6. AUTHOR(S) Travis L. Chambers

  10. Influenza Vaccines: From Surveillance Through Production to Protection

    Science.gov (United States)

    Tosh, Pritish K.; Jacobson, Robert M.; Poland, Gregory A.

    2010-01-01

    Influenza is an important contributor to population and individual morbidity and mortality. The current influenza pandemic with novel H1N1 has highlighted the need for health care professionals to better understand the processes involved in creating influenza vaccines, both for pandemic as well as for seasonal influenza. This review presents an overview of influenza-related topics to help meet this need and includes a discussion of the burden of disease, virology, epidemiology, viral surveillance, and vaccine strain selection. We then present an overview of influenza vaccine—related topics, including vaccine production, vaccine efficacy and effectiveness, influenza vaccine misperceptions, and populations that are recommended to receive vaccination. English-language articles in PubMed published between January 1, 1970, and October 7, 2009, were searched using key words human influenza, influenza vaccines, influenza A, and influenza B. PMID:20118381

  11. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia

    Directory of Open Access Journals (Sweden)

    Aurélien Jamotte

    2016-07-01

    Full Text Available Abstract Background Annual trivalent influenza vaccines (TIV containing three influenza strains (A/H1N1, A/H3N2, and one B have been recommended for the prevention of influenza. However, worldwide co-circulation of two distinct B lineages (Victoria and Yamagata and difficulties in predicting which lineage will predominate each season have led to the development of quadrivalent influenza vaccines (QIV, which include both B lineages. Our analysis evaluates the public health benefit and associated influenza-related costs avoided which would have been obtained by using QIV rather than TIV in Australia over the period 2002–2012. Methods A static model stratified by age group was used, focusing on people at increased risk of influenza as defined by the Australian vaccination recommendations. B-lineage cross-protection was accounted for. We calculated the potential impact of QIV compared with TIV over the seasons 2002–2012 (2009 pandemic year excluded using Australian data on influenza circulation, vaccine coverage, hospitalisation and mortality rates as well as unit costs, and international data on vaccine effectiveness, influenza attack rate, GP consultation rate and working days lost. Third-party payer and societal influenza-related costs were estimated in 2014 Australian dollars. Sensitivity analyses were conducted. Results Using QIV instead of TIV over the period 2002–2012 would have prevented an estimated 68,271 additional influenza cases, 47,537 GP consultations, 3,522 hospitalisations and 683 deaths in the population at risk of influenza. These results translate into influenza-related societal costs avoided of $46.5 million. The estimated impact of QIV was higher for young children and the elderly. The overall impact of QIV depended mainly on vaccine effectiveness and the influenza attack rate attributable to the mismatched B lineage. Conclusion The broader protection offered by QIV would have reduced the number of influenza infections

  12. Clinical validation of a point-of-care multiplexed in vitro immunoassay using monoclonal antibodies (the MSD influenza test) in four hospitals in Vietnam.

    Science.gov (United States)

    van Doorn, H Rogier; Kinh, Nguyen van; Tuan, Ha Manh; Tuan, Tran Anh; Minh, Ngo Ngoc Quang; Bryant, Juliet E; Hang, Vu thi Ty; Uyen, Le thi Tham; Thinh, Le Quoc; Anh, Tran thi Ngoc; Lan, Nguyen Phu Huong; Trung, Nguyen Vu; Taylor, Walter; Merson, Laura; Wertheim, Heiman F L; Farrar, Jeremy; Wolbers, Marcel; Chau, Nguyen van Vinh; de Jong, Menno D

    2012-05-01

    Point-of-care (POC) diagnostic tests for influenza can considerably shorten the time to clinical decision making. An investigational POC test based on a multiplexed immunoassay was developed by Meso Scale Diagnostics, LLC (MSD), with the objective to make a more sensitive rapid test that can also subtype influenza A viruses (1977 H1, H3, and H5). Between February and November 2010, we conducted a prospective multicenter study at four hospitals in Vietnam and compared the performance of this test to that of the WHO/CDC real-time reverse transcriptase PCR (RT-PCR) on nasal and throat swab specimens from patients presenting with influenza-like illness. Five hundred sixty-three adults and children with a median age of 25 months were enrolled. Sensitivity and specificity of the test with combined results from nasal and throat swab samples were 74.0% (131/177) and 99.7% (351/352), respectively, compared to RT-PCR. The POC test was as sensitive for influenza virus B as for influenza virus A (74.4% [64/86] versus 73.6% [67/91]). The positivity rate was associated with lower cycle threshold values (a marker for higher viral loads), sample type (73.6% for nasal swab versus 52.4% for throat swab), and younger age. A total of 210 (18.7%) out of 1,126 MSD tests failed, and for 34 (6%) of patients, both test samples failed (these were excluded from the performance analysis). Subtyping could be assessed only for influenza virus A/H3N2, as 1977 H1N1 was not circulating at the time and no H5N1-infected patients were enrolled, and was successful only in 9/54 patients infected with H3 influenza virus who had a positive POC test result for influenza virus A. This novel POC test provided highly sensitive detection of influenza viruses A and B compared to the reported sensitivities of other rapid tests. However, 18.7% of tests failed for technical reasons and subtyping for H3 was poor. Drawbacks to the technology include the requirement for a dedicated reader instrument and the need for

  13. Assessment of the RNASound RNA Sampling Card for the preservation of influenza virus RNA

    Directory of Open Access Journals (Sweden)

    Hilda Lau

    2016-11-01

    Full Text Available Shipping influenza virus specimens, isolates or purified RNA is normally conducted at ultra-low temperatures using dry ice to ensure minimal degradation of the samples but this is expensive and requires special packaging and shipping conditions. Therefore, alternative methods for shipping influenza viruses or RNA at ambient temperatures would be desirable.The RNASound RNA Sampling Card (FortiusBio LLC, CA, USA is a device that enables specimens or isolates to be applied to a card, whereby viruses are inactivated, while RNA is preserved and purified RNA can also easily be eluted. To evaluate this card, we applied influenza virus cell culture isolate supernatants to either the RNASound card or Whatman Grade No. 1 filter paper (GE Healthcare, NSW, Australia and compared the preservation to that of material stored in liquid form. Preservation was tested using influenza A and B viruses at two different storage temperatures (cool 2-8oC or room temperature 18-22oC and these were compared with control material stored at -80°C, for 7, 14 or 28 days. The quality of the RNA recovered was assessed using real time RT-PCR and Sanger sequencing. The RNASound card was effective in preserving influenza RNA at room temperature for up to 28 days, with only a minor change in real-time RT-PCR cycle threshold values for selected gene targets when comparing between viruses applied to the card or stored at -80°C. Similar results were obtained with filter paper, whilst virus in liquid form performed the worst. Nevertheless, as the RNASound card also has the capability to inactivate viruses in addition to preserving RNA at room temperature for many weeks, this makes it feasible to send samples to laboratories using regular mail, and thus avoid the need for expensive shipping conditions requiring biohazard containers and dry ice. Moreover, the quick and simple RNA recovery from the RNASound card allows recipient labs to obtain RNA without the need for special reagents

  14. Diagnosis of influenza viruses with special reference to novel H1N1 2009 influenza virus

    OpenAIRE

    Broor, Shobha; Chahar, Harendra Singh; Kaushik, Samander

    2009-01-01

    On 15 April and 17 April 2009, novel swineorigin influenza A (H1N1) virus was identifi ed in specimens obtained from two epidemiologically unlinked patients in the United States. The ongoing outbreak of novel H1N1 2009 influenza (swine influenza) has caused more than 3,99,232 laboratory confi rmed cases of pandemic influenza H1N1 and over 4735 deaths globally. This novel 2009 influenza virus designated as H1N1 A/swine/California/04/2009 virus is not zoonotic swine flu and is transmitted from ...

  15. Stockpiling Ventilators for Influenza Pandemics.

    Science.gov (United States)

    Huang, Hsin-Chan; Araz, Ozgur M; Morton, David P; Johnson, Gregory P; Damien, Paul; Clements, Bruce; Meyers, Lauren Ancel

    2017-06-01

    In preparing for influenza pandemics, public health agencies stockpile critical medical resources. Determining appropriate quantities and locations for such resources can be challenging, given the considerable uncertainty in the timing and severity of future pandemics. We introduce a method for optimizing stockpiles of mechanical ventilators, which are critical for treating hospitalized influenza patients in respiratory failure. As a case study, we consider the US state of Texas during mild, moderate, and severe pandemics. Optimal allocations prioritize local over central storage, even though the latter can be deployed adaptively, on the basis of real-time needs. This prioritization stems from high geographic correlations and the slightly lower treatment success assumed for centrally stockpiled ventilators. We developed our model and analysis in collaboration with academic researchers and a state public health agency and incorporated it into a Web-based decision-support tool for pandemic preparedness and response.

  16. Transmission of Influenza A Viruses

    Science.gov (United States)

    Neumann, Gabriele; Kawaoka, Yoshihiro

    2015-01-01

    Influenza A viruses cause respiratory infections that range from asymptomatic to deadly in humans. Widespread outbreaks (pandemics) are attributable to ‘novel’ viruses that possess a viral hemagglutinin (HA) gene to which humans lack immunity. After a pandemic, these novel viruses form stable virus lineages in humans and circulate until they are replaced by other novel viruses. The factors and mechanisms that facilitate virus transmission among hosts and the establishment of novel lineages are not completely understood, but the HA and basic polymerase 2 (PB2) proteins are thought to play essential roles in these processes by enabling avian influenza viruses to infect mammals and replicate efficiently in their new host. Here, we summarize our current knowledge of the contributions of HA, PB2, and other viral components to virus transmission and the formation of new virus lineages. PMID:25812763

  17. [Influenza--always present among us].

    Science.gov (United States)

    Turkulov, V; Madle-Samardzija, N

    2000-01-01

    Influenza virus infects about 10 million persons worldwide each year. Two important characteristics of influenza are its epidemic outbreak and high mortality rate, mostly caused by complications. Influenza virus is characterised by a great antigenic variability. Major modifications, called antigenic shifts or type changes, occur approximately three times per century and result in worldwide epidemics--pandemics. Minor modifications, called antigenic drifts or strain changes demand new vaccine compositions each year. Pandemics and epidemics caused by influenza virus, such as the "Spanish Flu", the "Asian Flu", the "Hong Kong Flu" killed many people worldwide. Presently the epidemic, caused by influenza A virus Sydney/97 H3N2 is spreading over USA and most of Europe, including Yugoslavia. EPIDEMIOLOGY AND CLINICAL FEATURES: In humans influenza virus spreads over respiratory secretions, thrown out by coughing and sneezing. Children and older people, as well as immunosuppressed patients are prone to the infection. The onset of illness is sudden, with fever usually over 39 degrees C. Headache and myalgia are prominent. Other signs include fatigue, sore throat, nasal congestion and red eyes. Cough is a very important symptom, which starts as dry and progresses to wet with thick mucous. Pneumonia is the main cause of death among the high-risk patients. Bronchitis and tracheobronchitis also occur. Croup is a serious complication, often encountered in small children. Cardiac complications, especially myocarditis, are described as influenza complications. Neurological complications include encephalitis, encephalopathy, myelitis, Guillain-Barré syndrome, Reye syndrome, etc. Neurotropism of the influenza virus is under investigation. DIFFERENTIAL DIAGNOSIS AND DIAGNOSIS: Differential diagnosis of influenza includes all diseases which exhibit by increased body temperature, cough, headache, sore throat, myalgia and lethargy. Among serious diseases, pneumonia, sepsis, and

  18. Travellers and influenza: risks and prevention.

    Science.gov (United States)

    Goeijenbier, M; van Genderen, P; Ward, B J; Wilder-Smith, A; Steffen, R; Osterhaus, A D M E

    2017-01-01

    Influenza viruses are among the major causes of serious human respiratory tract infection worldwide. In line with the high disease burden attributable to influenza, these viruses play an important, but often neglected, role in travel medicine. Guidelines and recommendations regarding prevention and management of influenza in travellers are scarce. Of special interest for travel medicine are risk populations and also circumstances that facilitate influenza virus transmission and spread, like travel by airplane or cruise ship and mass gatherings. We conducted a PUBMED/MEDLINE search for a combination of the MeSH terms Influenza virus, travel, mass gathering, large scale events and cruise ship. In addition we gathered guidelines and recommendations from selected countries and regarding influenza prevention and management in travellers. By reviewing these search results in the light of published knowledge in the fields of influenza prevention and management, we present best practice advice for the prevention and management of influenza in travel medicine. Seasonal influenza is among the most prevalent infectious diseases in travellers. Known host-associated risk factors include extremes of age and being immune-compromised, while the most relevant environmental factors are associated with holiday cruises and mass gatherings. Pre-travel advice should address influenza and its prevention for travellers, whenever appropriate on the basis of the epidemiological situation concerned. Preventative measures should be strongly recommended for travellers at high-risk for developing complications. In addition, seasonal influenza vaccination should be considered for any traveller wishing to reduce the risk of incapacitation, particularly cruise ship crew and passengers, as well as those participating in mass gatherings. Besides advice concerning preventive measures and vaccination, advice on the use of antivirals may be considered for some travellers. © International Society of

  19. Does influenza vaccination improve pediatric asthma outcomes?

    Science.gov (United States)

    Ong, Bruce A; Forester, Joseph; Fallot, Andre

    2009-06-01

    Controversy exists regarding the effectiveness of influenza vaccination in preventing influenza-related asthma exacerbations in the pediatric population. While yearly influenza immunization is widely recommended for children with asthma, there is currently little evidence to support this practice. Several studies have demonstrated no measurable benefit in asthma outcomes. This study sought to determine whether influenza vaccination status is associated with indicators of asthma morbidity within the military pediatric population. A survey was conducted of patients 3 to 18 years of age with a diagnosis of asthma enrolled in the pediatric clinics of Brooke Army Medical Center, Fort Sam Houston, Texas, and Wilford Hall Medical Center, Lackland Air Force Base, Texas. Management practices and outcomes for 80 children were evaluated. Data were analyzed using the statistical package SPSS version 12 (SPSS Inc., Chicago). Univariate analyses were performed to identify associations between influenza vaccination, selected demographic variables and asthma exacerbation defined by oral steroid prescription, hospital visits, and unscheduled clinic or emergency department visits for asthma symptoms. Logistic regression analyses were conducted to detect possible confounding variables. In the univariate analyses, current influenza vaccination status was associated with a significant reduction of oral steroid use in the 12 months before the survey. This relationship was appreciated to a lesser extent with emergency department or unscheduled clinic visits in the last 12 months. No significant differences were found regarding the distribution of influenza vaccination status across selected demographic variables. In the multivariate analyses, current influenza vaccination status was independently associated with significantly decreased odds of using oral steroids in the previous 12 months. There was no evidence of confounding or effect modification. This study suggests influenza

  20. 77 FR 68757 - Clean River Power MR-1, LLC; Clean River Power MR-2, LLC; Clean River Power MR-3, LLC; Clean...

    Science.gov (United States)

    2012-11-16

    ... environmental analysis at this time. n. The proposed Beverly Lock and Dam Water Power Project would be located... operate all seven projects in a run-of- river mode, such that the water surface elevations within each..., P-13406-002, P-13407-002, P- 13408-002, P-13411-002, and P-13412-002] Clean River Power MR-1, LLC...

  1. viruses associated with human and animal influenza - a review 40

    African Journals Online (AJOL)

    DR. AMINU

    ABSTRACT. In this review, the most important viruses associated with human and animal influenza are reported. These include Influenza A,B and C. Influenza viruses are members of the family. Orthomyxoviridae. Influenza A virus being the most pathogenic and wide spread with many subtypes has constantly cause ...

  2. Viruses associated with human and animal influenza - a review ...

    African Journals Online (AJOL)

    In this review, the most important viruses associated with human and animal influenza are reported. These include Influenza A,B and C. Influenza viruses are members of the family Orthomyxoviridae. Influenza A virus being the most pathogenic and wide spread with many subtypes has constantly cause epidemics in several ...

  3. Key Facts about Influenza (Flu) and Flu Vaccine

    Science.gov (United States)

    ... Collection of Respiratory Specimens for Influenza Virus Testing Clinical Signs & Symptoms of Influenza Symptoms & Laboratory Diagnosis Information for ... Submit" /> Archived Flu Emails Influenza Types Seasonal Avian Swine Variant Pandemic Other ... This Page What is Influenza (also called Flu)? Signs and Symptoms of Flu How Flu Spreads Period ...

  4. Development of stable influenza vaccine powder formulations : Challenges and possibilities

    NARCIS (Netherlands)

    Amorij, J-P; Huckriede, A; Wilschut, J; Frijlink, H W; Hinrichs, W L J

    2008-01-01

    Influenza vaccination represents the cornerstone of influenza prevention. However, today all influenza vaccines are formulated as liquids that are unstable at ambient temperatures and have to be stored and distributed under refrigeration. In order to stabilize influenza vaccines, they can be brought

  5. How Experience Shapes Health Beliefs: The Case of Influenza Vaccination

    Science.gov (United States)

    Shahrabani, Shosh; Benzion, Uri

    2012-01-01

    This study examines the impact of past experience with influenza and the influenza vaccine on four categories of the Health Belief Model: beliefs about susceptibility to contracting influenza, severity of illness, perceived benefits of the vaccine in preventing influenza, and perceived barriers to getting vaccinated. The study population comprised…

  6. Nicotinamide ribosyl uptake mutants in Haemophilus influenzae.

    Science.gov (United States)

    Herbert, Mark; Sauer, Elizabeta; Smethurst, Graeme; Kraiss, Anita; Hilpert, Anna-Karina; Reidl, Joachim

    2003-09-01

    The gene for the nicotinamide riboside (NR) transporter (pnuC) was identified in Haemophilus influenzae. A pnuC mutant had only residual NR uptake and could survive in vitro with high concentrations of NR, but could not survive in vivo. PnuC may represent a target for the development of inhibitors for preventing H. influenzae disease.

  7. Influenza virus activity in Papua New Guinea.

    Science.gov (United States)

    Sungu, M; Sanders, R

    1991-09-01

    Influenza viruses remain a major cause of respiratory disease in both developed and developing countries. A great deal of information concerning the structure, pathology and modes of transmission of these viruses has been accumulated, but no means of successfully combating them have, as yet, been devised. The most appropriate strategy for limiting the effects of influenza is to monitor the emergence and spread of new strains carefully and warn the public and at-risk groups of impending epidemics. In Papua New Guinea, as in most other developing countries, the major at-risk groups are the very young and the elderly. In the past, influenza epidemics were rare and affected the whole community, but with modern development and increased mobility the transmission dynamics of influenza have changed. The only influenza surveillance centre in Papua New Guinea is at the Papua New Guinea Institute of Medical Research in Goroka, and the surveillance activities of this centre are limited to the immediately surrounding areas. There is a need to establish a national influenza surveillance network, to provide nation-wide monitoring of influenza activity, and to provide a central repository of current information on influenza infections in the country.

  8. The virosome concept for influenza vaccines

    NARCIS (Netherlands)

    Huckriede, A; Bungener, L; Stegmann, T; Daemen, T; Medema, J; Palache, AM; Wilschut, J

    2005-01-01

    There is a need for more efficacious inactivated influenza vaccines, since current formulations show suboptimal immunogenicity in at-risk populations, like the elderly. More effective vaccines are also urgently needed for an improved influenza pandemic preparedness. In this context, there is

  9. Avian Influenza A Virus Infections in Humans

    Science.gov (United States)

    ... in People Spread of Bird Flu Viruses Between Animals and People Examples of Human Infections with Avian Influenza A ... Influenza A (H5N1) H5N1 in Birds and Other Animals H5N1 in People Public Health Threat of Highly Pathogenic Asian Avian ...

  10. Avian Influenza Policy Analysis | IDRC - International Development ...

    International Development Research Centre (IDRC) Digital Library (Canada)

    Governments in Southeast Asia have adopted a range of policies aimed at controlling the disease in animals, preventing its spread to humans and strengthening national preparedness for an avian influenza pandemic. The Asia Partnership for Avian Influenza Research (APAIR) brings together national research agencies ...

  11. Replicon particle vaccine protects swine against influenza.

    Science.gov (United States)

    Bosworth, B; Erdman, M M; Stine, D L; Harris, I; Irwin, C; Jens, M; Loynachan, A; Kamrud, K; Harris, D L

    2010-12-01

    An alphavirus derived replicon particle (RP) vaccine expressing the cluster IV H3N2 swine influenza virus (SIV) hemagglutinin (HA) gene induced protective immunity against homologous influenza virus challenge. However, pigs with maternal antibody had no protective immunity against challenge after vaccination with RP vaccines expressing HA gene alone or in combination with nucleoprotein gene. Copyright © 2010 Elsevier Ltd. All rights reserved.

  12. Increasing Influenza Vaccine Uptake. A Comprehensive Approach

    NARCIS (Netherlands)

    Looijmans - van den Akker, I.

    2009-01-01

    General introduction: To prevent influenza virus infection, immunization against influenza has been recommended for individuals with increased risk of complications. These groups comprise individuals of 60 years and older, individuals with risk-elevating co-morbid conditions, residents of nursing

  13. Pandemic Influenza Pediatric Office Plan Template

    Energy Technology Data Exchange (ETDEWEB)

    HCTT CHE

    2010-01-01

    This is a planning tool developed by pediatric stakeholders that is intended to assist pediatric medical offices that have no pandemic influenza plan in place, but may experience an increase in patient calls/visits or workload due to pandemic influenza.

  14. Influenza and diabetes ; immunological and epidemiological aspects

    NARCIS (Netherlands)

    R.J.A. Diepersloot (Rob)

    1989-01-01

    textabstractInfluenza may jeopardize the health of patients with diabetes mellitus in several ways. In the first place influenza infection may inbalance a carefully established metabolic control, and in some cases trigger a process of metabolic deterioration which eventually may lead to

  15. Dried influenza vaccines : Over the counter vaccines

    NARCIS (Netherlands)

    Saluja, Vinay; Hinrichs, Wouter L. J.; Frijlink, Henderik W.

    2010-01-01

    Since last year influenza pandemic has struck again after 40 years, this is the right moment to discuss the different available formulation options for influenza vaccine. Looking back to the last 4 decades, most vaccines are still formulated as liquid solution. These vaccines have shown a poor

  16. Emerging influenza virus: A global threat

    Indian Academy of Sciences (India)

    2008-10-15

    Oct 15, 2008 ... Home; Journals; Journal of Biosciences; Volume 33; Issue 4. Emerging influenza virus: A global threat. M Khanna P Kumar ... Since 1918, influenza virus has been one of the major causes of morbidity and mortality, especially among young children. Though the commonly circulating strain of the virus is not ...

  17. Naturligt forekommende oseltamivirresistens hos influenza A

    DEFF Research Database (Denmark)

    Madsen, Laura; Nielsen, Alex; Lundgren, Jens

    2010-01-01

    During the last two influenza seasons, one of the predominant influenza A types (H1N1) has developed complete resistance to oseltamivir, the primary treatment option. The virus does, however, remain sensitive to zanamavir and amantadine. There is no unequivocal explanation for this slide...

  18. Persistence of influenza on surfaces.

    Science.gov (United States)

    Thompson, K-A; Bennett, A M

    2017-02-01

    Close contact transmission (either direct or large droplet/droplet nuclei) is considered the main driver of influenza outbreaks but there is limited information regarding the role of fomites in transmission. To investigate the surface stability of influenza strains and thereby the role of fomites in transmission. The viability and quantitative reverse transcription-polymerase chain reaction (qt-RT-PCR) signal of five influenza strains (A/PR/8/34/H1N1, A/Cal/7/09/H1N1, A/Cal/4/09/H1N1, A/Sol/54/06/H1N1, and A/Bris/59/07/H1N1) seeded on to three surfaces (cotton, microfibre, and stainless steel) were assessed over time. Coupons of material were seeded with 10μL of a 10 6 -10 8 pfu/mL suspension of cell culture-derived virus stock supplemented with 0.3% bovine serum albumin. Coupons were assayed by plaque assay and qt-RT-PCR at 1, 24h, and weekly for seven weeks using a vortex-mixing elution method. Viable virus was detected from coupons for up to two weeks (stainless steel) and one week (cotton and microfibre), whereas detection of viruses by PCR was made for the entire seven-week study period. No strain differences were found. Ninety-nine percent reduction values (as a function of the seeding stock) were determined to be 17.7h for cotton (R 2 =0.86), 34.3h for microfibre (R 2 =0.80), and 174.9h for stainless steel (R 2 =0.98). Viable influenza was recovered from surfaces for up to two weeks. By contrast, influenza could be detected by PCR for more than seven weeks. These results have important implications for determining infection control protocols, cleaning regimes and sampling methods in healthcare settings. Crown Copyright © 2016. Published by Elsevier Ltd. All rights reserved.

  19. DNA-based influenza vaccines as immunoprophylactic agents toward universality.

    Science.gov (United States)

    Zhang, Han; El Zowalaty, Mohamed E

    2016-01-01

    Influenza is an illness of global public health concern. Influenza viruses have been responsible for several pandemics affecting humans. Current influenza vaccines have proved satisfactory safety; however, they have limitations and do not provide protection against unexpected emerging influenza virus strains. Therefore, there is an urgent need for alternative approaches to conventional influenza vaccines. The development of universal influenza vaccines will help alleviate the severity of influenza pandemics. Influenza DNA vaccines have been the subject of many studies over the past decades due to their ability to induce broad-based protective immune responses in various animal models. The present review highlights the recent advances in influenza DNA vaccine research and its potential as an affordable universal influenza vaccine.

  20. Viral vector-based influenza vaccines

    Science.gov (United States)

    de Vries, Rory D.; Rimmelzwaan, Guus F.

    2016-01-01

    ABSTRACT Antigenic drift of seasonal influenza viruses and the occasional introduction of influenza viruses of novel subtypes into the human population complicate the timely production of effective vaccines that antigenically match the virus strains that cause epidemic or pandemic outbreaks. The development of game-changing vaccines that induce broadly protective immunity against a wide variety of influenza viruses is an unmet need, in which recombinant viral vectors may provide. Use of viral vectors allows the delivery of any influenza virus antigen, or derivative thereof, to the immune system, resulting in the optimal induction of virus-specific B- and T-cell responses against this antigen of choice. This systematic review discusses results obtained with vectored influenza virus vaccines and advantages and disadvantages of the currently available viral vectors. PMID:27455345

  1. Viral vector-based influenza vaccines.

    Science.gov (United States)

    de Vries, Rory D; Rimmelzwaan, Guus F

    2016-11-01

    Antigenic drift of seasonal influenza viruses and the occasional introduction of influenza viruses of novel subtypes into the human population complicate the timely production of effective vaccines that antigenically match the virus strains that cause epidemic or pandemic outbreaks. The development of game-changing vaccines that induce broadly protective immunity against a wide variety of influenza viruses is an unmet need, in which recombinant viral vectors may provide. Use of viral vectors allows the delivery of any influenza virus antigen, or derivative thereof, to the immune system, resulting in the optimal induction of virus-specific B- and T-cell responses against this antigen of choice. This systematic review discusses results obtained with vectored influenza virus vaccines and advantages and disadvantages of the currently available viral vectors.

  2. Managing influenza: amantadine, rimantadine and beyond.

    Science.gov (United States)

    Fleming, D M

    2001-04-01

    Amantadine and rimantadine are effective in the treatment and prophylaxis of influenza A. Neither drug, however, has achieved widespread acceptance because of the rapid development of viral resistance, their lack of activity against influenza B and, in the case of amantadine, adverse events. Complete cross-resistance occurs with these compounds and is associated with a single nucleotide change in the M2 protein. Resistant variants are transmissible and fully pathogenic. Zanamivir is the first widely approved neuraminidase inhibitor for the treatment of influenza. It is delivered directly to the primary site of viral replication, the respiratory tract, and is well tolerated and effective in the treatment of both influenza A and B. Data in prophylaxis are also encouraging. During the extensive clinical programme no evidence for the emergence of drug-resistant strains with acute therapy was found. Zanamivir represents a significant advance over older agents in the management of influenza A and B.

  3. Influenza viruses: from birds to humans.

    Science.gov (United States)

    Reperant, Leslie A; Kuiken, Thijs; Osterhaus, Albert D M E

    2012-01-01

    Avian influenza viruses are the precursors of human influenza A viruses. They may be transmitted directly from avian reservoirs, or infect other mammalian species before subsequent transmission to their human host. So far, avian influenza viruses have caused sporadic-yet increasingly more frequently recognized-cases of infection in humans. They have to adapt to and circulate efficiently in human populations, before they may trigger a worldwide human influenza outbreak or pandemic. Cross-species transmission of avian influenza viruses from their reservoir hosts-wild waterbirds-to terrestrial poultry and to humans is based on different modes of transmission and results in distinctive pathogenetic manifestations, which are reviewed in this paper.

  4. Modeling human influenza infection in the laboratory

    Directory of Open Access Journals (Sweden)

    Radigan KA

    2015-08-01

    Full Text Available Kathryn A Radigan,1 Alexander V Misharin,2 Monica Chi,1 GR Scott Budinger11Division of Pulmonary and Critical Care Medicine, 2Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: Influenza is the leading cause of death from an infectious cause. Because of its clinical importance, many investigators use animal models to understand the biologic mechanisms of influenza A virus replication, the immune response to the virus, and the efficacy of novel therapies. This review will focus on the biosafety, biosecurity, and ethical concerns that must be considered in pursuing influenza research, in addition to focusing on the two animal models – mice and ferrets – most frequently used by researchers as models of human influenza infection.Keywords: mice, ferret, influenza, animal model, biosafety

  5. Concepts and applications for influenza antigenic cartography

    Science.gov (United States)

    Cai, Zhipeng; Zhang, Tong; Wan, Xiu-Feng

    2011-01-01

    Influenza antigenic cartography projects influenza antigens into a two or three dimensional map based on immunological datasets, such as hemagglutination inhibition and microneutralization assays. A robust antigenic cartography can facilitate influenza vaccine strain selection since the antigenic map can simplify data interpretation through intuitive antigenic map. However, antigenic cartography construction is not trivial due to the challenging features embedded in the immunological data, such as data incompleteness, high noises, and low reactors. To overcome these challenges, we developed a computational method, temporal Matrix Completion-Multidimensional Scaling (MC-MDS), by adapting the low rank MC concept from the movie recommendation system in Netflix and the MDS method from geographic cartography construction. The application on H3N2 and 2009 pandemic H1N1 influenza A viruses demonstrates that temporal MC-MDS is effective and efficient in constructing influenza antigenic cartography. The web sever is available at http://sysbio.cvm.msstate.edu/AntigenMap. PMID:21761589

  6. Influenza Vaccination Coverage Among Pregnant Women - United States, 2016-17 Influenza Season.

    Science.gov (United States)

    Ding, Helen; Black, Carla L; Ball, Sarah; Fink, Rebecca V; Williams, Walter W; Fiebelkorn, Amy Parker; Lu, Peng-Jun; Kahn, Katherine E; D'Angelo, Denise V; Devlin, Rebecca; Greby, Stacie M

    2017-09-29

    Pregnant women and their infants are at increased risk for severe influenza-associated illness (1), and since 2004, the Advisory Committee on Immunization Practices (ACIP) has recommended influenza vaccination for all women who are or might be pregnant during the influenza season, regardless of the trimester of the pregnancy (2). To assess influenza vaccination coverage among pregnant women during the 2016-17 influenza season, CDC analyzed data from an Internet panel survey conducted during March 28-April 7, 2017. Among 1,893 survey respondents pregnant at any time during October 2016-January 2017, 53.6% reported having received influenza vaccination before (16.2%) or during (37.4%) pregnancy, similar to coverage during the preceding four influenza seasons. Also similar to the preceding influenza season, 67.3% of women reported receiving a provider offer for influenza vaccination, 11.9% reported receiving a recommendation but no offer, and 20.7% reported receiving no recommendation; among these women, reported influenza vaccination coverage was 70.5%, 43.7%, and 14.8%, respectively. Among women who received a provider offer for vaccination, vaccination coverage differed by race/ethnicity, education, insurance type, and other sociodemographic factors. Use of evidence-based practices such as provider reminders and standing orders could reduce missed opportunities for vaccination and increase vaccination coverage among pregnant women.

  7. Avian Influenza infection in Human

    Directory of Open Access Journals (Sweden)

    Mohan. M

    2008-08-01

    Full Text Available Outbreaks caused by the H5N1 strain are presently of the greatest concern for human health. In assessing risks to human health, it is important to know exactly which avian virus strains are causing the outbreaks in birds.All available evidence points to an increased risk of transmission to humans when outbreaks of highly pathogenic avian H5N1 influenza are widespread in poultry. There is mounting evidence that this strain has a unique capacity to jump the species barrier and cause severe disease, with high mortality, in humans. There is no evidence, to date that efficient human to human transmission of H5N1 strain has occurred and very often. Efficient transmission among humans is a key property of pandemic strains and a property that the avian H5N1 and H9N2 viruses apparently lacked. The biological and molecular basis for effective aerosol transmission among humans is not known. The virus can improve its transmissibility among humans via two principal mechanisms. The first is a “reassortment” event, in which genetic material is exchanged between human and avian viruses during co-infection of a human or pig.Reassortment could result in a fully transmissible pandemic virus, announced by a sudden surge of cases with explosive spread. The second mechanism is a more gradual process of adaptive mutation, whereby the capability of the virus to bind to human cells increases during subsequent infections of humans. Adaptive mutation, expressed initially as small clusters of human cases with some evidence of human-to-human transmission, would probably give the world some time to take defensive action, if detected sufficiently early. As the number of human infections grows, the risk increases that a new virus subtype could emerge, triggering an influenza pandemic. Humans as well as swine must now be considered a potential mixing vessel for the generation of such a virus. This link between widespread infection in poultry and increased risk of human

  8. Economic and policy implications of pandemic influenza.

    Energy Technology Data Exchange (ETDEWEB)

    Smith, Braeton J.; Starks, Shirley J.; Loose, Verne W.; Brown, Theresa Jean; Warren, Drake E.; Vargas, Vanessa N.

    2010-03-01

    Pandemic influenza has become a serious global health concern; in response, governments around the world have allocated increasing funds to containment of public health threats from this disease. Pandemic influenza is also recognized to have serious economic implications, causing illness and absence that reduces worker productivity and economic output and, through mortality, robs nations of their most valuable assets - human resources. This paper reports two studies that investigate both the short- and long-term economic implications of a pandemic flu outbreak. Policy makers can use the growing number of economic impact estimates to decide how much to spend to combat the pandemic influenza outbreaks. Experts recognize that pandemic influenza has serious global economic implications. The illness causes absenteeism, reduced worker productivity, and therefore reduced economic output. This, combined with the associated mortality rate, robs nations of valuable human resources. Policy makers can use economic impact estimates to decide how much to spend to combat the pandemic influenza outbreaks. In this paper economists examine two studies which investigate both the short- and long-term economic implications of a pandemic influenza outbreak. Resulting policy implications are also discussed. The research uses the Regional Economic Modeling, Inc. (REMI) Policy Insight + Model. This model provides a dynamic, regional, North America Industrial Classification System (NAICS) industry-structured framework for forecasting. It is supported by a population dynamics model that is well-adapted to investigating macro-economic implications of pandemic influenza, including possible demand side effects. The studies reported in this paper exercise all of these capabilities.

  9. Memory CD4 T cells in influenza.

    Science.gov (United States)

    Zens, Kyra D; Farber, Donna L

    2015-01-01

    Influenza A virus is a significant cause of morbidity and mortality worldwide, particularly among young children and the elderly. Current vaccines induce neutralizing antibody responses directed toward highly variable viral surface proteins, resulting in limited heterosubtypic protection to new viral serotypes. By contrast, memory CD4 T cells recognize conserved viral proteins and are cross-reactive to multiple influenza strains. In humans, virus-specific memory CD4 T cells were found to be the protective correlate in human influenza challenge studies, suggesting their key role in protective immunity. In mouse models, memory CD4 T cells can mediate protective responses to secondary influenza infection independent of B cells or CD8 T cells, and can influence innate immune responses. Importantly, a newly defined, tissue-resident CD4 memory population has been demonstrated to be retained in lung tissue and promote optimal protective responses to an influenza infection. Here, we review the current state of results regarding the generation of memory CD4 T cells following primary influenza infection, mechanisms for their enhanced efficacy in protection from secondary challenge including their phenotype, localization, and function in the context of both mouse models and human infection. We also discuss the generation of memory CD4 T cells in response to influenza vaccines and its future implications for vaccinology.

  10. Increasing herd immunity with influenza revaccination.

    Science.gov (United States)

    Mooring, E Q; Bansal, S

    2016-04-01

    Seasonal influenza is a significant public health concern globally. While influenza vaccines are the single most effective intervention to reduce influenza morbidity and mortality, there is considerable debate surrounding the merits and consequences of repeated seasonal vaccination. Here, we describe a two-season influenza epidemic contact network model and use it to demonstrate that increasing the level of continuity in vaccination across seasons reduces the burden on public health. We show that revaccination reduces the influenza attack rate not only because it reduces the overall number of susceptible individuals, but also because it better protects highly connected individuals, who would otherwise make a disproportionately large contribution to influenza transmission. We also demonstrate that our results hold on an empirical contact network, in the presence of assortativity in vaccination status, and are robust for a range of vaccine coverage and efficacy levels. Our work contributes a population-level perspective to debates about the merits of repeated influenza vaccination and advocates for public health policy to incorporate individual vaccine histories.

  11. Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study.

    Science.gov (United States)

    Macintyre, C Raina; Heywood, Anita E; Kovoor, Pramesh; Ridda, Iman; Seale, Holly; Tan, Timothy; Gao, Zhanhai; Katelaris, Anthea L; Siu, Ho Wai Derrick; Lo, Vincent; Lindley, Richard; Dwyer, Dominic E

    2013-12-01

    Abundant, indirect epidemiological evidence indicates that influenza contributes to all-cause mortality and cardiovascular hospitalisations with studies showing increases in acute myocardial infarction (AMI) and death during the influenza season. To investigate whether influenza is a significant and unrecognised underlying precipitant of AMI. Case-control study. Tertiary referral hospital in Sydney, Australia, during 2008 to 2010. Cases were inpatients with AMI and controls were outpatients without AMI at a hospital in Sydney, Australia. Primary outcome was laboratory evidence of influenza. Secondary outcome was baseline self-reported acute respiratory tract infection. Of 559 participants, 34/275 (12.4%) cases and 19/284 (6.7%) controls had influenza (OR 1.97, 95% CI 1.09 to 3.54); half were vaccinated. None were recognised as having influenza during their clinical encounter. After adjustment, influenza infection was no longer a significant predictor of recent AMI. However, influenza vaccination was significantly protective (OR 0.55, 95% CI 0.35 to 0.85), with a vaccine effectiveness of 45% (95% CI 15% to 65%). Recent influenza infection was an unrecognised comorbidity in almost 10% of hospital patients. Influenza did not predict AMI, but vaccination was significantly protective but underused. The potential population health impact of influenza vaccination, particularly in the age group 50-64 years, who are at risk for AMI but not targeted for vaccination, should be further explored. Our data should inform vaccination policy and cardiologists should be aware of missed opportunities to vaccinate individuals with ischaemic heart disease against influenza.

  12. Meningoencephalitis syndrome following influenza vaccination.

    Science.gov (United States)

    Gross, W L; Ravens, K G; Hansen, H W

    1978-02-14

    Immunological reactions to non-virus substances of vaccines may be of considerable significance to the pathogenesis of neurological complications after anti-influenza vaccination. A 60 year old female patient with a known allergic diathesis developed a meningoencephalitis syndrome a few hours after vaccination. The case history as well as the clinical course suggested an immunopathogenetic mechanism. We therefore analyzed the immune profile. Intracutaneous testing with chicken meat and chicken egg protein lead to a striking local anaphylactic reaction which is discussed in causal relation to the postvaccination complication.

  13. Modeling Influenza Virus Infection: A Roadmap for Influenza Research

    Directory of Open Access Journals (Sweden)

    Alessandro Boianelli

    2015-10-01

    Full Text Available Influenza A virus (IAV infection represents a global threat causing seasonal outbreaks and pandemics. Additionally, secondary bacterial infections, caused mainly by Streptococcus pneumoniae, are one of the main complications and responsible for the enhanced morbidity and mortality associated with IAV infections. In spite of the significant advances in our knowledge of IAV infections, holistic comprehension of the interplay between IAV and the host immune response (IR remains largely fragmented. During the last decade, mathematical modeling has been instrumental to explain and quantify IAV dynamics. In this paper, we review not only the state of the art of mathematical models of IAV infection but also the methodologies exploited for parameter estimation. We focus on the adaptive IR control of IAV infection and the possible mechanisms that could promote a secondary bacterial coinfection. To exemplify IAV dynamics and identifiability issues, a mathematical model to explain the interactions between adaptive IR and IAV infection is considered. Furthermore, in this paper we propose a roadmap for future influenza research. The development of a mathematical modeling framework with a secondary bacterial coinfection, immunosenescence, host genetic factors and responsiveness to vaccination will be pivotal to advance IAV infection understanding and treatment optimization.

  14. Universal influenza vaccines: Shifting to better vaccines.

    Science.gov (United States)

    Berlanda Scorza, Francesco; Tsvetnitsky, Vadim; Donnelly, John J

    2016-06-03

    Influenza virus causes acute upper and lower respiratory infections and is the most likely, among known pathogens, to cause a large epidemic in humans. Influenza virus mutates rapidly, enabling it to evade natural and vaccine-induced immunity. Furthermore, influenza viruses can cross from animals to humans, generating novel, potentially pandemic strains. Currently available influenza vaccines induce a strain specific response and may be ineffective against new influenza viruses. The difficulty in predicting circulating strains has frequently resulted in mismatch between the annual vaccine and circulating viruses. Low-resource countries remain mostly unprotected against seasonal influenza and are particularly vulnerable to future pandemics, in part, because investments in vaccine manufacturing and stockpiling are concentrated in high-resource countries. Antibodies that target conserved sites in the hemagglutinin stalk have been isolated from humans and shown to confer protection in animal models, suggesting that broadly protective immunity may be possible. Several innovative influenza vaccine candidates are currently in preclinical or early clinical development. New technologies include adjuvants, synthetic peptides, virus-like particles (VLPs), DNA vectors, messenger RNA, viral vectors, and attenuated or inactivated influenza viruses. Other approaches target the conserved exposed epitope of the surface exposed membrane matrix protein M2e. Well-conserved influenza proteins, such as nucleoprotein and matrix protein, are mainly targeted for developing strong cross-protective T cell responses. With multiple vaccine candidates moving along the testing and development pipeline, the field is steadily moving toward a product that is more potent, durable, and broadly protective than previously licensed vaccines. Copyright © 2016 World Health Organization. Published by Elsevier Ltd.. All rights reserved.

  15. [Shared surveillance: meningococcal disease vs influenza].

    Science.gov (United States)

    Moreno-Civantos, A; Díaz-Jiménez, J; Domínguez-Berjón, M F

    2000-01-01

    To analyse the association between the behavior of meningococcal disease and influenza, using for this purpose population statistics for Spain for the period of 1964 to 1997. Ecological study of the incidence of meningococcal disease and influenza in Spain from 1964 to 1997, inclusive. The study used weekly statistical data for these diseases supplied by the Compulsory Disease Reporting System (Enfermedades de Declaración Obligatoria, EDO). The deterministic component of the meningococcal disease and influenza series was studied by means of spectral analysis based on the Fast Fourier Transformation, and the non-deterministic component was studied using the ARIMA model. The Box-Jenkins method was used for pre-bleaching the series, and a cross-correlation was subsequently established between the residuals in order to detect the presence of any significant correlations between the meningococcal disease and influenza series. During the period from 1964 to 1997, the week that showed, on average, the greatest number of cases for the season was week 7 in the case of meningococcal disease and week 6 in the case of influenza. Spectral analysis of the meningococcal disease and influenza series clearly demonstrated the annual periodicity of both series, and periodicity of nearly 11 years for meningococcal disease and slightly over 10 years for influenza. When cross-correlation is established after prebleaching the series, positive correlations are obtained in the results of lags 0, 1, 2, and 3. Introducing influenza as an exogenous variable in the multivariate model of meningococcal disease corroborates these results. There was a statistically significant relationship between the two processes during the same week and with a three-week lapse. By means of a methodology not previously applied to this subject, and by the use of prolonged time-span, country-comprehensive population statistics (which includes several epidemics waves), an association was shown to exist between

  16. The global transmission and control of influenza.

    Directory of Open Access Journals (Sweden)

    Eben Kenah

    2011-05-01

    Full Text Available New strains of influenza spread around the globe via the movement of infected individuals. The global dynamics of influenza are complicated by different patterns of influenza seasonality in different regions of the world. We have released an open-source stochastic mathematical model of the spread of influenza across 321 major, strategically located cities of the world. Influenza is transmitted between cities via infected airline passengers. Seasonality is simulated by increasing the transmissibility in each city at the times of the year when influenza has been observed to be most prevalent. The spatiotemporal spread of pandemic influenza can be understood through clusters of global transmission and links between them, which we identify using the epidemic percolation network (EPN of the model. We use the model to explain the observed global pattern of spread for pandemic influenza A(H1N1 2009-2010 (pandemic H1N1 2009 and to examine possible global patterns of spread for future pandemics depending on the origin of pandemic spread, time of year of emergence, and basic reproductive number (. We also use the model to investigate the effectiveness of a plausible global distribution of vaccine for various pandemic scenarios. For pandemic H1N1 2009, we show that the biggest impact of vaccination was in the temperate northern hemisphere. For pandemics starting in the temperate northern hemisphere in May or April, vaccination would have little effect in the temperate southern hemisphere and a small effect in the tropics. With the increasing interconnectedness of the world's population, we must take a global view of infectious disease transmission. Our open-source, computationally simple model can help public health officials plan for the next pandemic as well as deal with interpandemic influenza.

  17. C&S Enterprise, L.L.C.

    Science.gov (United States)

    The EPA is providing notice of a proposed Administrative Penalty Assessment against C & S Enterprise, L.L.C. (“Respondent”), a business located at 2454 480th Ave, Deep River, IA 52222, for alleged violations of the Clean Water Act at property owned by Resp

  18. 77 FR 77070 - Black Bear Hydro Partners, LLC;

    Science.gov (United States)

    2012-12-31

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 2727-086] Black Bear Hydro...: October 24, 2012. d. Submitted By: Black Bear Hydro Partners, LLC (Black Bear Hydro). e. Name of Project... designating Black Bear Hydro as the Commission's non-federal representative for carrying out informal...

  19. 78 FR 69405 - Enable Gas Transmission, LLC; Notice of Application

    Science.gov (United States)

    2013-11-19

    ... October 28, 2013, Enable Gas Transmission, LLC (Enable), 1111 Louisiana Street, Houston, Texas 77002... Commission staff will either complete its environmental assessment (EA) and place it into the Commission's... complete all federal authorizations within 90 days of the date of issuance of the Commission staff's FEIS...

  20. Majestic C Team, LLC - Clean Water Act Public Notice

    Science.gov (United States)

    The EPA is providing notice of a proposed Administrative Penalty Assessment against Majestic C Team, LLC., which owns a residential construction site located at 168th St and State St in Omaha, NE for alleged violations of its NPDES permit (permit No. NER11

  1. Procyon LLC: From Music Recommendations to Preference Mapping

    Science.gov (United States)

    Chinn, Susan J.

    2011-01-01

    Procyon LLC had re-launched and renamed their music discovery site, Electra, to Capella, in 2008. Its core strength had originated from Electra's proprietary technology, which used music libraries from real people, its members, to generating "automated word-of-mouth" recommendations, targeted advertising and editorial content. With the re-launch,…

  2. Analysis and implementation of LLC-T series parallel resonant ...

    African Journals Online (AJOL)

    A prototype 300 W, 100 kHz converter is designed and built to experimentally demonstrate, dynamic and steady state performance for the LLC-T series parallel resonant converter. A comparative study is performed between experimental results and the simulation studies. The analysis shows that the output of converter is ...

  3. 78 FR 36017 - MCM Rail Services LLC, d/b/a Baltimore Industrial Railroad-Operation Exemption-Hilco SP Rail, LLC

    Science.gov (United States)

    2013-06-14

    ... DEPARTMENT OF TRANSPORTATION Surface Transportation Board [Docket No. FD 35725] MCM Rail Services LLC, d/b/a Baltimore Industrial Railroad-- Operation Exemption--Hilco SP Rail, LLC MCM Rail Services... under 49 CFR 1150.31 to operate as a common carrier over an approximately 12-mile line of railroad in...

  4. 77 FR 70434 - Petal Gas Storage, L.L.C., Hattiesburg Industrial Gas Sales, L.L.C.; Notice of Offer of Settlement

    Science.gov (United States)

    2012-11-26

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. CP12-464-000] Petal Gas Storage, L.L.C., Hattiesburg Industrial Gas Sales, L.L.C.; Notice of Offer of Settlement Take notice that... aspects of the terms and conditions of the 311 firm storage service offered by Hattiesburg. Petal agrees...

  5. Characterization of influenza virus among influenza like illness cases in Mumbai, India.

    Science.gov (United States)

    Roy, Soumen; Dahake, Ritwik; Patil, Deepak; Tawde, Shweta; Mukherjee, Sandeepan; Athlekar, Shrikant; Chowdhary, Abhay; Deshmukh, Ranjana

    2014-01-01

    The present study was carried out to monitor influenza viruses by identifying the virus and studying the seasonal variation during 2007-2009 in Mumbai. A total of 193 clinical respiratory samples (nasal and throat swab) were collected from patients having influenza like illness in Mumbai region. One-step real-time reverse-transcriptase PCR (rRTPCR) was used to detect Influenza type A (H1 and H3) and Influenza type B virus. Isolation of the virus was carried out using in vitro system which was further confirmed and typed by hemagglutination assay and hemagglutination inhibition assay. Out of 193 samples 24 (12.4 3%) samples tested positive for influenza virus, of which 13 (6.73 %) were influenza type A virus and 10 (5.18 %) were influenza type B virus, while 1 sample (0.51 %) was positive for both. By culture methods, 3 (1.55 %) viral isolates were obtained. All the three isolates were found to be Influenza type B/Malaysia (Victoria lineage) by Hemagglutination Inhibition Assay. The data generated from the present study reveals that both Influenza type A and B are prevalent in Mumbai with considerable activity. The peak activity was observed during monsoon season.

  6. Naturligt forekommende oseltamivirresistens hos influenza A

    DEFF Research Database (Denmark)

    Madsen, Laura; Nielsen, Alex; Lundgren, Jens

    2010-01-01

    in the development of resistance. The best prevention strategy remains vaccination of the general population to avoid immunity. Future antiviral treatment calls for knowledge about resistance to existing types of influenza and the availability of all three types of antiviral medication.......During the last two influenza seasons, one of the predominant influenza A types (H1N1) has developed complete resistance to oseltamivir, the primary treatment option. The virus does, however, remain sensitive to zanamavir and amantadine. There is no unequivocal explanation for this slide...

  7. [Naturally occurring oseltamivir resistance in influenza A.

    DEFF Research Database (Denmark)

    Madsen, Laura; Nielsen, Alex; Lundgren, Jens

    2010-01-01

    in the development of resistance. The best prevention strategy remains vaccination of the general population to avoid immunity. Future antiviral treatment calls for knowledge about resistance to existing types of influenza and the availability of all three types of antiviral medication. Udgivelsesdato: 2010-Aug......During the last two influenza seasons, one of the predominant influenza A types (H1N1) has developed complete resistance to oseltamivir, the primary treatment option. The virus does, however, remain sensitive to zanamavir and amantadine. There is no unequivocal explanation for this slide...

  8. Naturligt forekommende oseltamivirresistens hos influenza A

    DEFF Research Database (Denmark)

    Madsen, Laura; Nielsen, Alex; Lundgren, Jens

    2010-01-01

    During the last two influenza seasons, one of the predominant influenza A types (H1N1) has developed complete resistance to oseltamivir, the primary treatment option. The virus does, however, remain sensitive to zanamavir and amantadine. There is no unequivocal explanation for this slide...... in the development of resistance. The best prevention strategy remains vaccination of the general population to avoid immunity. Future antiviral treatment calls for knowledge about resistance to existing types of influenza and the availability of all three types of antiviral medication....

  9. [Naturally occurring oseltamivir resistance in influenza A.

    DEFF Research Database (Denmark)

    Madsen, Laura; Nielsen, Alex; Lundgren, Jens

    2010-01-01

    During the last two influenza seasons, one of the predominant influenza A types (H1N1) has developed complete resistance to oseltamivir, the primary treatment option. The virus does, however, remain sensitive to zanamavir and amantadine. There is no unequivocal explanation for this slide...... in the development of resistance. The best prevention strategy remains vaccination of the general population to avoid immunity. Future antiviral treatment calls for knowledge about resistance to existing types of influenza and the availability of all three types of antiviral medication. Udgivelsesdato: 2010-Aug...

  10. Influenza in Bristol Bay, 1919

    Directory of Open Access Journals (Sweden)

    Maria Gilson deValpine

    2015-03-01

    Full Text Available The 1918 influenza pandemic has been blamed for as many as 50 million deaths worldwide. Like all major disasters, the full story of the pandemic includes smaller, less noted episodes that have not attracted historical attention. The story of the 1919 wave of the influenza pandemic in Bristol Bay Alaska is one such lost episode. It is an important story because the most accessible accounts—the Congressional Record and the Coast Guard Report—are inconsistent with reports made by employees, health care workers, and volunteers at the site of the disaster. Salmon fishing industry supervisors and medical officers recorded their efforts to save the region’s Native Alaskans in private company reports. The federal Bureau of Education physician retained wireless transmission, reports, and letters of events. The Coast Guard summarized its work in its Annual Report of 1920. The independent Bureau of Fisheries report to the Department of Commerce reveals the Coast Guard report at striking odds with others and reconciles only one account. This article explores the historical oversight, and attempts to tell the story of the 1919 wave of the pandemic which devastated the Native Alaskan population in this very remote place.

  11. An overview on avian influenza

    Directory of Open Access Journals (Sweden)

    Nelson Rodrigo da Silva Martins

    2012-06-01

    Full Text Available Avian influenza (AI is considered an exotic disease in the Brazilian poultry industry, according to the National Avian Health Program (PNSA, with permanent monitoring of domestic, exotic and native avian species. Brazil presents privileged environmental conditions of reduced risk. In addition, all commercial poultry and conservation holdings are registered in state or national inventories and geographically located (GPS for health control. Poultry health standards are adopted for the conformity to the international market, mostly for the intensified poultry destined for exportation, but also for companion exotic and native conservation facilities. Guidelines for monitoring and the diagnosis of AI are published by the PNSA and follow the standards proposed by the international health code (World Organization for Animal Health, Organization International des Epizooties - OIE and insure the free of status for avian influenza virus (AIV of LPAIV-low pathogenicity AIV and HPAIV-high pathogenicity AIV. In addition, the infections by mesogenic and velogenic Newcastle disease virus, Mycoplasma gallisepticum, M. synoviae and M. meleagridis, Salmonella enteric subspecies enterica serovar Gallinarum biovars Gallinarum and Pullorum are eradicated from reproduction. Controlled infections by S.enterica subspecies enterica serovars Enteritidis and Typhimurium are monitored for breeders. The vaccination of chickens in ovo or at hatch against Marek's disease is mandatory. Broiler production is an indoor activity, confinement which insures biosecurity, with safe distances from the potential AIV reservoir avian species. Worldwide HPAIV H5N1 notifications to the OIE, in March 2011, included 51 countries.

  12. 77 FR 41475 - El Expreso Group, LLC-Asset Acquisition-CUSA EE, LLC D/B/A El Expreso

    Science.gov (United States)

    2012-07-13

    ... the assets of CUSA EE, LLC d/b/a El Expreso (CUSA EE) (MC-463171), an interstate motor passenger... Expreso Group's application identified Tornado Bus Company, Inc. (Tornado), an affiliate, as a second... passenger carrier, are owned and controlled by Jan Vazquez, an individual. In addition to interstate common...

  13. 75 FR 34170 - Chrysler Group LLC, Formally Known as Chrysler LLC, Kenosha Engine Plant, Including On-Site...

    Science.gov (United States)

    2010-06-16

    ... certification for workers of the subject firm. The workers are engaged in activities in production of V-6 automobile engines. The company reports that workers leased from Caravan Knight Facilities Management, LLC... under the control of the subject firm to be considered leased workers. Based on these findings, the...

  14. 76 FR 19473 - Chrysler Financial Services Americas, LLC, a Subsidiary of FinCo Intermediate Holding Co., LLC...

    Science.gov (United States)

    2011-04-07

    ... Employment and Training Administration Chrysler Financial Services Americas, LLC, a Subsidiary of FinCo... Application for Reconsideration for the workers and former workers of Chrysler Financial Services Americas... financial services to dealers and consumers, including retail and wholesale financing, remarketing, and...

  15. 78 FR 12750 - FirstEnergy Solutions Corp., Allegheny Energy Supply Company, LLC v. PJM Interconnection, L.L.C...

    Science.gov (United States)

    2013-02-25

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission FirstEnergy Solutions Corp., Allegheny Energy Supply Company, LLC v. PJM... sections 206 and 306 of the Federal Power Act, 16 U.S.C. 824(e) and 825(e), FirstEnergy Solutions Corp. and...

  16. 77 FR 790 - FirstEnergy Solutions Corp., Allegheny Energy Supply Company, LLC v. PJM Interconnection, L.L.C...

    Science.gov (United States)

    2012-01-06

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission FirstEnergy Solutions Corp., Allegheny Energy Supply Company, LLC v. PJM...) Rules of Practice and Procedures, 18 CFR 385.206, FirstEnergy Solutions Corp., Allegheny Energy Supply...

  17. 77 FR 20019 - FirstEnergy Solutions Corp., Allegheny Energy Supply Company, LLC v. PJM Interconnection, L.L.C...

    Science.gov (United States)

    2012-04-03

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission FirstEnergy Solutions Corp., Allegheny Energy Supply Company, LLC v. PJM... Practice and Procedure, 18 CFR 385.206 and 206(h), FirstEnergy Solutions Corp. (FirstEnergy Solutions) and...

  18. 77 FR 25155 - Atlantic Power Energy Services (US) LLC; White Eagle Trading, LLC; Morgan Stanley Capital Group...

    Science.gov (United States)

    2012-04-27

    ... Eagle Trading, Order granting blanket LLC.. authority to export natural gas to Mexico. 03/14/12 12-20... export natural gas to Mexico. 03/14/12 12-23-NG National Fuel Order granting blanket Resources, Inc... Orders Granting Authority To Import and Export Natural Gas and Liquefied Natural Gas During March 2012...

  19. Age- and influenza activity-stratified case definitions of influenza-like illness: experience from hospital-based influenza surveillance in South Korea.

    Directory of Open Access Journals (Sweden)

    Tae Un Yang

    Full Text Available OBJECTIVES: This study aims to identify clinical case definitions of influenza with higher accuracy in patients stratified by age group and influenza activity using hospital-based surveillance system. METHODS: In seven tertiary hospitals across South Korea during 2011-2012 influenza season, respiratory specimens were obtained from patients presenting an influenza-like illness (ILI, defined as having fever plus at least one of following symptoms: cough, sore throat or rhinorrhea. Influenza was confirmed by reverse transcriptase-polymerase chain reaction. We performed multivariate logistic regression analyses to identify clinical variables with better relation with laboratory-confirmed influenza, and compared the accuracy of combinations. RESULTS: Over the study period, we enrolled 1417 patients, of which 647 had laboratory-confirmed influenza. Patients with cough, rhinorrhea, sore throat or headache were more likely to have influenza (p<0.05. The most accurate criterion across the study population was the combination of cough, rhinorrhea, sore throat and headache (sensitivity 71.3%, specificity 60.1% and AUROC 0.66. The combination of rhinorrhea, sore throat and sputum during the peak influenza activity period in the young age group showed higher accuracy than that using the whole population (sensitivity 89.3%, specificity 72.1%, and AUROC 0.81. CONCLUSIONS: The accuracy of clinical case definitions of influenza differed across age groups and influenza activity periods. Categorizing the entire population into subgroups would improve the detection of influenza patients in the hospital-based surveillance system.

  20. Influenza-associated mortality in South Africa, 2009-2013: The importance of choices related to influenza infection proxies.

    Science.gov (United States)

    Gul, Desmond; Cohen, Cheryl; Tempia, Stefano; Newall, Anthony T; Muscatello, David J

    2018-01-01

    Regression modeling methods are commonly used to estimate influenza-associated mortality using covariates such as laboratory-confirmed influenza activity in the population as a proxy of influenza incidence. We examined the choices of influenza proxies that can be used from influenza laboratory surveillance data and their impact on influenza-associated mortality estimates. Semiparametric generalized additive models with a smoothing spline were applied on national mortality data from South Africa and influenza surveillance data as covariates to obtain influenza-associated mortality estimates from respiratory causes from 2009 to 2013. Proxies examined included alternative ways of expressing influenza laboratory surveillance data such as weekly or yearly proportion or rate of positive samples, using influenza subtypes, or total influenza data and expressing the data as influenza season-specific or across all seasons. Based on model fit, weekly proportion and influenza subtype-specific proxy formulation provided the best fit. The choice of proxies used gave large differences to mortality estimates, but the 95% confidence interval of these estimates overlaps. Regardless of proxy chosen, mortality estimates produced may be broadly consistent and not statistically significant for public health practice. © 2017 The Authors. Influenza and Other Respiratory Viruses. Published by John Wiley & Sons Ltd.

  1. Repeated influenza vaccination for preventing severe and fatal influenza infection in older adults: a multicentre case-control study.

    Science.gov (United States)

    Casado, Itziar; Domínguez, Ángela; Toledo, Diana; Chamorro, Judith; Astray, Jenaro; Egurrola, Mikel; Fernández-Sierra, María Amelia; Martín, Vicente; Morales-Suárez-Varela, María; Godoy, Pere; Castilla, Jesús

    2018-01-08

    The effectiveness of repeated vaccination for influenza to prevent severe cases remains unclear. We evaluated the effectiveness of influenza vaccination on preventing admissions to hospital for influenza and reducing disease severity. We conducted a case-control study in 20 hospitals in Spain during the 2013/14 and 2014/15 influenza seasons. Community-dwelling adults aged 65 years or older who were admitted to hospital for laboratory-confirmed influenza were matched with inpatient controls by sex, age, hospital and admission date. The effectiveness of vaccination in the current and 3 previous seasons in preventing influenza was estimated for inpatients with nonsevere influenza and for those with severe influenza who were admitted to intensive care units (ICUs) or who died. We enrolled 130 inpatients with severe and 598 with nonsevere influenza who were matched to 333 and 1493 controls, respectively. Compared with patients who were unvaccinated in the current and 3 previous seasons, adjusted effectiveness of influenza vaccination in the current and any previous season was 31% (95% confidence interval [CI] 13%-46%) in preventing admission to hospital for nonsevere influenza, 74% (95% CI 42%-88%) in preventing admissions to ICU and 70% (95% CI 34%-87%) in preventing death. Vaccination in the current season only had no significant effect on cases of severe influenza. Among inpatients with influenza, vaccination in the current and any previous season reduced the risk of severe outcomes (adjusted odds ratio 0.45, 95% CI 0.26-0.76). Among older adults, repeated vaccination for influenza was twice as effective in preventing severe influenza compared with nonsevere influenza in patients who were admitted to hospital, which is attributable to the combination of the number of admissions to hospital for influenza that were prevented and reduced disease severity. These results reinforce recommendations for annual vaccination for influenza in older adults. © 2018 Joule Inc. or

  2. Evaluation of the Sofia Influenza A + B fluorescent immunoassay for the rapid diagnosis of influenza A and B.

    Science.gov (United States)

    Hazelton, Briony; Nedeljkovic, Gordana; Ratnamohan, V Mala; Dwyer, Dominic E; Kok, Jen

    2015-01-01

    Rapid influenza diagnostic tests (RIDTs) can facilitate the appropriate prescription of antivirals for influenza, obviate the need for unnecessary testing and antibacterial agents and allow the implementation of infection control measures. However, the reported sensitivities and specificities of different RIDTs vary widely in clinical settings, as does assay ability to distinguish between influenza types and subtypes. To evaluate the performance of the Sofia Influenza A + B fluorescent immunoassay (FIA) for the detection of influenza A and B during the 2013 Southern Hemisphere influenza season, a total of 209 consecutive respiratory tract swabs from adult patients with an influenza-like illness were tested by both Sofia Influenza A + B and an in-house real-time, reverse transcription-polymerase chain reaction (RT-PCR) assay. Compared to RT-PCR, the sensitivity and specificity of the Sofia Influenza A + B FIA for detection of influenza A was 72.4% and 98.3%, respectively. Too few influenza B positive samples were available during the study to accurately assess the Sofia's performance for influenza B detection. The sensitivity of Sofia Influenza A + B FIA for both influenza A and B detection correlated with the amount of influenza RNA present in the sample as indicated indirectly by the RT-PCR cycle threshold (Ct ). In conclusion, the Sofia Influenza A + B FIA continues to perform well as a RIDT with the circulating influenza strains of the 2013 Southern Hemisphere influenza season. © 2014 Wiley Periodicals, Inc.

  3. Influenza pneumonia surveillance among hospitalized adults may underestimate the burden of severe influenza disease.

    Directory of Open Access Journals (Sweden)

    Justin R Ortiz

    Full Text Available Studies seeking to estimate the burden of influenza among hospitalized adults often use case definitions that require presence of pneumonia. The goal of this study was to assess the extent to which restricting influenza testing to adults hospitalized with pneumonia could underestimate the total burden of hospitalized influenza disease.We conducted a modelling study using the complete State Inpatient Databases from Arizona, California, and Washington and regional influenza surveillance data acquired from CDC from January 2003 through March 2009. The exposures of interest were positive laboratory tests for influenza A (H1N1, influenza A (H3N2, and influenza B from two contiguous US Federal Regions encompassing the study area. We identified the two outcomes of interest by ICD-9-CM code: respiratory and circulatory hospitalizations, as well as critical illness hospitalizations (acute respiratory failure, severe sepsis, and in-hospital death. We linked the hospitalization datasets with the virus surveillance datasets by geographic region and month of hospitalization. We used negative binomial regression models to estimate the number of influenza-associated events for the outcomes of interest. We sub-categorized these events to include all outcomes with or without pneumonia diagnosis codes.We estimated that there were 80,834 (95% CI 29,214-174,033 influenza-associated respiratory and circulatory hospitalizations and 26,760 (95% CI 14,541-47,464 influenza-associated critical illness hospitalizations. When a pneumonia diagnosis was excluded, the estimated number of influenza-associated respiratory and circulatory hospitalizations was 24,816 (95% CI 6,342-92,624. The estimated number of influenza-associated critical illness hospitalizations was 8,213 (95% CI 3,764-20,799. Around 30% of both influenza-associated respiratory and circulatory hospitalizations, as well as influenza-associated critical illness hospitalizations did not have pneumonia diagnosis

  4. Streptococcus pneumoniae and Haemophilus influenzae at the initial stage of influenza.

    Science.gov (United States)

    Takano, Misao; Ozaki, Kyoko; Nitahara, Yoshiyuki; Higuchi, Wataru; Takano, Tomomi; Nishiyama, Akihito; Yamamoto, Tatsuo

    2009-10-01

    Streptococcus pneumoniae and Haemophilus influenzae infections in children with influenza have been noted because of the severity of co-infection. In Japan, vaccination against S. pneumoniae and H. influenzae infections has been listed in the vaccine program in 2008, but the characteristics of the two organisms, colonizing at the initial stage of influenza infection, have not been investigated in detail. Nasopharyngeal swabs from children with influenza (flu(+)) (n= 236; mean age, 6.2 years) were examined for bacterial pathogens, including S. pneumoniae and H. influenzae. They were then examined for serotypes, drug susceptibilities, and resistance genes (or gene mutations). As a reference, children with upper respiratory tract infection (URTI(+), flu(-); n = 189; mean age, 6.2 years) were also examined. S. pneumoniae, beta-streptococci (groups A, B, and G), methicillin-susceptible and -resistant S. aureus, Moraxella catarrhalis, and H. influenzae were isolated. For S. pneumoniae, nine serotypes were detected with prevalent types of 3, 6, 19 and 23. Penicillin resistance was detected in types 19 and 23, while resistance to macrolide and clindamycin was found in various types. For H. influenzae, only b serotype was detected, with marked ampicillin resistance. The majority was non-typeable. Very similar results were obtained even in URTI(+) (flu(-)) cases. Multiple drug-resistant S. pneumoniae with major serotypes, for example, 19 and 23 and H. influenzae with serotype b were already present at the initial stage of influenza infection, similar to URTI(+) flu(-) cases. They could be prevented by current vaccines, but drug-resistant non-typeable H. influenzae is troubling.

  5. Potent peptidic fusion inhibitors of influenza virus

    Energy Technology Data Exchange (ETDEWEB)

    Kadam, Rameshwar U.; Juraszek, Jarek; Brandenburg, Boerries; Buyck, Christophe; Schepens, Wim B. G.; Kesteleyn, Bart; Stoops, Bart; Vreeken, Rob J.; Vermond, Jan; Goutier, Wouter; Tang, Chan; Vogels, Ronald; Friesen, Robert H. E.; Goudsmit, Jaap; van Dongen, Maria J. P.; Wilson, Ian A.

    2017-09-28

    Influenza therapeutics with new targets and mechanisms of action are urgently needed to combat potential pandemics, emerging viruses, and constantly mutating strains in circulation. We report here on the design and structural characterization of potent peptidic inhibitors of influenza hemagglutinin. The peptide design was based on complementarity-determining region loops of human broadly neutralizing antibodies against the hemagglutinin (FI6v3 and CR9114). The optimized peptides exhibit nanomolar affinity and neutralization against influenza A group 1 viruses, including the 2009 H1N1 pandemic and avian H5N1 strains. The peptide inhibitors bind to the highly conserved stem epitope and block the low pH–induced conformational rearrangements associated with membrane fusion. These peptidic compounds and their advantageous biological properties should accelerate the development of new small molecule– and peptide-based therapeutics against influenza virus.

  6. NNDSS - Table II. Giardiasis to Haemophilus influenza

    Data.gov (United States)

    U.S. Department of Health & Human Services — NNDSS - Table II. Giardiasis to Haemophilus influenza - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the...

  7. Uptake of the Influenza Vaccination in Pregnancy

    LENUS (Irish Health Repository)

    Crosby, DA

    2016-09-01

    Influenza is caused by a highly infectious RNA virus, which usually occurs in a seasonal pattern with epidemics in the winter months. The objective of this study was to determine the uptake of the influenza vaccine in a pregnant population and ascertain the reasons why some women did not receive it. A prospective cohort study was conducted over a two-week period in January 2016 in the National Maternity Hospital Dublin, a tertiary referral maternity hospital delivering over 9000 infants per year. There were 504 women studied over the 2-week period. Overall, 197(39.1%) women received the vaccine at a mean gestational age 20.9 weeks (SD 7.0). Given the increased rates of influenza in the community and the associated implications for mother and infant, it is important that pregnant women are educated regarding the risks of influenza in pregnancy and encourage this cohort to be vaccinated.

  8. NNDSS - Table II. Giardiasis to Haemophilus influenza

    Data.gov (United States)

    U.S. Department of Health & Human Services — NNDSS - Table II. Giardiasis to Haemophilus influenza - 2018. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the...

  9. NNDSS - Table II. Giardiasis to Haemophilus influenza

    Data.gov (United States)

    U.S. Department of Health & Human Services — NNDSS - Table II. Giardiasis to Haemophilus influenza - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the...

  10. Diagnosis and Treatment of Influenza in Children

    Directory of Open Access Journals (Sweden)

    M. S. Savenkova

    2016-01-01

    Full Text Available The article presents data on influenza epidemiology, pathogenesis, classification, clinical variants, diagnosis. Given the variety of antiviral drugs, highlighted the most relevant and used in pediatric patients, depending on age and mixed-flow options viral infections.

  11. Pandemic influenza and pediatric intensive care

    NARCIS (Netherlands)

    Nap, Raoul E.; Andriessen, Maarten P. H. M.; Meessen, Nico E. L.; Albers, Marcel J. I. J.; van der Werf, Tjip S.

    Objective: To assess the adequacy of preparedness planning for an influenza pandemic by modeling the pediatric surge capacity of healthcare facility and pediatric intensive care unit (PICU) requirements over time. Governments and Public Health authorities have planned preparedness activities and

  12. NNDSS - Table II. Giardiasis to Haemophilus influenza

    Data.gov (United States)

    U.S. Department of Health & Human Services — NNDSS - Table II. Giardiasis to Haemophilus influenza - 2018. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the...

  13. NNDSS - Table II. Giardiasis to Haemophilus influenza

    Data.gov (United States)

    U.S. Department of Health & Human Services — NNDSS - Table II. Giardiasis to Haemophilus influenza - 2016. In this Table, provisional* cases of selected† notifiable diseases (≥1,000 cases reported during the...

  14. NNDSS - Table II. Giardiasis to Haemophilus influenza

    Data.gov (United States)

    U.S. Department of Health & Human Services — NNDSS - Table II. Giardiasis to Haemophilus influenza - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the...

  15. Secondary Bacterial Infections Associated with Influenza Pandemics

    Directory of Open Access Journals (Sweden)

    Denise E. Morris

    2017-06-01

    Full Text Available Lower and upper respiratory infections are the fourth highest cause of global mortality (Lozano et al., 2012. Epidemic and pandemic outbreaks of respiratory infection are a major medical concern, often causing considerable disease and a high death toll, typically over a relatively short period of time. Influenza is a major cause of epidemic and pandemic infection. Bacterial co/secondary infection further increases morbidity and mortality of influenza infection, with Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus reported as the most common causes. With increased antibiotic resistance and vaccine evasion it is important to monitor the epidemiology of pathogens in circulation to inform clinical treatment and development, particularly in the setting of an influenza epidemic/pandemic.

  16. NNDSS - Table II. Giardiasis to Haemophilus influenza

    Data.gov (United States)

    U.S. Department of Health & Human Services — NNDSS - Table II. Giardiasis to Haemophilus influenza - 2014. In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000...

  17. Reassortment patterns in Swine influenza viruses.

    Directory of Open Access Journals (Sweden)

    Hossein Khiabanian

    Full Text Available Three human influenza pandemics occurred in the twentieth century, in 1918, 1957, and 1968. Influenza pandemic strains are the results of emerging viruses from non-human reservoirs to which humans have little or no immunity. At least two of these pandemic strains, in 1957 and in 1968, were the results of reassortments between human and avian viruses. Also, many cases of swine influenza viruses have reportedly infected humans, in particular, the recent H1N1 influenza virus of swine origin, isolated in Mexico and the United States. Pigs are documented to allow productive replication of human, avian, and swine influenza viruses. Thus it has been conjectured that pigs are the "mixing vessel" that create the avian-human reassortant strains, causing the human pandemics. Hence, studying the process and patterns of viral reassortment, especially in pigs, is a key to better understanding of human influenza pandemics. In the last few years, databases containing sequences of influenza A viruses, including swine viruses, collected since 1918 from diverse geographical locations, have been developed and made publicly available. In this paper, we study an ensemble of swine influenza viruses to analyze the reassortment phenomena through several statistical techniques. The reassortment patterns in swine viruses prove to be similar to the previous results found in human viruses, both in vitro and in vivo, that the surface glycoprotein coding segments reassort most often. Moreover, we find that one of the polymerase segments (PB1, reassorted in the strains responsible for the last two human pandemics, also reassorts frequently.

  18. Influenza and pneumococcal vaccination: patient perceptions.

    Science.gov (United States)

    Findlay, P F; Gibbons, Y M; Primrose, W R; Ellis, G; Downie, G

    2000-04-01

    The efficacy of the influenza vaccine in reducing mortality and hospital admissions is established, particularly in the elderly. However, up to 50% of those at risk do not receive the vaccine. These patients are also at risk from pneumococcal infection and there is considerable overlap between the target group for each vaccine. This study sought to identify at risk individuals from consecutive admissions to an acute geriatric unit and to gain an insight into their perceptions with regard to vaccination. The awareness of each vaccine was recorded, together with the vaccination history. Seventy four per cent of the final cohort had heard of the influenza vaccine, while only 13% had heard of the pneumococcal vaccine. Fifty per cent perceived themselves to be at risk from influenza and its complications and 87% of the cohort believed it to be a serious infection. Influenza vaccine was judged to confer good protection by 72% of the sample and yet up to 50% believed that the vaccine can make the recipient ill. Influenza is perceived as a serious infection by patients and yet many do not believe themselves to be at particular risk. Although influenza vaccination is believed to confer protection, the decision whether, or not, to accept the vaccine is coloured by many factors, including popular myths and anecdotal information from friends and relatives. The uptake of influenza vaccine is suboptimal and the awareness of the pneumococcal vaccine certainly in the elderly is poor. The need for a comprehensive nationwide education campaign promoting both influenza and pneumococcal vaccine is highlighted.

  19. Isolation of avian influenza virus in Texas.

    Science.gov (United States)

    Glass, S E; Naqi, S A; Grumbles, L C

    1981-01-01

    An avian influenza virus with surface antigens similar to those of fowl plague virus (Hav 1 Nav 2) was isolated in 1979 from 2 commercial turkey flocks in Central Texas. Two flocks in contact with these infected flocks developed clinical signs, gross lesions, and seroconversion but yielded no virus. This was the first recorded incidence of clinical avian influenza in Texas turkeys and only the second time that an agent with these surface antigens was isolated from turkeys in U.S.

  20. Influenza forecasting with Google Flu Trends.

    Science.gov (United States)

    Dugas, Andrea Freyer; Jalalpour, Mehdi; Gel, Yulia; Levin, Scott; Torcaso, Fred; Igusa, Takeru; Rothman, Richard E

    2013-01-01

    We developed a practical influenza forecast model based on real-time, geographically focused, and easy to access data, designed to provide individual medical centers with advanced warning of the expected number of influenza cases, thus allowing for sufficient time to implement interventions. Secondly, we evaluated the effects of incorporating a real-time influenza surveillance system, Google Flu Trends, and meteorological and temporal information on forecast accuracy. Forecast models designed to predict one week in advance were developed from weekly counts of confirmed influenza cases over seven seasons (2004-2011) divided into seven training and out-of-sample verification sets. Forecasting procedures using classical Box-Jenkins, generalized linear models (GLM), and generalized linear autoregressive moving average (GARMA) methods were employed to develop the final model and assess the relative contribution of external variables such as, Google Flu Trends, meteorological data, and temporal information. A GARMA(3,0) forecast model with Negative Binomial distribution integrating Google Flu Trends information provided the most accurate influenza case predictions. The model, on the average, predicts weekly influenza cases during 7 out-of-sample outbreaks within 7 cases for 83% of estimates. Google Flu Trend data was the only source of external information to provide statistically significant forecast improvements over the base model in four of the seven out-of-sample verification sets. Overall, the p-value of adding this external information to the model is 0.0005. The other exogenous variables did not yield a statistically significant improvement in any of the verification sets. Integer-valued autoregression of influenza cases provides a strong base forecast model, which is enhanced by the addition of Google Flu Trends confirming the predictive capabilities of search query based syndromic surveillance. This accessible and flexible forecast model can be used by

  1. Influenza forecasting with Google Flu Trends.

    Directory of Open Access Journals (Sweden)

    Andrea Freyer Dugas

    Full Text Available BACKGROUND: We developed a practical influenza forecast model based on real-time, geographically focused, and easy to access data, designed to provide individual medical centers with advanced warning of the expected number of influenza cases, thus allowing for sufficient time to implement interventions. Secondly, we evaluated the effects of incorporating a real-time influenza surveillance system, Google Flu Trends, and meteorological and temporal information on forecast accuracy. METHODS: Forecast models designed to predict one week in advance were developed from weekly counts of confirmed influenza cases over seven seasons (2004-2011 divided into seven training and out-of-sample verification sets. Forecasting procedures using classical Box-Jenkins, generalized linear models (GLM, and generalized linear autoregressive moving average (GARMA methods were employed to develop the final model and assess the relative contribution of external variables such as, Google Flu Trends, meteorological data, and temporal information. RESULTS: A GARMA(3,0 forecast model with Negative Binomial distribution integrating Google Flu Trends information provided the most accurate influenza case predictions. The model, on the average, predicts weekly influenza cases during 7 out-of-sample outbreaks within 7 cases for 83% of estimates. Google Flu Trend data was the only source of external information to provide statistically significant forecast improvements over the base model in four of the seven out-of-sample verification sets. Overall, the p-value of adding this external information to the model is 0.0005. The other exogenous variables did not yield a statistically significant improvement in any of the verification sets. CONCLUSIONS: Integer-valued autoregression of influenza cases provides a strong base forecast model, which is enhanced by the addition of Google Flu Trends confirming the predictive capabilities of search query based syndromic surveillance. This

  2. A computational framework for influenza antigenic cartography.

    Science.gov (United States)

    Cai, Zhipeng; Zhang, Tong; Wan, Xiu-Feng

    2010-10-07

    Influenza viruses have been responsible for large losses of lives around the world and continue to present a great public health challenge. Antigenic characterization based on hemagglutination inhibition (HI) assay is one of the routine procedures for influenza vaccine strain selection. However, HI assay is only a crude experiment reflecting the antigenic correlations among testing antigens (viruses) and reference antisera (antibodies). Moreover, antigenic characterization is usually based on more than one HI dataset. The combination of multiple datasets results in an incomplete HI matrix with many unobserved entries. This paper proposes a new computational framework for constructing an influenza antigenic cartography from this incomplete matrix, which we refer to as Matrix Completion-Multidimensional Scaling (MC-MDS). In this approach, we first reconstruct the HI matrices with viruses and antibodies using low-rank matrix completion, and then generate the two-dimensional antigenic cartography using multidimensional scaling. Moreover, for influenza HI tables with herd immunity effect (such as those from Human influenza viruses), we propose a temporal model to reduce the inherent temporal bias of HI tables caused by herd immunity. By applying our method in HI datasets containing H3N2 influenza A viruses isolated from 1968 to 2003, we identified eleven clusters of antigenic variants, representing all major antigenic drift events in these 36 years. Our results showed that both the completed HI matrix and the antigenic cartography obtained via MC-MDS are useful in identifying influenza antigenic variants and thus can be used to facilitate influenza vaccine strain selection. The webserver is available at http://sysbio.cvm.msstate.edu/AntigenMap.

  3. Reverse Genetics Approaches for the Development of Influenza Vaccines

    Science.gov (United States)

    Nogales, Aitor; Martínez-Sobrido, Luis

    2016-01-01

    Influenza viruses cause annual seasonal epidemics and occasional pandemics of human respiratory disease. Influenza virus infections represent a serious public health and economic problem, which are most effectively prevented through vaccination. However, influenza viruses undergo continual antigenic variation, which requires either the annual reformulation of seasonal influenza vaccines or the rapid generation of vaccines against potential pandemic virus strains. The segmented nature of influenza virus allows for the reassortment between two or more viruses within a co-infected cell, and this characteristic has also been harnessed in the laboratory to generate reassortant viruses for their use as either inactivated or live-attenuated influenza vaccines. With the implementation of plasmid-based reverse genetics techniques, it is now possible to engineer recombinant influenza viruses entirely from full-length complementary DNA copies of the viral genome by transfection of susceptible cells. These reverse genetics systems have provided investigators with novel and powerful approaches to answer important questions about the biology of influenza viruses, including the function of viral proteins, their interaction with cellular host factors and the mechanisms of influenza virus transmission and pathogenesis. In addition, reverse genetics techniques have allowed the generation of recombinant influenza viruses, providing a powerful technology to develop both inactivated and live-attenuated influenza vaccines. In this review, we will summarize the current knowledge of state-of-the-art, plasmid-based, influenza reverse genetics approaches and their implementation to provide rapid, convenient, safe and more effective influenza inactivated or live-attenuated vaccines. PMID:28025504

  4. Innate Immune Sensing and Response to Influenza

    Science.gov (United States)

    Pulendran, Bali; Maddur, Mohan S.

    2015-01-01

    Influenza viruses pose a substantial threat to human and animal health worldwide. Recent studies in mouse models have revealed an indispensable role for the innate immune system in defense against influenza virus. Recognition of the virus by innate immune receptors in a multitude of cell types activates intricate signaling networks, functioning to restrict viral replication. Downstream effector mechanisms include activation of innate immune cells and, induction and regulation of adaptive immunity. However, uncontrolled innate responses are associated with exaggerated disease, especially in pandemic influenza virus infection. Despite advances in the understanding of innate response to influenza in the mouse model, there is a large knowledge gap in humans, particularly in immunocom-promised groups such as infants and the elderly. We propose here, the need for further studies in humans to decipher the role of innate immunity to influenza virus, particularly at the site of infection. These studies will complement the existing work in mice and facilitate the quest to design improved vaccines and therapeutic strategies against influenza. PMID:25078919

  5. Annually repeated influenza vaccination improves humoral responses to several influenza virus strains in healthy elderly

    NARCIS (Netherlands)

    I.A. de Bruijn (Iris); E.J. Remarque (Edmond); W.E.Ph. Beyer (Walter); S. le Cessie (Saskia); N. Masurel (Nic); G.L. Ligthart (Gerard)

    1997-01-01

    textabstractThe benefit of annually repeated influenza vaccination on antibody formation is still under debate. In this study the effect of annually repeated influenza vaccination on haemagglutination inhibiting (HI) antibody formation in the elderly is investigated. Between 1990 and 1993 healthy

  6. Emerging influenza viruses and the prospect of a universal influenza virus vaccine.

    Science.gov (United States)

    Krammer, Florian

    2015-05-01

    Influenza viruses cause annual seasonal epidemics and pandemics at irregular intervals. Several cases of human infections with avian and swine influenza viruses have been detected recently, warranting enhanced surveillance and the development of more effective countermeasures to address the pandemic potential of these viruses. The most effective countermeasure against influenza virus infection is the use of prophylactic vaccines. However, vaccines that are currently in use for seasonal influenza viruses have to be re-formulated and re-administered in a cumbersome process every year due to the antigenic drift of the virus. Furthermore, current seasonal vaccines are ineffective against novel pandemic strains. This paper reviews zoonotic influenza viruses with pandemic potential and technological advances towards better vaccines that induce broad and long lasting protection from influenza virus infection. Recent efforts have focused on the development of broadly protective/universal influenza virus vaccines that can provide immunity against drifted seasonal influenza virus strains but also against potential pandemic viruses. Copyright © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

  7. Missed Opportunities for Influenza Vaccination Among Hospitalized Children With Influenza at a Tertiary Care Facility.

    Science.gov (United States)

    Rao, Suchitra; Williams, Joshua T B; Torok, Michelle R; Cunningham, Maureen A; Glodè, Mary P; Wilson, Karen M

    2016-09-01

    To identify the extent and characteristics of missed opportunities for influenza vaccination among children hospitalized with influenza at a tertiary children's hospital. We conducted a retrospective cohort study of hospitalized patients with polymerase chain reaction-confirmed influenza admitted to Children's Hospital Colorado from 2010 to 2014. We reviewed medical records for vaccination status and previous visits. The primary outcome was the proportion of underimmunized patients hospitalized with influenza with at least 1 missed opportunity visit (visit before influenza diagnosis in which an eligible patient did not receive the influenza vaccine). The relationship between sociodemographic characteristics and the primary outcome were examined using χ(2) tests and nonparametric tests, and variables with P vaccination. Multivariate analysis demonstrated that high-risk status (adjusted odds ratio 6.9, 95% confidence interval 3.8-12.4) was associated with increased odds of having a missed opportunity visit. Most missed opportunity visits were to subspecialty clinics (42%), and most visits (71%) occurred from September to November. More than 40% of hospitalizations for influenza in children are associated with at least 1 missed opportunity visit at a tertiary center. Our findings highlight the potential role of tertiary care institutions in increasing influenza vaccination rates among children. Copyright © 2016 by the American Academy of Pediatrics.

  8. Seasonal trivalent inactivated influenza vaccine protects against 1918 Spanish influenza virus in ferrets

    Science.gov (United States)

    The influenza H1N1 pandemic of 1918 was one of the worst medical disasters in human history. Recent studies have demonstrated that the hemagglutinin (HA) protein of the 1918 virus and 2009 H1N1 pandemic virus, the latter now a component of the seasonal trivalent inactivated influenza vaccine (TIV),...

  9. Influenza research database: an integrated bioinformatics resource for influenza virus research

    Science.gov (United States)

    The Influenza Research Database (IRD) is a U.S. National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Bioinformatics Resource Center dedicated to providing bioinformatics support for influenza virus research. IRD facilitates the research and development of vaccines, diagnostics, an...

  10. Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination.

    Science.gov (United States)

    Grijalva, Carlos G; Zhu, Yuwei; Williams, Derek J; Self, Wesley H; Ampofo, Krow; Pavia, Andrew T; Stockmann, Chris R; McCullers, Jonathan; Arnold, Sandra R; Wunderink, Richard G; Anderson, Evan J; Lindstrom, Stephen; Fry, Alicia M; Foppa, Ivo M; Finelli, Lyn; Bramley, Anna M; Jain, Seema; Griffin, Marie R; Edwards, Kathryn M

    2015-10-13

    Few studies have evaluated the relationship between influenza vaccination and pneumonia, a serious complication of influenza infection. To assess the association between influenza vaccination status and hospitalization for community-acquired laboratory-confirmed influenza pneumonia. The Etiology of Pneumonia in the Community (EPIC) study was a prospective observational multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010 through June 2012 at 4 US sites. In this case-control study, we used EPIC data from patients 6 months or older with laboratory-confirmed influenza infection and verified vaccination status during the influenza seasons and excluded patients with recent hospitalization, from chronic care residential facilities, and with severe immunosuppression. Logistic regression was used to calculate odds ratios, comparing the odds of vaccination between influenza-positive (case) and influenza-negative (control) patients with pneumonia, controlling for demographics, comorbidities, season, study site, and timing of disease onset. Vaccine effectiveness was estimated as (1 - adjusted odds ratio) × 100%. Influenza vaccination, verified through record review. Influenza pneumonia, confirmed by real-time reverse-transcription polymerase chain reaction performed on nasal/oropharyngeal swabs. Overall, 2767 patients hospitalized for pneumonia were eligible for the study; 162 (5.9%) had laboratory-confirmed influenza. Twenty-eight of 162 cases (17%) with influenza-associated pneumonia and 766 of 2605 controls (29%) with influenza-negative pneumonia had been vaccinated. The adjusted odds ratio of prior influenza vaccination between cases and controls was 0.43 (95% CI, 0.28-0.68; estimated vaccine effectiveness, 56.7%; 95% CI, 31.9%-72.5%). Among children and adults hospitalized with community-acquired pneumonia, those with laboratory-confirmed influenza-associated pneumonia, compared with those with pneumonia not

  11. Association between hospitalization with community acquired laboratory-confirmed influenza pneumonia and prior receipt of influenza vaccination

    Science.gov (United States)

    Grijalva, Carlos G.; Zhu, Yuwei; Williams, Derek J.; Self, Wesley H.; Ampofo, Krow; Pavia, Andrew T.; Stockmann, Chris R.; McCullers, Jonathan; Arnold, Sandra R.; Wunderink, Richard G.; Anderson, Evan J.; Lindstrom, Stephen; Fry, Alicia M.; Foppa, Ivo M.; Finelli, Lyn; Bramley, Anna M.; Jain, Seema; Griffin, Marie R.; Edwards, Kathryn M.

    2015-01-01

    Importance Few studies have evaluated the relationship between influenza vaccination and pneumonia, a serious complication of influenza infection. Objective Assess the association between influenza vaccination status and hospitalization for community-acquired laboratory-confirmed influenza pneumonia. Design, Setting and Participants The Etiology of Pneumonia in the Community (EPIC) study was a prospective observational multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010 through June 2012 in four US sites. We used EPIC study data from patients ≥6 months of age with laboratory-confirmed influenza infection and verified vaccination status during the influenza seasons, and excluded patients with recent hospitalization, from chronic care residential facilities, and with severe immunosuppression. Logistic regression was used to calculate odds ratios, comparing the odds of vaccination between influenza-positive (cases) and influenza-negative (controls) pneumonia patients, controlling for demographics, co-morbidities, season, study site and timing of disease onset. Vaccine effectiveness was estimated as (1-odds ratio) × 100%. Exposure Influenza vaccination, verified through record review. Outcome Influenza pneumonia, confirmed by real-time reverse transcription-polymerase chain reaction performed on nasal/oropharyngeal swabs. Results Overall, 2767 patients hospitalized for pneumonia were eligible for the study; 162 (5.9%) were influenza positive. Twenty-eight (17%) of 162 cases with influenza-associated pneumonia and 766 (29%) of 2605 controls with influenza-negative pneumonia had been vaccinated. The adjusted odds ratio of prior influenza vaccination between cases and controls was 0.43 (95% CI 0.28–0.68 [estimated vaccine effectiveness 56.7% (95% CI 31.9–72.5)]). Conclusions and relevance Among children and adults hospitalized with community-acquired pneumonia, those with laboratory confirmed influenza

  12. The Influenza NS1 Protein: What Do We Know in Equine Influenza Virus Pathogenesis?

    Directory of Open Access Journals (Sweden)

    Marta Barba

    2016-08-01

    Full Text Available Equine influenza virus remains a serious health and potential economic problem throughout most parts of the world, despite intensive vaccination programs in some horse populations. The influenza non-structural protein 1 (NS1 has multiple functions involved in the regulation of several cellular and viral processes during influenza infection. We review the strategies that NS1 uses to facilitate virus replication and inhibit antiviral responses in the host, including sequestering of double-stranded RNA, direct modulation of protein kinase R activity and inhibition of transcription and translation of host antiviral response genes such as type I interferon. Details are provided regarding what it is known about NS1 in equine influenza, especially concerning C-terminal truncation. Further research is needed to determine the role of NS1 in equine influenza infection, which will help to understand the pathophysiology of complicated cases related to cytokine imbalance and secondary bacterial infection, and to investigate new therapeutic and vaccination strategies.

  13. On the epidemiology of influenza: reply to Radonovich et al

    Directory of Open Access Journals (Sweden)

    Scragg Robert

    2009-08-01

    Full Text Available Abstract On the epidemiology of influenza: reply to Radonovich LJ, Martinello RA, Hodgson M, Milton DK, Nardell EA. Influenza and ultraviolet germicidal irradiation. Virol J. 2008, 5:149

  14. Influenza A (H3N2) Variant Virus

    Science.gov (United States)

    ... Swine Variant Pandemic Other Influenza A (H3N2) Variant Virus Language: English (US) Español Recommend on Facebook Tweet Share Compartir Influenza viruses that normally circulate in pigs are called “variant” ...

  15. Broadly protective influenza vaccines: Redirecting the antibody response through adjuvation

    NARCIS (Netherlands)

    Cox, F.

    2016-01-01

    Influenza virus infections are responsible for significant morbidity worldwide and current vaccines have limited coverage, therefore it remains a high priority to develop broadly protective vaccines. With the discovery of broadly neutralizing antibodies (bnAbs) against influenza these vaccines

  16. Novel Platforms for the Development of a Universal Influenza Vaccine

    Directory of Open Access Journals (Sweden)

    Arun Kumar

    2018-03-01

    Full Text Available Despite advancements in immunotherapeutic approaches, influenza continues to cause severe illness, particularly among immunocompromised individuals, young children, and elderly adults. Vaccination is the most effective way to reduce rates of morbidity and mortality caused by influenza viruses. Frequent genetic shift and drift among influenza-virus strains with the resultant disparity between circulating and vaccine virus strains limits the effectiveness of the available conventional influenza vaccines. One approach to overcome this limitation is to develop a universal influenza vaccine that could provide protection against all subtypes of influenza viruses. Moreover, the development of a novel or improved universal influenza vaccines may be greatly facilitated by new technologies including virus-like particles, T-cell-inducing peptides and recombinant proteins, synthetic viruses, broadly neutralizing antibodies, and nucleic acid-based vaccines. This review discusses recent scientific advances in the development of next-generation universal influenza vaccines.

  17. Influenza Virus and Glycemic Variability in Diabetes: A Killer Combination?

    Directory of Open Access Journals (Sweden)

    Katina D. Hulme

    2017-05-01

    Full Text Available Following the 2009 H1N1 influenza virus pandemic, numerous studies identified the striking link between diabetes mellitus and influenza disease severity. Typically, influenza virus is a self-limiting infection but in individuals who have a pre-existing chronic illness, such as diabetes mellitus, severe influenza can develop. Here, we discuss the latest clinical and experimental evidence for the role of diabetes in predisposing the host to severe influenza. We explore the possible mechanisms that underlie this synergy and highlight the, as yet, unexplored role that blood glucose oscillations may play in disease development. Diabetes is one of the world’s fastest growing chronic diseases and influenza virus represents a constant and pervasive threat to human health. It is therefore imperative that we understand how diabetes increases influenza severity in order to mitigate the burden of future influenza epidemics and pandemics.

  18. Impact of influenza vaccination on mortality risk among the elderly

    NARCIS (Netherlands)

    Groenwold, R. H. H.; Hoes, A. W.; Hak, E.

    Estimates of influenza vaccine effectiveness have mostly been derived from nonrandomised studies and therefore are potentially confounded. The aim of the current study was to estimate influenza vaccine effectiveness in preventing mortality among the elderly, taking both measured and unmeasured

  19. 77 FR 10794 - Self-Regulatory Organizations; The NASDAQ Stock Market LLC; Notice of Filing and Immediate...

    Science.gov (United States)

    2012-02-23

    ...-Regulatory Organizations; The NASDAQ Stock Market LLC; Notice of Filing and Immediate Effectiveness of... February 13, 2012, The NASDAQ Stock Market LLC (``NASDAQ'' or ``Exchange'') filed with the Securities and... Change The NASDAQ Stock Market LLC proposes to modify Chapter XV, Section 2, governing pricing for NASDAQ...

  20. 76 FR 71088 - Self-Regulatory Organizations; The NASDAQ Stock Market LLC; Notice of Filing and Immediate...

    Science.gov (United States)

    2011-11-16

    ...-Regulatory Organizations; The NASDAQ Stock Market LLC; Notice of Filing and Immediate Effectiveness of... November 1, 2011, The NASDAQ Stock Market LLC (``NASDAQ'' or ``Exchange'') filed with the Securities and... Change The NASDAQ Stock Market LLC proposes to create a new Rule 7056 entitled ``NASDAQ Options Fee...

  1. 77 FR 63384 - Self-Regulatory Organizations; The NASDAQ Stock Market LLC; Notice of Filing and Immediate...

    Science.gov (United States)

    2012-10-16

    ...-Regulatory Organizations; The NASDAQ Stock Market LLC; Notice of Filing and Immediate Effectiveness of... is hereby given that on October 1, 2012, The NASDAQ Stock Market LLC (``NASDAQ'' or ``Exchange... of the Proposed Rule Change The NASDAQ Stock Market LLC proposes to modify Chapter XV, entitled...

  2. 76 FR 21743 - Indigo Logistics, LLC, Liliya Ivanenko, and Leonid Ivanenko-Possible Violations of Section 19 of...

    Science.gov (United States)

    2011-04-18

    ... FEDERAL MARITIME COMMISSION [Docket No. 11-06] Indigo Logistics, LLC, Liliya Ivanenko, and Leonid... Order of Investigation and Hearing entitled Indigo Logistics, LLC; Liliya Ivanenko; and Leonid Ivanenko... instituted to determine: (1) Whether Indigo Logistics, LLC, Liliya Ivanenko, and Leonid Ivanenko violated...

  3. 78 FR 3042 - J.P. Morgan Securities LLC, et al.; Notice of Application and Temporary Order

    Science.gov (United States)

    2013-01-15

    ... SECURITIES AND EXCHANGE COMMISSION [Release No. IC-30347; 812-14094] J.P. Morgan Securities LLC... entered against J.P. Morgan Securities LLC (``JPMS''), EMC Mortgage, LLC (``EMC''), Bear Stearns Asset... Inc. (``SACO'') and J.P. Morgan Acceptance Corporation I (``JPMAC'') (together, the ``Defendants'') on...

  4. 77 FR 72837 - Golden Pass Products LLC; Application for Long-Term Authorization To Export Liquefied Natural Gas...

    Science.gov (United States)

    2012-12-06

    ... Florida Gas Transmission Company, LLC; Golden Triangle Storage, Inc.; Natural Gas Pipeline Company of... DEPARTMENT OF ENERGY [FE Docket No. 12-156-LNG] Golden Pass Products LLC; Application for Long... notice of receipt of an application (Application) filed on October 26, 2012, by Golden Pass Products LLC...

  5. 77 FR 51837 - Self-Regulatory Organizations; NYSE MKT LLC; Notice of Filing and Immediate Effectiveness of...

    Science.gov (United States)

    2012-08-27

    ... Amending the NYSE Amex Options LLC Limited Liability Company Agreement To Eliminate Certain Restrictions... Options LLC (``NYSE Amex Options'') Limited Liability Company Agreement (``LLC Agreement'') to eliminate... securities exchange or facility thereof (including, but not limited to, internalization of orders for...

  6. 76 FR 78021 - Notice of Availability of the Record of Decision for the Rice Solar Energy, LLC, Rice Solar...

    Science.gov (United States)

    2011-12-15

    ... LVRWB10B3780] Notice of Availability of the Record of Decision for the Rice Solar Energy, LLC, Rice Solar... Solar Energy, LLC, a subsidiary of SolarReserve, LLC plans to construct a 150 megawatt (MW) solar... allows solar energy to be captured throughout the day and retained in a molten salt heat transfer fluid...

  7. 77 FR 23241 - Lock+ Hydro Friends Fund XXX, LLC; Notice of Intent To File License Application, Filing of Pre...

    Science.gov (United States)

    2012-04-18

    ... Friends Fund XXX, LLC; Notice of Intent To File License Application, Filing of Pre-Application Document.... Date Filed: February 20, 2012. d. Submitted By: Lock+ Hydro Friends Fund XXX, LLC. e. Name of Project... Applicant Contact: Mr. Mark R. Stover, Lock+\\TM\\ Hydro Friends Fund XXX, c/o Hydro Green Energy, LLC, 900...

  8. 77 FR 55212 - North Star Hydro Services CA, LLC; Notice of Preliminary Permit Application Accepted for Filing...

    Science.gov (United States)

    2012-09-07

    ... Energy Regulatory Commission North Star Hydro Services CA, LLC; Notice of Preliminary Permit Application..., 2012, North Star Hydro Services CA, LLC, Oklahoma, filed an application for a preliminary permit...: David Holland, North Star Hydro Services CA, LLC, 1110 West 131st Street South, Jenks, Oklahoma 74037...

  9. 75 FR 16514 - Bayer Material Science, LLC, Formally Known as Sheffield Plastics, Including On-Site Leased...

    Science.gov (United States)

    2010-04-01

    ... Employment and Training Administration Bayer Material Science, LLC, Formally Known as Sheffield Plastics... Material Science, LLC, formally known as Sheffield Plastics, including on-site leased workers from... that Bayer Material Science, LLC was formally known as Sheffield Plastics. Some workers separated from...

  10. 78 FR 22909 - Mondelez Global LLC, Business Services Center, Including On-Site Leased Workers From Abacus...

    Science.gov (United States)

    2013-04-17

    ... group at Mondelez Global LLC, Business Services Center, San Antonio, Texas. The leasing agencies are... agencies worked on-site at Mondelez Global LLC, Business Services Center, San Antonio, Texas. The intent of... applicable to TA-W-82,339 is hereby issued as follows: ``All workers of Mondelez Global LLC, Business...

  11. 77 FR 14009 - Carbon Zero, LLC.; Notice of Application Tendered for Filing With the Commission, Intent To Waive...

    Science.gov (United States)

    2012-03-08

    ... and would generate an annual average of approximately 1,454 megawatt-hours. o. Carbon Zero, LLC... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 14308-001] Carbon Zero, LLC...: February 17, 2012. d. Applicant: Carbon Zero, LLC. e. Name of Project: Vermont Tissue Mill Hydroelectric...

  12. 78 FR 55069 - Whitewater Green Energy, LLC; Notice of Intent to File License Application, Filing of Pre...

    Science.gov (United States)

    2013-09-09

    ... Energy Regulatory Commission Whitewater Green Energy, LLC; Notice of Intent to File License Application... Green Energy, LLC. e. Name of Project: Whitewater Creek Hydroelectric Project. f. Location: On... Preservation at 36 CFR 800.2. l. Whitewater Green Energy, LLC, filed with the Commission a Pre- Application...

  13. 77 FR 24195 - Green River Energy BFD, LLC; Notice of Preliminary Permit Application Accepted for Filing and...

    Science.gov (United States)

    2012-04-23

    ... Energy Regulatory Commission Green River Energy BFD, LLC; Notice of Preliminary Permit Application..., 2012, Green River Energy BFD, LLC filed an application for a preliminary permit, pursuant to section 4... Boumansour, Green River Energy BFD, LLC, 1035 Pearl Street 4th Floor, Boulder, CO 80302. (720) 295-3317. FERC...

  14. 75 FR 51987 - Birch Power Company and Sorenson Engineering; Birch Power Company and Sorenson Leasing L.L.C...

    Science.gov (United States)

    2010-08-24

    ... Company and Sorenson Engineering; Birch Power Company and Sorenson Leasing L.L.C.; Notice of Application... Leasing, L.L.C. (transferees) filed an application for transfer of license for the Birch Creek... Sorenson Leasing L.L.C., 5203 South 11th East, Idaho Falls, Idaho 83404, phone (208) 589-6908. FERC Contact...

  15. 75 FR 38128 - Ceva Freight, LLC, Dell Logistics Division, Including On-Site Leased Workers From Prologistix and...

    Science.gov (United States)

    2010-07-01

    ... DEPARTMENT OF LABOR Employment and Training Administration [TA-W-72,900] Ceva Freight, LLC, Dell... 19, 2010, applicable to workers of CEVA Freight, LLC, Dell Logistics Division, including on-site..., North Carolina location of CEVA Freight, LLC, Dell Logistics Division. The Department has determined...

  16. 76 FR 27366 - CEVA Freight, LLC, Dell Logistics Division, Including On-Site Leased Workers From Prologistix...

    Science.gov (United States)

    2011-05-11

    ... DEPARTMENT OF LABOR Employment and Training Administration [TA-W-72,900] CEVA Freight, LLC, Dell..., applicable to workers of CEVA Freight, LLC, Dell Logistics Division, including on-site leased workers from... workers employed at CEVA Freight, LLC, Dell Logistics Division, Winston-Salem, North Carolina who were...

  17. 76 FR 18212 - E.ON Climate & RenewablesNorth America, LLC, et al. v. Midwest Independent Transmission System...

    Science.gov (United States)

    2011-04-01

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission E.ON Climate & RenewablesNorth America, LLC, et al. v. Midwest Independent... Climate & Renewables North America, LLC, Horizon Wind Energy LLC, Iberdrola Renewables, Inc. and Invenergy...

  18. 76 FR 54801 - Reynolds Food Packaging LLC, a Subsidiary of Reynolds Group Holding Limited, Grove City, PA...

    Science.gov (United States)

    2011-09-02

    ... Employment and Training Administration Reynolds Food Packaging LLC, a Subsidiary of Reynolds Group Holding... Reynolds Food Packaging LLC, a subsidiary of Reynolds Group Holding Limited, Grove City, Pennsylvania... make the following certification: All workers of Reynolds Food Packaging LLC, a subsidiary of Reynolds...

  19. Improving the representativeness of influenza viruses shared within the WHO Global Influenza Surveillance and Response System.

    Science.gov (United States)

    Pereyaslov, Dmitriy; Zemtsova, Galina; Gruessner, Christine; Daniels, Rodney S; McCauley, John W; Brown, Caroline S

    2016-03-01

    Sharing influenza viruses within the WHO Global Influenza Surveillance and Response System is crucial for monitoring evolution of influenza viruses. Analysis of timeliness and geographic representativeness of viruses shared by National Influenza Centres (NICs) in the WHO European Region with the London WHO Collaborating Centre for Reference and Research on Influenza for the Northern Hemisphere's 2010-2011 and 2011-2012 influenza seasons. Data from NICs on influenza-positive specimens shared with WHO CC London for the above-mentioned influenza seasons were analyzed for timeliness of sharing with respect to the February deadline (31 January) for inclusion in the WHO consultations on the composition of influenza virus vaccines for the Northern Hemisphere and geographic representativeness. The 2010-2011 and 2011-2012 seasons were different in terms of the seasonal pattern, the timing of the epidemic, and the dominant virus. Consistent patterns of virus sharing across the seasons were observed. Approximately half the viruses collected before the deadline were not shared within the deadline; the average delay between date of specimen collection and shipment receipt was 3 and 1·5 months for the first and second season, respectively. A baseline was provided for future work on enhancement of specimen sharing in the WHO European Region and improving the vaccine virus selection process. Greater insight into virus selection criteria applied by countries and the causes of delays in shipment are needed to understand the representativeness of viruses shared and to assess the importance of this for vaccine strain selection. © 2015 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

  20. Influenza vaccination coverage among health-care personnel--United States, 2012-13 influenza season.

    Science.gov (United States)

    2013-09-27

    Routine influenza vaccination of health-care personnel (HCP) every influenza season can reduce influenza-related illness and its potentially serious consequences among HCP and their patients. To protect HCP and their patients, the Advisory Committee on Immunization Practices (ACIP) recommends that all HCP be vaccinated against influenza during each influenza season. To estimate influenza vaccination coverage among HCP during the 2012-13 season, CDC conducted an opt-in Internet panel survey of 1,944 self-selected HCP during April 1-16, 2013. This report summarizes the results of that survey, which found that, overall, 72.0% of HCP reported having had an influenza vaccination for the 2012-13 season, an increase from 66.9% vaccination coverage during the 2011-12 season. By occupation type, coverage was 92.3% among physicians, 89.1% among pharmacists, 88.5% among nurse practitioners/physician assistants, and 84.8% among nurses. By occupational setting, vaccination coverage was highest among hospital-based HCP (83.1%) and was lowest among HCP at long-term care facilities (LTCF) (58.9%). Vaccination coverage was higher for HCP in occupational settings offering vaccination on-site at no cost for one (75.7%) or multiple (86.2%) days compared with HCP in occupational settings not offering vaccination on-site at no cost (55.3%). Widespread implementation of comprehensive influenza vaccination strategies that focus on improving access to vaccination services is needed to improve HCP vaccination coverage. Influenza vaccination of HCP in all health-care settings might be increased by providing 1) HCP with information on vaccination benefits and risks for themselves and their patients, 2) vaccinations in the workplace at convenient locations and times, and 3) influenza vaccinations at no cost.

  1. Influenza and Memory T Cells: How to Awake the Force

    OpenAIRE

    Spitaels, Jan; Roose, Kenny; Saelens, Xavier

    2016-01-01

    Annual influenza vaccination is an effective way to prevent human influenza. Current vaccines are mainly focused on eliciting a strain-matched humoral immune response, requiring yearly updates, and do not provide protection for all vaccinated individuals. The past few years, the importance of cellular immunity, and especially memory T cells, in long-lived protection against influenza virus has become clear. To overcome the shortcomings of current influenza vaccines, eliciting both humoral and...

  2. Influenza immunization during pregnancy: Benefits for mother and infant

    OpenAIRE

    Sakala, Isaac G.; Honda-Okubo, Yoshikazu; Fung, Johnson; Petrovsky, Nikolai

    2016-01-01

    The serious consequences of influenza infection during pregnancy have been recognized for almost a century. In this article, we reviewed the evidence on the immunogenicity, safety and impact of maternal influenza immunization for both mother and child. After vaccination, pregnant women have similar protective titers of anti-influenza antibodies as non-pregnant women, demonstrating that pregnancy does not alter the trivalent inactivated influenza vaccine immune response. Studies from the Unite...

  3. Perception and Attitudes of Korean Obstetricians about Maternal Influenza Vaccination

    OpenAIRE

    Noh, Ji Yun; Seo, Yu Bin; Song, Joon Young; Choi, Won Suk; Lee, Jacob; Jung, Eunju; Kang, Seonghui; Choi, Min Joo; Jun, Jiho; Yoon, Jin Gu; Lee, Saem Na; Hyun, Hakjun; Lee, Jin-Soo; Cheong, Hojin; Cheong, Hee Jin

    2016-01-01

    Pregnant women are prioritized to receive influenza vaccination. However, the maternal influenza vaccination rate has been low in Korea. To identify potential barriers for the vaccination of pregnant women against influenza, a survey using a questionnaire on the perceptions and attitudes about maternal influenza vaccination was applied to Korean obstetricians between May and August of 2014. A total of 473 respondents participated in the survey. Most respondents (94.8%, 442/466) recognized tha...

  4. Haemophilus influenzae Type a Meningitis in Immunocompetent Child, Oman, 2015.

    Science.gov (United States)

    Sawardekar, Kiran P

    2017-07-01

    Meningitis caused by Haemophilus influenzae type b (Hib) was eliminated in Oman after the introduction of Hib vaccine in 2001. However, a case of H. influenzae type a meningitis was diagnosed in a child from Oman in 2015, which highlights the need to monitor the incidence of invasive non-Hib H. influenzae disease.

  5. Considerable progress in European preparations for a potential influenza pandemic.

    NARCIS (Netherlands)

    Paget, J.

    2005-01-01

    The threat of an influenza pandemic has been heightened in the past two years by outbreaks of avian influenza concentrated in South East Asia which have resulted in human deaths. So far, the avian influenza virus seems difficult to transmit from human to human, but changes in the virus genome may

  6. Influenza: the next pandemic?: a review | Adungo, | East African ...

    African Journals Online (AJOL)

    Due to the diversity of susceptible reservoirs of influenza viruses and the interspecies transmission recently reported, a mutated strain of the virus to which people have no immunity could cause an influenza pandemic once the virus gains efficient and sustained human-to-human transmission. The fear that avian influenza ...

  7. Benefits and limitations of the Witwatersrand influenza and acute ...

    African Journals Online (AJOL)

    1993-03-25

    Mar 25, 1993 ... The Viral Watch Programme of the Institute was established in 1984 to obtain influenza isolates and measure influenza epidemics in this country! Over the past 2 years, parameters of influenza activity such as mortality data and respiratory morbidity indices have been added to the programme's activities.

  8. Abbreviated Pandemic Influenza Planning Template for Primary Care Offices

    Energy Technology Data Exchange (ETDEWEB)

    HCTT CHE

    2010-01-01

    The Abbreviated Pandemic Influenza Plan Template for Primary Care Provider Offices is intended to assist primary care providers and office managers with preparing their offices for quickly putting a plan in place to handle an increase in patient calls and visits, whether during the 2009-2010 influenza season or future influenza seasons.

  9. 75 FR 2049 - National Influenza Vaccination Week, 2010

    Science.gov (United States)

    2010-01-13

    ... Part IV The President Proclamation 8472--National Influenza Vaccination Week, 2010 #0; #0; #0..., 2010 National Influenza Vaccination Week, 2010 By the President of the United States of America A... hospitalization or even death. We know that influenza vaccination is the best way to protect ourselves against the...

  10. Influenza vaccination in children being treated with chemotherapy for cancer

    NARCIS (Netherlands)

    Goossen, Ginette M.; Kremer, Leontien C. M.; van de Wetering, Marianne D.

    2009-01-01

    Influenza infection is a potential cause of severe morbidity in children with cancer, therefore vaccination against influenza is recommended. However, there are conflicting data concerning the immune response to influenza vaccination in children with cancer and the value of vaccination remains

  11. Influenza vaccination in children being treated with chemotherapy for cancer

    NARCIS (Netherlands)

    Goossen, Ginette M.; Kremer, Leontien C. M.; van de Wetering, Marianne D.

    2013-01-01

    Influenza infection is a potential cause of severe morbidity in children with cancer; therefore vaccination against influenza is recommended. However, data are conflicting regarding the immune response to influenza vaccination in children with cancer, and the value of vaccination remains unclear. 1.

  12. Epidemiological characteristics of Pandemic Influenza A (H1N1 ...

    African Journals Online (AJOL)

    Background: A novel influenza A virus strain (H1N1-2009) spread first in Mexico and the United Stated in late April 2009, leading to the first influenza pandemic of the 21st century. The objective of this study was to determine the epidemiological and virological characteristics of the pandemic influenza A (H1N1-2009) in ...

  13. 77 FR 13329 - Pandemic Influenza Vaccines-Amendment

    Science.gov (United States)

    2012-03-06

    ... DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Pandemic Influenza Vaccines... Secretary issued a declaration for pandemic influenza vaccines, which has been amended a number of times. The original pandemic influenza vaccine declaration was published on January 26, 2007,\\1\\ and was...

  14. Influenza A (H1N1) 2009: a pandemic alarm

    Indian Academy of Sciences (India)

    Keywords. Antigenic shift; genetic reassortment; H1N1; pandemic; swine influenza; zoonosis. Abstract. At this critical juncture when the world has not yet recovered from the threat of avian influenza, the virus has returned in the disguise of swine influenza, a lesser known illness common in pigs. It has reached pandemic ...

  15. Influenza virus resistance to oseltamivir: what are the implications?

    NARCIS (Netherlands)

    Fleming, D.M.; Elliot, A.J.; Meijer, A.; Paget, W.J.

    2009-01-01

    Influenza caused by an oseltamivir-resistant influenza A(H1N1) virus was widespread across Europe during the 2007–08 winter. About 25% of A(H1N1) viruses tested in the European Influenza Surveillance Scheme (EISS) were resistant with an H274Y mutation in the neuraminidase glycoprotein. Early

  16. Predictive validation of an influenza spread model.

    Directory of Open Access Journals (Sweden)

    Ayaz Hyder

    Full Text Available BACKGROUND: Modeling plays a critical role in mitigating impacts of seasonal influenza epidemics. Complex simulation models are currently at the forefront of evaluating optimal mitigation strategies at multiple scales and levels of organization. Given their evaluative role, these models remain limited in their ability to predict and forecast future epidemics leading some researchers and public-health practitioners to question their usefulness. The objective of this study is to evaluate the predictive ability of an existing complex simulation model of influenza spread. METHODS AND FINDINGS: We used extensive data on past epidemics to demonstrate the process of predictive validation. This involved generalizing an individual-based model for influenza spread and fitting it to laboratory-confirmed influenza infection data from a single observed epidemic (1998-1999. Next, we used the fitted model and modified two of its parameters based on data on real-world perturbations (vaccination coverage by age group and strain type. Simulating epidemics under these changes allowed us to estimate the deviation/error between the expected epidemic curve under perturbation and observed epidemics taking place from 1999 to 2006. Our model was able to forecast absolute intensity and epidemic peak week several weeks earlier with reasonable reliability and depended on the method of forecasting-static or dynamic. CONCLUSIONS: Good predictive ability of influenza epidemics is critical for implementing mitigation strategies in an effective and timely manner. Through the process of predictive validation applied to a current complex simulation model of influenza spread, we provided users of the model (e.g. public-health officials and policy-makers with quantitative metrics and practical recommendations on mitigating impacts of seasonal influenza epidemics. This methodology may be applied to other models of communicable infectious diseases to test and potentially improve

  17. Predictive Validation of an Influenza Spread Model

    Science.gov (United States)

    Hyder, Ayaz; Buckeridge, David L.; Leung, Brian

    2013-01-01

    Background Modeling plays a critical role in mitigating impacts of seasonal influenza epidemics. Complex simulation models are currently at the forefront of evaluating optimal mitigation strategies at multiple scales and levels of organization. Given their evaluative role, these models remain limited in their ability to predict and forecast future epidemics leading some researchers and public-health practitioners to question their usefulness. The objective of this study is to evaluate the predictive ability of an existing complex simulation model of influenza spread. Methods and Findings We used extensive data on past epidemics to demonstrate the process of predictive validation. This involved generalizing an individual-based model for influenza spread and fitting it to laboratory-confirmed influenza infection data from a single observed epidemic (1998–1999). Next, we used the fitted model and modified two of its parameters based on data on real-world perturbations (vaccination coverage by age group and strain type). Simulating epidemics under these changes allowed us to estimate the deviation/error between the expected epidemic curve under perturbation and observed epidemics taking place from 1999 to 2006. Our model was able to forecast absolute intensity and epidemic peak week several weeks earlier with reasonable reliability and depended on the method of forecasting-static or dynamic. Conclusions Good predictive ability of influenza epidemics is critical for implementing mitigation strategies in an effective and timely manner. Through the process of predictive validation applied to a current complex simulation model of influenza spread, we provided users of the model (e.g. public-health officials and policy-makers) with quantitative metrics and practical recommendations on mitigating impacts of seasonal influenza epidemics. This methodology may be applied to other models of communicable infectious diseases to test and potentially improve their predictive

  18. School-based influenza vaccination: parents' perspectives.

    Science.gov (United States)

    Lind, Candace; Russell, Margaret L; MacDonald, Judy; Collins, Ramona; Frank, Christine J; Davis, Amy E

    2014-01-01

    School-age children are important drivers of annual influenza epidemics yet influenza vaccination coverage of this population is low despite universal publicly funded influenza vaccination in Alberta, Canada. Immunizing children at school may potentially increase vaccine uptake. As parents are a key stakeholder group for such a program, it is important to consider their concerns. We explored parents' perspectives on the acceptability of adding an annual influenza immunization to the immunization program that is currently delivered in Alberta schools, and obtained suggestions for structuring such a program. Forty-eight parents of children aged 5-18 years participated in 9 focus groups. Participants lived in urban areas of the Alberta Health Services Calgary Zone. Three major themes emerged: Advantages of school-based influenza vaccination (SBIV), Disadvantages of SBIV, and Implications for program design & delivery. Advantages were perceived to occur for different populations: children (e.g. emotional support), families (e.g. convenience), the community (e.g. benefits for school and multicultural communities), the health sector (e.g. reductions in costs due to burden of illness) and to society at large (e.g. indirect conduit of information about health services, building structure for pandemic preparedness, building healthy lifestyles). Disadvantages, however, might also occur for children (e.g. older children less likely to be immunized), families (e.g. communication challenges, perceived loss of parental control over information, choices and decisions) and the education sector (loss of instructional time). Nine second-level themes emerged within the major theme of Implications for program design & delivery: program goals/objectives, consent process, stakeholder consultation, age-appropriate program, education, communication, logistics, immunizing agent, and clinic process. Parents perceived advantages and disadvantages to delivering annual seasonal influenza

  19. Experiences with influenza-like illness and attitudes regarding influenza prevention--United States, 2003-04 influenza season.

    Science.gov (United States)

    2004-12-17

    Despite advances in medical treatment, influenza results in approximately 36,000 deaths each year in the United States. Vaccination has been a mainstay of influenza prevention, with annual vaccination recommended for adults and children at high risk; efforts to interrupt person-to-person transmission are also important. In October 2003, CDC recommended that health-care facilities implement a Universal Respiratory Hygiene Strategy, including providing masks or facial tissues in waiting rooms to persons with respiratory symptoms. To gather information on influenza-like illness (ILI) and attitudes regarding prevention of ILI (including use of vaccine and respiratory hygiene), CDC and 11 Emerging Infections Programs (EIPs) conducted a random-digit-dialed telephone survey of noninstitutionalized U.S. civilian adults in February 2004. This report summarizes the results of that survey, which determined that 43% of adults and 69% of children aged 6 months-17 years with ILI visited a health-care provider for the illness. Eight percent of adults with ILI reported having been asked by a health-care provider to wear a mask; 82% said they would wear a mask if requested. With the limited availability of influenza vaccine this season, the use of masks by persons with cough illnesses in health-care settings, a component of the Universal Respiratory Hygiene Strategy, might be a helpful and acceptable method for decreasing influenza transmission.

  20. Performance of the Quidel Sofia rapid influenza diagnostic test during the 2012-2013 and 2013-2014 influenza seasons.

    Science.gov (United States)

    Kammerer, Peter E; Radin, Jennifer M; Hawksworth, Anthony W; Myers, Chris A; Brice, Gary T

    2016-05-01

    The Quidel Sofia Influenza A+B Fluorescent Immunoassay was used to test nasal swab specimens from patients with influenza-like illness at US-Mexico border-area clinics in the 2012-2013 and 2013-2014 influenza seasons. Compared with real-time reverse transcription polymerase chain reaction, the overall sensitivities and specificities were 83% and 81%, and 62% and 93%, respectively. © 2016 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

  1. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012.

    Science.gov (United States)

    Heikkinen, Terho; Ikonen, Niina; Ziegler, Thedi

    2014-12-01

    Influenza B virus strains in trivalent influenza vaccines are frequently mismatched to the circulating B strains, but the population-level impact of such mismatches is unknown. We assessed the impact of vaccine mismatch on the epidemiology of influenza B during 12 recent seasonal outbreaks of influenza in Finland. We analyzed all available nationwide data on virologically confirmed influenza infections in all age groups in Finland between 1 July 1999 and 30 June 2012, with the exclusion of the pandemic season of 2009-2010. We derived data on influenza infections and the circulation of different lineages of B viruses during each season from the Infectious Diseases Register and the National Influenza Center, National Institute for Health and Welfare, Finland. A total of 34 788 cases of influenza were recorded. Influenza A accounted for 74.0% and influenza B for 26.0% of all typed viruses. Throughout the 12 seasons, we estimated that 41.7% (3750 of 8993) of all influenza B infections were caused by viruses representing the other genetic lineage than the one in the vaccine. Altogether, opposite-lineage influenza B viruses accounted for 10.8% of all influenza infections in the population, the proportion being highest (16.8%) in children aged 10-14 years and lowest (2.6%) in persons aged ≥70 years. The population-level impact of lineage-level mismatch between the vaccine and circulating strains of influenza B viruses is substantial, especially among children and adolescents. The results provide strong support for the inclusion of both influenza B lineages in seasonal influenza vaccines. © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

  2. Evaluation of an Influenza-Like Illness Case Definition in the Diagnosis of Influenza Among Patients with Acute Febrile Illness in Cambodia

    Science.gov (United States)

    2010-01-01

    reassortment swine-origin influenza A virus which is the agent associated with the WHO declared influenza pan- demic [4]. Influenza viruses are...of a novel swine- origin influenza A ( H1N1 ) virus in humans. The New England journal of medicine 2009, 360(25):2605-2615. 5. Dilantika C, Sedyaningsih...RESEARCH ARTICLE Open Access Evaluation of an influenza -like illness case definition in the diagnosis of influenza among patients with acute febrile

  3. STIMULATION OF THE BUSINESS ENVIRONMENT THROUGH LLC-DEBUTANT

    Directory of Open Access Journals (Sweden)

    CLAUDIA ISAC

    2015-10-01

    Full Text Available The important contribution of SMEs to the economic growth is a fact widely recognized due to the social and economic effects which have influenced the classification of SMEs as an engine of the national economy. Thus, in the first part of the paper we have presented, in addition to the defining characteristics of SMEs, legislative aspects with regard to the start-up and the development of LLC-D in Romania, as a stimulus of SMEs to develop entrepreneurial attitudes. Further on we have highlighted the benefits of setting up such companies, advantages that cover both organizational and financial aspects, namely tax exemptions and facilities to finance the activities of the LLC-D. At the end of the paper we have made a statistical analysis on the evolution of the number of LLC-D based on various criteria, such as: the number of companies/inhabitants, the number of companies within a county, the number of companies according to the main object of activity, etc.

  4. 75 FR 60095 - Sempra LNG Marketing, LLC; Application for Blanket Authorization To Export Liquefied Natural Gas

    Science.gov (United States)

    2010-09-29

    ... DEPARTMENT OF ENERGY [FE Docket No. 10-110-LNG] Sempra LNG Marketing, LLC; Application for Blanket... receipt of an application, filed on September 2, 2010, by Sempra LNG Marketing, LLC (Sempra), requesting..., Louisiana to any country with the capacity to import LNG via ocean-going carrier and with which trade is not...

  5. 78 FR 4400 - Eni USA Gas Marketing LLC; Application for Blanket Authorization To Export Previously Imported...

    Science.gov (United States)

    2013-01-22

    ... DEPARTMENT OF ENERGY [FE Docket No. 12-161-LNG] Eni USA Gas Marketing LLC; Application for Blanket..., by Eni USA Gas Marketing LLC (Eni USA Gas Marketing), requesting blanket authorization to export... country with the capacity to import LNG via ocean-going carrier and with which trade is not prohibited by...

  6. 77 FR 25711 - Cheniere Marketing, LLC; Application for Blanket Authorization To Export Previously Imported...

    Science.gov (United States)

    2012-05-01

    ... DEPARTMENT OF ENERGY [FE Docket No. 12-36-LNG] Cheniere Marketing, LLC; Application for Blanket... Cheniere Marketing, LLC (CMI), requesting blanket authorization to export liquefied natural gas (LNG) that... ocean- going carrier and with which trade is not prohibited by U.S. law or policy. CMI is requesting...

  7. 75 FR 19954 - Cheniere Marketing, LLC; Application for Blanket Authorization To Export Liquefied Natural Gas

    Science.gov (United States)

    2010-04-16

    ... DEPARTMENT OF ENERGY [FE Docket No. 10-31-LNG] Cheniere Marketing, LLC; Application for Blanket... receipt of an application, filed on March 23, 2010, by Cheniere Marketing, LLC (CMI), requesting blanket... capacity to import LNG via ocean-going carrier and with which trade is not prohibited by U.S. law or policy...

  8. 75 FR 54215 - East Penn Railroad, LLC-Abandonment Exemption-in Montgomery County, PA

    Science.gov (United States)

    2010-09-03

    ... DEPARTMENT OF TRANSPORTATION Surface Transportation Board [Docket No. AB 1020 (Sub-No. 1X)] East Penn Railroad, LLC--Abandonment Exemption--in Montgomery County, PA East Penn Railroad, LLC (ESPN... milepost 2.14 at Henderson Road in Upper Merion Township, in Montgomery County, Pa. The line traverses...

  9. 76 FR 3188 - Self-Regulatory Organizations; NASDAQ Stock Market LLC; Notice of Filing and Immediate...

    Science.gov (United States)

    2011-01-19

    ...-Regulatory Organizations; NASDAQ Stock Market LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to Routing Fees for the NASDAQ Options Market January 12, 2011. Pursuant to... is hereby given that on January 6, 2011, The NASDAQ Stock Market LLC (``NASDAQ'' or ``Exchange...

  10. 78 FR 46622 - Application of Topaz Exchange, LLC for Registration as a National Securities Exchange; Findings...

    Science.gov (United States)

    2013-08-01

    ..., Opinion, and Order of the Commission July 26, 2013. I. Introduction On July 3, 2012, Topaz Exchange, LLC... Exchange is structured as a Delaware limited liability company ] (``LLC''), and is a wholly-owned... directors, including three Non-Industry Directors),\\45\\ a Finance and Audit Committee (consisting of between...

  11. 78 FR 68497 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2013-11-14

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to Exchange Trading Days and Hours of Business and Trading Halts November 7, 2013... thereunder,\\2\\ notice is hereby given that, on October 31, 2013, the International Securities Exchange, LLC...

  12. 77 FR 76334 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2012-12-27

    ...-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate... Prices Until the Close of Trading on the Second Business Day Prior to Monthly Expiration in Unusual... December 19, 2012, the International Securities Exchange, LLC (the ``Exchange'' or the ``ISE'') filed with...

  13. 78 FR 33461 - Self-Regulatory Organizations; Miami International Securities Exchange LLC; Notice of Filing and...

    Science.gov (United States)

    2013-06-04

    ...-Regulatory Organizations; Miami International Securities Exchange LLC; Notice of Filing and Immediate... the Second Business Day Prior to Expiration in Unusual Market Conditions May 29, 2013. Pursuant to... is hereby given that, on May 20, 2013, Miami International Securities Exchange LLC (the ``Exchange...

  14. 76 FR 53436 - Free Flow Power Corporation; Northland Power Mississippi River LLC; Notice of Competing...

    Science.gov (United States)

    2011-08-26

    ... Mississippi River, near the town of Luling, in St. Charles Parish, Louisiana. The sole purpose of a.... 14091-000] Free Flow Power Corporation; Northland Power Mississippi River LLC; Notice of Competing... Mississippi River LLC (Northland) filed preliminary permit applications, pursuant to section 4(f) of the...

  15. 76 FR 53427 - Free Flow Power Corporation; Northland Power Mississippi River LLC; Notice of Competing...

    Science.gov (United States)

    2011-08-26

    ... Mississippi River, near the town of Killona, in St. Charles Parish, Louisiana. The sole purpose of a.... 14092-000] Free Flow Power Corporation; Northland Power Mississippi River LLC; Notice of Competing... Mississippi River LLC (Northland) filed preliminary permit applications, pursuant to section 4(f) of the...

  16. 77 FR 55817 - Delek Crude Logistics, LLC; Notice of Petition for Waiver

    Science.gov (United States)

    2012-09-11

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. OR12-19-000] Delek Crude Logistics, LLC; Notice of Petition for Waiver Take notice that on June 11, 2012, Delek Crude Logistics, LLC... East Texas Crude Logistics crude oil pipeline system. Any person desiring to intervene or to protest in...

  17. 78 FR 34359 - NET Mexico Pipeline Partners, LLC; Notice of Application

    Science.gov (United States)

    2013-06-07

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. CP13-482-000] NET Mexico Pipeline Partners, LLC; Notice of Application Take notice that on May 20, 2013, NET Mexico Pipeline Partners, LLC (NET Mexico), 5847 San Felipe Street, Suite 1910, Houston, Texas 77057, filed an application...

  18. 77 FR 11515 - Application to Export Electric Energy; NRG Power Marketing LLC

    Science.gov (United States)

    2012-02-27

    ... Application to Export Electric Energy; NRG Power Marketing LLC AGENCY: Office of Electricity Delivery and Energy Reliability, DOE. ] ACTION: Notice of application. SUMMARY: NRG Power Marketing LLC (NRGPML) has... would be surplus energy purchased from electric utilities and Federal power marketing agencies within...

  19. 77 FR 74472 - Application to Export Electric Energy; Energia Renovable S.C., LLC

    Science.gov (United States)

    2012-12-14

    ... Application to Export Electric Energy; Energia Renovable S.C., LLC AGENCY: Office of Electricity Delivery and Energy Reliability, DOE. ACTION: Notice of application. SUMMARY: Energia Renovable S.C., LLC (Energia... application from Energia Renovable for authority to transmit electric energy from the United States to Mexico...

  20. 78 FR 25259 - Notice of Intent To Grant an Exclusive License; Integrata Security, LLC

    Science.gov (United States)

    2013-04-30

    ...; Integrata Security, LLC AGENCY: National Security Agency, DoD. ACTION: Notice. SUMMARY: The National Security Agency hereby gives notice of its intent to grant Integrata Security, LLC a revocable, non.... Patent No. 8,069,483 entitled: ``Device for and Method of Wireless Intrusion Detection,'' issued by the U...

  1. 76 FR 70117 - Notice of Intent To Grant an Exclusive License; Voltage Networking, LLC

    Science.gov (United States)

    2011-11-10

    ...; Voltage Networking, LLC AGENCY: National Security Agency, Department of Defense (DoD). ACTION: Notice. SUMMARY: The National Security Agency hereby gives notice of its intent to grant Voltage Networking, LLC a... described in the following: Patent No. 6,835,581 entitled ``Method of coating optical device facets with...

  2. 77 FR 50486 - Application To Export Electric Energy; TexMex Energy, LLC

    Science.gov (United States)

    2012-08-21

    ... DEPARTMENT OF ENERGY [OE Docket No. EA-294-B] Application To Export Electric Energy; TexMex Energy, LLC AGENCY: Office of Electricity Delivery and Energy Reliability, DOE. ACTION: Notice of application. SUMMARY: TexMex Energy, LLC (TexMex) has applied to renew its authority to transmit electric energy from...

  3. 78 FR 61387 - Supermedia LLC, Publishing Operations Divison, Account Management Group, a Subsidiary of Dex...

    Science.gov (United States)

    2013-10-03

    ... LLC, Publishing Operations Divison, Account Management Group, a Subsidiary of Dex Media Inc..., Publishing Operations Divison, Listing Management Group, a Subsidiary of Dex Media Inc., Including On-Site... to workers and former workers of SuperMedia LLC, Publishing Operation Division, Account Management...

  4. 77 FR 20808 - Black Bear Hydro Partners, LLC; Notice of Application Accepted for Filing, Ready for...

    Science.gov (United States)

    2012-04-06

    ... March 14, 2012. d. Applicant: Black Bear Hydro Partners, LLC. e. Name of Projects: Orono Project 2710.... 791a-825r. h. Applicant Contact: Mr. Scott D. Hall, Black Bear Hydro Partners, LLC, P.O. Box 276... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project Nos. 2710-057; 2712-074] Black...

  5. 76 FR 30338 - Hill-Lake Gas Storage, LLC; Notice of Filing

    Science.gov (United States)

    2011-05-25

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. PR11-110-000] Hill-Lake Gas Storage, LLC; Notice of Filing Take notice that on May 13, 2011, Hill-Lake Gas Storage, LLC filed to update its address and to clarify definitions for Maximum Daily Withdrawal Quantity and Maximum Daily...

  6. 75 FR 63465 - Hill-Lake Gas Storage, LLC; Notice of Filing

    Science.gov (United States)

    2010-10-15

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. PR10-137-000] Hill-Lake Gas Storage, LLC; Notice of Filing October 7, 2010. Take notice that on September 30, 2010, Hill-Lake Gas Storage, LLC (Hill-Lake) filed a revised Statement of Operating Conditions (SOC) for its Storage Services...

  7. 78 FR 55057 - Subzone 29J, Authorization of Production Activity, LLFlex, LLC; (Foil Backed Paperboard...

    Science.gov (United States)

    2013-09-09

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF COMMERCE Foreign-Trade Zones Board Subzone 29J, Authorization of Production Activity, LLFlex, LLC; (Foil Backed Paperboard), Louisville, Kentucky On May 6, 2013, LLFlex, LLC submitted a notification of proposed production...

  8. 76 FR 25320 - Hawthorn Water LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting...

    Science.gov (United States)

    2011-05-04

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Hawthorn Water LLC; Notice of Preliminary Permit Application Accepted for..., Hawthorn Water LLC filed an application, pursuant to section 4(f) of the Federal Power Act, proposing to...

  9. 76 FR 64341 - Big Sandy Pipeline, LLC; Notice of Cost and Revenue Study

    Science.gov (United States)

    2011-10-18

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. CP06-275-003] Big Sandy Pipeline, LLC; Notice of Cost and Revenue Study Take notice that on April 8, 2011, Big Sandy Pipeline, LLC... protestants parties to the proceeding. Such protests must be filed on or before the date as indicated below...

  10. 78 FR 6316 - Enterprise Texas Pipeline LLC; Notice of Compliance Filing

    Science.gov (United States)

    2013-01-30

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. PR13-23-000] Enterprise Texas Pipeline LLC; Notice of Compliance Filing Take notice that on January 17, 2013, Enterprise Texas Pipeline LLC filed a revised Statement of Operating Conditions to comply with a Commission order issued in...

  11. 77 FR 38275 - Notice of Intent To Grant Exclusive Patent License; Emerging Growth Enterprise LLC

    Science.gov (United States)

    2012-06-27

    ... DEPARTMENT OF DEFENSE Department of the Navy Notice of Intent To Grant Exclusive Patent License; Emerging Growth Enterprise LLC AGENCY: Department of the Navy, DoD. ACTION: Notice. SUMMARY: The Department of the Navy hereby gives notice of its intent to grant Emerging Growth Enterprise LLC a revocable...

  12. 78 FR 30300 - Enterprise TE Products Pipeline Company LLC; Notice of Petition for Declaratory Order

    Science.gov (United States)

    2013-05-22

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [ Docket No. OR13-20-000] Enterprise TE Products Pipeline Company LLC; Notice of Petition for Declaratory Order Take notice that on May 14, 2013...), Enterprise TE Products Pipeline Company LLC filed a petition seeking a declaratory order approving priority...

  13. 77 FR 70432 - Enterprise Liquids Pipeline LLC; Notice of Petition for Declaratory Order

    Science.gov (United States)

    2012-11-26

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. OR13-7-000] Enterprise Liquids Pipeline LLC; Notice of Petition for Declaratory Order Take notice that on November 14, 2012...), Enterprise Liquids Pipeline LLC, filed a petition seeking a declaratory order approving the rate structures...

  14. 76 FR 73618 - Enterprise Texas Pipeline LLC; Notice of Compliance Filing

    Science.gov (United States)

    2011-11-29

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket Nos. PR11-92-001] Enterprise Texas Pipeline LLC; Notice of Compliance Filing Take notice that on November 22, 2011, Enterprise Texas Pipeline LLC (Enterprise Texas) filed a revised Statement of Operating Conditions to comply with a...

  15. 75 FR 70732 - Enterprise Texas Pipeline LLC; Notice of Baseline Filing

    Science.gov (United States)

    2010-11-18

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. PR10-92-001] Enterprise Texas Pipeline LLC; Notice of Baseline Filing November 10, 2010. Take notice that on November 9, 2010, Enterprise Texas Pipeline LLC submitted a revised baseline filing of its Statement of Operating Conditions...

  16. 76 FR 13610 - Enterprise Texas Pipeline LLC; Notice of Compliance Filing

    Science.gov (United States)

    2011-03-14

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket Nos. PR10-14-002; PR11-92-000] Enterprise Texas Pipeline LLC; Notice of Compliance Filing Take notice that on March 1, 2011, Enterprise Texas Pipeline LLC (Enterprise Texas) filed a revised Statement of Rates to its Statement of Operating...

  17. 78 FR 34091 - Enterprise Liquids Pipeline LLC; Notice of Petition for Declaratory Order

    Science.gov (United States)

    2013-06-06

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. OR13-24-000] Enterprise Liquids Pipeline LLC; Notice of Petition for Declaratory Order Take notice that on May 29, 2013, pursuant...), Enterprise Liquids Pipeline LLC filed a petition seeking a declaratory order approving a proposed proration...

  18. 76 FR 18753 - Jefferson Island Storage & Hub, L.L.C.; Notice of Filing

    Science.gov (United States)

    2011-04-05

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. PR11-97-000] Jefferson Island Storage & Hub, L.L.C.; Notice of Filing Take notice that on March 28, 2011, Jefferson Island Storage & Hub, L.L.C. (Jefferson Island) submitted a revised Statement of Operating Conditions (SOC) for services provided under section 311 of the Natura...

  19. 78 FR 20314 - Jefferson Island Storage & Hub, L.L.C.; Notice of Filing

    Science.gov (United States)

    2013-04-04

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. PR13-44-000] Jefferson Island Storage & Hub, L.L.C.; Notice of Filing Take notice that on March 28, 2013, Jefferson Island Storage & Hub, L.L.C. filed to revise its Statement of Operating Conditions to among others, update, clarify and/or add certain provisions regarding the...

  20. 77 FR 77073 - York Haven Power Company, LLC; Notice of Meeting

    Science.gov (United States)

    2012-12-31

    ... Company, LLC; Notice of Meeting On Wednesday, January 9, 2013, Commission staff will meet with York Haven Power Company, LLC (applicant) in Washington, DC. The purpose of the meeting is to discuss the required... applicant's proposed nature-like fishway for the York Haven Hydroelectric Project No. 1888. The meeting will...

  1. 78 FR 57629 - Eagle Valley Clean Energy, LLC; Notice of Filing

    Science.gov (United States)

    2013-09-19

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket Nos. EL13-87-000; QF13-658-000] Eagle Valley Clean Energy, LLC; Notice of Filing Take notice that on September 9, 2013, Eagle Valley Clean Energy, LLC filed Form 556 and a petition for certification as a qualifying small power production...

  2. 77 FR 2972 - Thunder Bay Power Company, Thunder Bay Power, LLC, et al.

    Science.gov (United States)

    2012-01-20

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Thunder Bay Power Company, Thunder Bay Power, LLC, et al.; Notice of Application for Transfer of Licenses, and Soliciting Comments and Motions To Intervene Thunder Bay Power Company Project No. 2404-095 Thunder Bay Power, LLC Midwest Hydro, Inc...

  3. 76 FR 47627 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2011-08-05

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to Two Market Data Feeds August 1, 2011. Pursuant to Section 19(b)(1) of the... on August 1, 2011, the International Securities Exchange, LLC (the ``Exchange'' or the ``ISE'') filed...

  4. 78 FR 49311 - Self-Regulatory Organizations; International Securities Exchange, LLC; Order Approving Proposed...

    Science.gov (United States)

    2013-08-13

    ... Organizations; International Securities Exchange, LLC; Order Approving Proposed Rule Change Related to Market... International Securities Exchange, LLC (the ``Exchange'' or the ``ISE'') filed with the Securities and Exchange...'') \\1\\ and Rule 19b-4 thereunder,\\2\\ a proposed rule change related to market maker risk parameters and...

  5. 78 FR 7844 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2013-02-04

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Certain Market Maker Fees January 29, 2013. Pursuant to Section 19(b)(1) of the... on January 17, 2013, the International Securities Exchange, LLC (the ``Exchange'' or the ``ISE...

  6. 76 FR 47630 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2011-08-05

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to Market Data Fees August 1, 2011. Pursuant to Section 19(b)(1) of the Securities... 1, 2011, the International Securities Exchange, LLC (the ``Exchange'' or the ``ISE'') filed with the...

  7. 78 FR 21677 - Self-Regulatory Organizations; Miami International Securities Exchange LLC; Notice of Filing and...

    Science.gov (United States)

    2013-04-11

    ... (``PHLX'') and the International Stock Exchange LLC (``ISE''). For example, PHLX and ISE offer market data...-Regulatory Organizations; Miami International Securities Exchange LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Establish Fees for the MIAX Top of Market (ToM) Data Product April 5...

  8. 76 FR 51075 - Self-Regulatory Organizations; International Securities Exchange, LLC; Order Granting Approval to...

    Science.gov (United States)

    2011-08-17

    ... Organizations; International Securities Exchange, LLC; Order Granting Approval to a Proposed Rule Change Relating to Appointments to Competitive Market Makers August 11, 2011. I. Introduction On June 10, 2011, the International Securities Exchange, LLC (the ``Exchange'' or the ``ISE'') filed with the Securities...

  9. 77 FR 37722 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2012-06-22

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Eliminate the Rules and Fees Related to the Second Market June 18, 2012. Pursuant to...\\ notice is hereby given that on June 6, 2012, the International Securities Exchange, LLC (the ``Exchange...

  10. 78 FR 37870 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing of...

    Science.gov (United States)

    2013-06-24

    ... Organizations; International Securities Exchange, LLC; Notice of Filing of Proposed Rule Change Related to Market Maker Risk Parameters and Complex Orders June 18, 2013. Pursuant to Section 19(b)(1) of the... on June 5, 2013, the International Securities Exchange, LLC (the ``Exchange'' or the ``ISE'') filed...

  11. 78 FR 24271 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2013-04-24

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend the Market Maker Plus Rebate Program April 18, 2013. Pursuant to Section 19(b)(1... hereby given that on April 10, 2013, the International Securities Exchange, LLC (the ``Exchange'' or the...

  12. 77 FR 1757 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2012-01-11

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to a Market Maker Incentive Plan for Foreign Currency Options January 5, 2012...,\\2\\ notice is hereby given that on December 28, 2011, the International Securities Exchange, LLC (the...

  13. 78 FR 17988 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2013-03-25

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Regarding Market Maker Quoting Requirements March 19, 2013. Pursuant to Section 19(b)(1) of... given that on March 5, 2013, the International Securities Exchange, LLC (the ``Exchange'' or the ``ISE...

  14. 78 FR 45580 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2013-07-29

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change to Amend Certain Market Maker Fees July 23, 2013. Pursuant to Section 19(b)(1) of the... hereby given that on July 11, 2013, the International Securities Exchange, LLC (the ``Exchange'' or the...

  15. 76 FR 5412 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing of...

    Science.gov (United States)

    2011-01-31

    ... Organizations; International Securities Exchange, LLC; Notice of Filing of Proposed Rule Change To Establish a New Class of Market Participant for Index Options January 25, 2011. Pursuant to Section 19(b)(1) of... given that on January 12, 2011, International Securities Exchange, LLC (the ``Exchange'' or the ``ISE...

  16. 76 FR 6128 - Energy Exchange International, LLC; Supplemental Notice That Initial Market-Based Rate Filing...

    Science.gov (United States)

    2011-02-03

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. ER11-2730-000] Energy Exchange International, LLC; Supplemental Notice That Initial Market-Based Rate Filing Includes Request for... proceeding Energy Exchange International, LLC's application for market-based rate authority, with an...

  17. 76 FR 32382 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2011-06-06

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to Second Market Fees May 27, 2011. Pursuant to Section 19(b)(1) of the Securities..., 2011, the International Securities Exchange, LLC (the ``Exchange'' or the ``ISE'') filed with the...

  18. 76 FR 56832 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2011-09-14

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to a New Market Data Feed September 8, 2011. Pursuant to Section 19(b)(1) of the... on August 31, 2011, the International Securities Exchange, LLC (the ``Exchange'' or the ``ISE...

  19. 76 FR 61438 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Proposed Rule...

    Science.gov (United States)

    2011-10-04

    ... Organizations; International Securities Exchange, LLC; Notice of Proposed Rule Change Related to Trading Halts Due to Extraordinary Market Volatility September 28, 2011. Pursuant to Section 19(b)(1) of the... September 27, 2011, the International Securities Exchange, LLC (``Exchange'' or ``ISE'') filed with the...

  20. 76 FR 37863 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing of...

    Science.gov (United States)

    2011-06-28

    ... Organizations; International Securities Exchange, LLC; Notice of Filing of Proposed Rule Change Relating to Appointments to Competitive Market Makers June 22, 2011. Pursuant to Section 19(b)(1) of the Securities... that on June 10, 2011, the International Securities Exchange, LLC (the ``Exchange'' or the ``ISE...

  1. 76 FR 70178 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2011-11-10

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to Market Data Fees November 3, 2011. Pursuant to Section 19(b)(1) of the... that, on October 24, 2011, the International Securities Exchange, LLC (the ``Exchange'' or the ``ISE...

  2. 75 FR 42812 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2010-07-22

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to a Market Maker Incentive Plan for Foreign Currency Options July 15, 2010..., \\2\\ notice is hereby given that on June 30, 2010, International Securities Exchange, LLC (``ISE'' or...

  3. 76 FR 64417 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2011-10-18

    ... Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to Competitive Market Maker Trading Rights October 12, 2011. Pursuant to Section...\\ notice is hereby given that on October 3, 2011, the International Securities Exchange, LLC (the...

  4. 75 FR 71475 - Self-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2010-11-23

    ...-Regulatory Organizations; International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to Market Data Fees November 17, 2010. Pursuant to Section 19(b... hereby given that on November 4, 2010, the International Securities Exchange, LLC (the ``Exchange'' or...

  5. 76 FR 18747 - Teton Power Funding, LLC; Topsham Hydro Partners Limited Partnership; Topsham Hydroelectric...

    Science.gov (United States)

    2011-04-05

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 4784-081] Teton Power Funding, LLC; Topsham Hydro Partners Limited Partnership; Topsham Hydroelectric Generating Facility Trust No. 1; Brown Bear Power, LLC; Notice of Application for Partial Transfer of License, and Soliciting...

  6. 76 FR 51961 - Brown Bear Power, LLC, Topsham Hydroelectric Generating Facility Trust No. 1, Topsham Hydro...

    Science.gov (United States)

    2011-08-19

    ... On August 3, 2011, Brown Bear Power, LLC, Topsham Hydroelectric Generating Facility (Trust No. 1... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 4784-082] Brown Bear Power, LLC, Topsham Hydroelectric Generating Facility Trust No. 1, Topsham Hydro Partners Limited Partnership...

  7. 75 FR 41855 - Stream Energy Pennsylvania, LLC; Supplemental Notice That Initial Market-Based Rate Filing...

    Science.gov (United States)

    2010-07-19

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. ER10-1750-000] Stream Energy Pennsylvania, LLC; Supplemental Notice That Initial Market-Based Rate Filing Includes Request for Blanket... of Stream Energy Pennsylvania, LLC's application for market-based rate authority, with an...

  8. 75 FR 75994 - Application To Export Electric Energy; NRG Power Marketing LLC

    Science.gov (United States)

    2010-12-07

    ... Marketing LLC AGENCY: Office of Electricity Delivery and Energy Reliability, DOE. ACTION: Notice of application. SUMMARY: NRG Power Marketing LLC (NRGPML) has applied to renew its authority to transmit electric... to Canada would be surplus energy purchased from electric utilities, Federal power marketing agencies...

  9. 76 FR 23322 - Storage Development Partners, LLC; Notice of Preliminary Permit Application Accepted for Filing...

    Science.gov (United States)

    2011-04-26

    ... Development Partners, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications On April 1, 2011, Storage Development Partners, LLC, filed an application for a preliminary permit, pursuant to section 4(f) of the Federal Power Act...

  10. 75 FR 66082 - Bishop Tungsten Development, LLC; Notice of Preliminary Permit Application Accepted for Filing...

    Science.gov (United States)

    2010-10-27

    ... Development, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications October 20, 2010. On November 9, 2009, Bishop Tungsten Development, LLC filed an application for a preliminary permit, pursuant to section 4(f) of the Federal Power...

  11. 76 FR 24017 - Storage Development Partners, LLC; Notice of Preliminary Permit Application Accepted for Filing...

    Science.gov (United States)

    2011-04-29

    ... Development Partners, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications On April 1, 2011, Storage Development Partners, LLC, filed an application for a preliminary permit, pursuant to section 4(f) of the Federal Power Act...

  12. 75 FR 66079 - Bishop Tungsten Development, LLC; Notice of Preliminary Permit Application Accepted for Filing...

    Science.gov (United States)

    2010-10-27

    ... Development, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications October 20, 2010. On November 9, 2009, Bishop Tungsten Development, LLC filed an application for a preliminary permit, pursuant to section 4(f) of the Federal Power...

  13. 75 FR 70732 - BPUS Generation Development, LLC; Notice of Preliminary Permit Application Accepted for Filing...

    Science.gov (United States)

    2010-11-18

    ... Development, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications November 10, 2010. On October 4, 2010, BPUS Generation Development, LLC filed an application for a preliminary permit, pursuant to section 4(f) of the Federal Power...

  14. 76 FR 24018 - Storage Development Partners, LLC; Notice of Preliminary Permit Application Accepted for Filing...

    Science.gov (United States)

    2011-04-29

    ... Development Partners, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications On April 1, 2011, Storage Development Partners, LLC, filed an application for a preliminary permit, pursuant to section 4(f) of the Federal Power Act...

  15. 77 FR 70206 - Eastside Community Rail, LLC; Acquisition and Operation Exemption; GNP RLY, Inc.

    Science.gov (United States)

    2012-11-23

    ... Rail, LLC; Acquisition and Operation Exemption; GNP RLY, Inc. Eastside Community Rail, LLC (ECR), a... authority to acquire from BNSF an exclusive freight rail operating easement for operations on the Line in... Line for several years as an agent of GNP. ECR states that it will be a non- operating common carrier...

  16. 75 FR 68398 - Texas, Oklahoma & Eastern Railroad, LLC-Acquisition and Operation Exemption-Texas, Oklahoma...

    Science.gov (United States)

    2010-11-05

    ... DEPARTMENT OF TRANSPORTATION Surface Transportation Board [Docket No. FD 35430] Texas, Oklahoma & Eastern Railroad, LLC--Acquisition and Operation Exemption--Texas, Oklahoma & Eastern Railroad Company Texas, Oklahoma & Eastern Railroad, LLC (TOE), a noncarrier, has filed a verified notice of exemption...

  17. 78 FR 68814 - Subzone 183B; Authorization of Production Activity; Samsung Austin Semiconductor, LLC...

    Science.gov (United States)

    2013-11-15

    ... DEPARTMENT OF COMMERCE Foreign-Trade Zones Board [B-70-2013] Subzone 183B; Authorization of Production Activity; Samsung Austin Semiconductor, LLC (Semiconductors); Austin, Texas On June 26, 2013, Samsung Austin Semiconductor, LLC submitted a notification of proposed export production activity to the...

  18. 78 FR 48742 - Self-Regulatory Organizations; Miami International Securities Exchange LLC; Notice of Filing and...

    Science.gov (United States)

    2013-08-09

    ...-Regulatory Organizations; Miami International Securities Exchange LLC; Notice of Filing and Immediate...\\ notice is hereby given that on July 23, 2013, Miami International Securities Exchange LLC (``Exchange... allocated Marketing Fees for orders directed to that LMM. The text of the proposed rule change is available...

  19. 77 FR 74905 - Self-Regulatory Organizations; Miami International Securities Exchange, LLC; Notice of Filing and...

    Science.gov (United States)

    2012-12-18

    ...-Regulatory Organizations; Miami International Securities Exchange, LLC; Notice of Filing and Immediate...\\ notice is hereby given that on December 7, 2012, Miami International Securities Exchange LLC (``Exchange... provided by the MIAX. Marketing Fee MIAX will assess a Marketing Fee to all MIAX Market Makers for...

  20. 75 FR 65312 - Vortex Hydro Energy, LLC; Notice of Competing Preliminary Permit Application Accepted for Filing...

    Science.gov (United States)

    2010-10-22

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 13831-000] Vortex Hydro... Comments and Interventions October 15, 2010. On August 9, 2010, Vortex Hydro Energy, LLC filed an... 0.788 gigawatt-hours. Applicant Contact: Gus Simiao, CEO, Vortex Hydro Energy, LLC, 2512 Carpenter...

  1. 75 FR 24942 - Osprey I, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting...

    Science.gov (United States)

    2010-05-06

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 13709-000] Osprey I, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications April 29, 2010. On April 9, 2010, Osprey I, LLC filed an application...

  2. 75 FR 62121 - Osprey IV, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting...

    Science.gov (United States)

    2010-10-07

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 13812-000] Osprey IV, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications September 30, 2010. On July 12, 2010, Osprey IV, LLC filed an...

  3. 75 FR 65625 - Osprey II, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting...

    Science.gov (United States)

    2010-10-26

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 13800-000] Osprey II, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications October 19, 2010. On June 28, 2010, Osprey II, LLC filed an...

  4. 75 FR 24941 - Osprey III, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting...

    Science.gov (United States)

    2010-05-06

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [ Project No. 13715-000] Osprey III, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications April 29, 2010. On April 15, 2010, Osprey III, LLC filed an...

  5. 75 FR 62121 - Osprey V, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting...

    Science.gov (United States)

    2010-10-07

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Project No. 13811-000] Osprey V, LLC; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications September 30, 2010. On July 12, 2010, Osprey V, LLC filed an...

  6. 78 FR 16262 - Tesoro Refining & Marketing Company LLC; Supplemental Notice That Initial Market-Based Rate...

    Science.gov (United States)

    2013-03-14

    ... Refining & Marketing Company LLC; Supplemental Notice That Initial Market-Based Rate Filing Includes... proceeding, of Tesoro Refining & Marketing Company LLC's application for market- based rate authority, with... submission of protests and interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov...

  7. 78 FR 49508 - Tesoro Refining & Marketing Company LLC; Supplemental Notice That Initial Market-Based Rate...

    Science.gov (United States)

    2013-08-14

    ... Refining & Marketing Company LLC; Supplemental Notice That Initial Market-Based Rate Filing Includes... proceeding of Tesoro Refining & Marketing Company LLC's application for market-based rate authority, with an... of protests and interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov...

  8. 77 FR 5791 - Ocean Renewable Power Company Maine, LLC; Notice of Staff Participation in Meeting

    Science.gov (United States)

    2012-02-06

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Ocean Renewable Power Company Maine, LLC; Notice of Staff Participation in... representatives from Ocean Renewable Power Company Maine, LLC at the Federal Energy Regulatory Commission's...

  9. 76 FR 20651 - Application To Export Electric Energy; Cargill Power Markets, LLC

    Science.gov (United States)

    2011-04-13

    ... Application To Export Electric Energy; Cargill Power Markets, LLC AGENCY: Office of Electricity Delivery and Energy Reliability, DOE. ACTION: Notice of application. SUMMARY: Cargill Power Markets, LLC (CPM) has.... EA-378. An additional copy is be filed directly with Valerie L. Ege, Compliance Manager, Cargill...

  10. 78 FR 7773 - Cargill Power Markets, LLC v. NV Energy, Inc., Notice of Complaint

    Science.gov (United States)

    2013-02-04

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Cargill Power Markets, LLC v. NV Energy, Inc., Notice of Complaint Take... Power Act (FPA), 16 U.S.C. 824(e) (2006), Cargill Power Markets, LLC (Complainant or CPM) filed a formal...

  11. 76 FR 63917 - Ocean Renewable Power Company, LLC; Notice of Application Accepted for Filing, Soliciting Motions...

    Science.gov (United States)

    2011-10-14

    ... 32 feet wide by 35 feet long, housing the SatCon power inverter and the supervisory control and data... Federal Energy Regulatory Commission Ocean Renewable Power Company, LLC; Notice of Application Accepted.... d. Applicant: Ocean Renewable Power Company, LLC. e. Name of Project: Cobscook Bay Tidal Energy...

  12. 75 FR 80486 - ONEOK Field Services Company, L.L.C.; Notice of Compliance Filing

    Science.gov (United States)

    2010-12-22

    ... Federal Energy Regulatory Commission ONEOK Field Services Company, L.L.C.; Notice of Compliance Filing December 15, 2010. Take notice that on December 9, 2010, ONEOK Field Services Company, L.L.C. (OFS) filed... with any FERC Online service, please e-mail [email protected] , or call (866) 208-3676 (toll...

  13. 75 FR 41855 - ONEOK Field Services Company, LLC; Notice of Petition for Rate Approval

    Science.gov (United States)

    2010-07-19

    ... Energy Regulatory Commission ONEOK Field Services Company, LLC; Notice of Petition for Rate Approval July 13, 2010. Take notice that on July 1, 2010, ONEOK Field Services Company, LLC ] (OFS) filed a... is filing for approval for a new maximum rate for interruptible transportation service provided...

  14. 77 FR 67029 - Arden Investment Series Trust and Arden Asset Management LLC; Notice of Application

    Science.gov (United States)

    2012-11-08

    ... Investment Series Trust and Arden Asset Management LLC; Notice of Application November 2, 2012. AGENCY... disclosure requirements. Applicants: Arden Investment Series Trust (the ``Trust'') and Arden Asset Management..., 375 Park Avenue, 32nd Floor, New York, New York 10152 and Arden Asset Management LLC, 375 Park Avenue...

  15. 76 FR 79675 - DCP Raptor Pipeline, LLC; Notice of Extension of Time

    Science.gov (United States)

    2011-12-22

    ... Energy Regulatory Commission DCP Raptor Pipeline, LLC; Notice of Extension of Time On November 30, 2011, DCP Raptor Pipeline, LLC (Raptor) filed a request to extend the date for filing its next rate case... request, Raptor states that in Order No. 735 the Commission modified its policy concerning periodic...

  16. 75 FR 9201 - DCP Raptor Pipeline, LLC; Notice of Compliance Filing

    Science.gov (United States)

    2010-03-01

    ... Energy Regulatory Commission DCP Raptor Pipeline, LLC; Notice of Compliance Filing February 22, 2010. Take notice that on January 28, 2010, DCP Raptor Pipeline, LLC (Raptor) filed its Statement of... Docket Nos. PR09-32-000 and PR09-32-001. Raptor states that it made revisions to include a statement of...

  17. 77 FR 65025 - Trust for Professional Managers and Collins Capital Investments, LLC; Notice of Application

    Science.gov (United States)

    2012-10-24

    ... Professional Managers and Collins Capital Investments, LLC; Notice of Application October 18, 2012. AGENCY...: Trust for Professional Managers (the ``Trust'') and Collins Capital Investments, LLC (the ``Advisor..., allocates assets to and oversees the Subadvisors, and makes recommendations about their hiring, termination...

  18. 77 FR 28869 - Exelon Corporation, Public Service Electric and Gas Company, PSEG Power LLC, PSEG Energy...

    Science.gov (United States)

    2012-05-16

    ... Energy Regulatory Commission Exelon Corporation, Public Service Electric and Gas Company, PSEG Power LLC...(e), Exelon Corporation, Public Service Electric and Gas Company, PSEG Power LLC, and PSEG Energy... and is available for review in the Commission's Public Reference Room in Washington, DC There is an...

  19. 78 FR 40473 - Plainfield Renewable Energy, LLC; Supplemental Notice That Initial Market-Based Rate Filing...

    Science.gov (United States)

    2013-07-05

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. ER13-1734-000] Plainfield Renewable Energy, LLC; Supplemental Notice That Initial Market-Based Rate Filing Includes Request for... Plainfield Renewable Energy, LLC's application for market-based rate authority, with an accompanying rate...

  20. 77 FR 64980 - Chesapeake Renewable Energy LLC; Supplemental Notice That Initial Market-Based Rate Filing...

    Science.gov (United States)

    2012-10-24

    ... DEPARTMENT OF ENERGY Federal Energy Regulatory Commission [Docket No. ER13-28-000] Chesapeake Renewable Energy LLC; Supplemental Notice That Initial Market-Based Rate Filing Includes Request for Blanket... proceeding of Chesapeake Renewable Energy LLC's application for market-based rate authority, with an...